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The use of veterinary pharmaceuticals in today´s intensive farming of food-producing 
animals is essential for the humane treatment of animals and as well as for the prevention of 
outbreaks of infectious diseases. Improper administration of these drugs may lead to excessive 
levels of drug residues in the edible tissues of treated animals, posing a potentially serious risk to 
human health. Accordingly, monitoring of veterinary drug residues is an integral component of 
food safety programs worldwide. Reliable analytical methods play a crucial role in the endeavor 
to enforce regulations surrounding the use of veterinary drugs in food-producing animals. 
Recent advancements in liquid chromatography (LC) and mass spectrometry (MS) have 
facilitated the development of multi-class, multi-residue analytical methods capable of screening 
a large number of analytes in a single analytical run. However, due to the complexity of biological 
tissues, the large number of veterinary drugs to be monitored, and the wide variation in their 
physico-chemical properties, sample preparation constitute a major bottleneck of their analytical 
workflow. Sample preparation is critical in relation to sample turnaround and the reliability of the 
analytical outcome. In this context, an ideal sample preparation method for multi-class multi-
residue analysis should offer enough non-selectivity so as to cover a wide range of polarities and 
thus allow extraction of as many analytes as possible, while at the same time delivering a high 
degree of sample clean-up so as to reduce matrix effects. Solid phase microextraction (SPME) has 
been demonstrated as a suitable sample preparation tool that allows isolation/enrichment of 




The main objective of this thesis was to develop automated high-throughput analytical 
methods for quantitative analysis of multi-class multi-residue veterinary drugs in meat using liquid 
chromatography and mass spectrometric techniques. 
The introductory chapter offers an extensive review of veterinary drug classes used in food 
animal production and the current analytical methodologies used for their analysis. In addition, 
chapter 1 offers an extensive review of the most commonly used generic sample preparation 
techniques. The experimental section of this thesis is constituted of four chapters, 2-5. Chapter 2 
describes the development and validation of an automated high-throughput direct-immersion 
SPME method for the quantitative analysis of 77 veterinary drugs belonging to more than 12 
classes of drug compounds in homogenized tissue from chicken. In chapter 3, the scope of the 
SPME method presented in chapter 2 was expanded to a new matrix (beef tissue), and for detection 
of an additional 25 analytes. Moreover, the work also encompassed a comparison of the SPME 
method to two well-documented sample preparation procedures, namely solvent extraction (SE) 
and the quick, easy, cheap, effective, rugged, and safe (QuEChERS) method. Chapter 4 and 5 
present works aimed to increase efficiency and sample throughput through the development of 
rapid screening methods that involve the direct coupling of SPME to mass spectrometry. For this 
purpose, two different ambient ionization mass spectrometry techniques were studied, namely 
coated blade spray (CBS) and direct analysis in real time (DART). Finally, chapter 6 summarizes 
the main findings of this work and provides future directions to be considered with regards to the 
applicability of SPME towards multi-residue analysis of animal tissue. 
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Veterinary Drugs and Food Safety 
1.1 Introduction 
Food safety is of vital interest to consumers worldwide, a fact that is reflected in its frequent 
emergence as a prominent topic of discussion in the media.1 The topic of food safety is especially 
relevant to foodstuffs derived from animals, which play a major role in providing sufficient 
quantities of essential nutrients needed to sustain life and promote good health, such as proteins 
with high biological value, group B vitamins, minerals, and other important trace elements.2,3 On 
a global level, livestock products alone supply an estimated 28% of the protein consumed by 
humans.3 With the growth of the global population, there is an ever-growing demand for increased 
food production. In order to maximize production and profits, the animal food industry has adopted 
intensive production practices, including high stock density grazing, housing, and transportation. 
While these intensive farming practices have significantly increased the production of food 
worldwide, such practices are burdened by increased animal vulnerability to stress and disease − 
a factor that is largely associated with housing and transporting animals in high densities.1,4 
Consequently, veterinary dugs (VDs) are widely administered to food-producing animals as a 
means to reduce animal stress, as well as prevent and treat diseases.5,6 In addition, certain 
veterinary drugs are used in animal feed to promote growth and maximize production output.7–9 
Despite the obvious benefits of using VDs in animal production, malpractices such as 
improper dosage, fraudulent administration, or failure to keep the withdrawal period of approved 




Here, a residue is defined as the trace of a given substance that remains present in matrices derived 
from a given animal after administration of said substance to the animal.11 At excessive levels, 
most drug residues pose a potential risk to human health, and may lead to serious allergic, toxic, 
or carcinogenic reactions.7,12–19 One of the greatest concerns associated with the use of VDs is 
related to the misuse of antibiotics, which has been linked to the emergence of antibiotic-resistant 
strains of bacteria.19–22 Antibiotic resistance is an increasing global concern that requires 
immediate actions across governments and international organizations.23,24 
Other effects of VD use in food producing animals that may be considered of some 
importance are related to the quality of the resulting meat. Lone et al. demonstrated that while 
meat derived from animals treated with hormones or growth promoters tends to be leaner, it is also 
less tender due to the accumulation of connective tissue and the higher rate of collagen cross-
linking.25 Likewise, meat derived from animals treated with a class of drugs called thiouracils, 
which cause water retention in animals, tends to become dry upon cooking due to the retained 
water becoming rapidly lost during its preparation.26,27 
The presence of chemical residues in animals can also be a consequence of environmental 
contamination and naturally occurring toxicants in foods.7,28,29 
1.2 Classification of veterinary drugs 
In Canada, as per the Food and Drugs Act (R.S.C., 1985, c. F-27), a drug is defined as any 




1. diagnosis, treatment, mitigation or prevention of a disease, disorder, or abnormal 
physiological state, or its symptoms in human beings or animals, 
2. restoring, correcting or modifying organic functions in human beings or animals, or 
3. disinfection in premises in which food is manufactured, prepared or kept. 
Several classes of drugs, with varying chemical structures and properties, are currently used 
worldwide for treatment of food-producing animals.22 For the purpose of this thesis, the only 
classes that will be discussed are those that comprise the drugs of concern listed in the official 
multi-class multi-residue method developed by the United States Department of Agriculture 
(USDA)-Food Safety and Inspection Service (FSIS) for screening and confirmation of animal drug 
residues in bovine, poultry, porcine, caprine, and ovine kidney and muscle tissue as well as equine 
and fish muscle tissues.31,32 The following subsections provide brief descriptions of these classes. 
1.2.1 Antibiotics  
By strict definition, the term antibiotic refers to a substance produced by a microorganism 
which at a low concentration acts against competing microorganisms but with little or no damage 
to the host. An antimicrobial is any substance of natural, semi-synthetic, or synthetic origin which 
at a low concentration acts against the growth of competing microorganisms but causes little or no 
damage to the host. Nowadays, both terms are used interchangeably.19 In the same vein, while the 
term antimicrobial refers to all substances that act against all types of micro-organisms, such as 
bacteria, fungi, and protozoa, the term antibacterial is a sub-class of antimicrobials which act 




antimicrobials, the term antibacterial is also often used interchangeably with the term 
antimicrobial.33 
While the use of antibiotics is necessary to prevent or treat infections in animals, antibiotics 
have been widely exploited for economic reasons due to their growth-promoting effects in animals 
when used in sub-therapeutic doses.34,35 Antibiotics that have growth promotion effects are called 
antibacterial growth promoters (AGP), a characteristic that can be exploited for weight gain. The 
practice of using AGPs for growth promotion is prohibited in Canada, USA and the European 
Union (EU).19 
While antibiotic resistance does occur naturally, there is general consensus in the scientific 
and governmental communities that the abuse and misuse of antibiotics is largely responsible for 
accelerating the process.22 Anti-microbial resistance happens when microorganisms exposed to 
antimicrobial drugs change and ultimately become resistant to antibiotics used in human medicine. 
This concern about antibiotic resistance has led to a ban on the use of antimicrobials in animal feed 
as growth-promoting substances in most countries.36 
Currently, while hundreds of antibiotics are commercially available for human and animal 
treatment, only few of them are approved for use in food-producing animals, mainly due to 
concerns over the transfer of antibacterial resistance from animals to humans.19 The antibiotics 





The world’s first antibiotic, a β-lactam called penicillin, was first discovered in 1928 by 
Alexander Fleming.33 While the antibacterial properties of mold had been known previously, 
penicillin was not known until Fleming identified the Penicillium strain as the active substance.37 
Penicillin, however, was not recognized as a life-saving drug until a decade later, when Florey and 
Chain developed a method to purify and concentrate penicillin, and test its effects on laboratory 
mice.19 β-Lactams, divided into two major classes, the cephalosporins and penicillins, have at their 
basic structure a four-membered lactam ring, known as a β-lactam ring, and a variable side chain 
that accounts for the major differences in their chemical and pharmacological properties.  
Figure 1.1 Molecular structures of penicillin G, cloxacillin, and cephapirin. Structures were obtained 
from chemspider.com. 
The primary distinguishing structural difference between penicillins and cephalosporins is 
the thiazolidine ring attached to the lactam ring. In penicillins, such as penicillin G, the lactam ring 
is fused to a five-member thiazolidine ring, while in cephalosporins such as cephapirin shown in 




activity as well as for reduced stability in alcohols and acidic solutions. β-lactams are also 
thermolabile.38–40 Representative compounds for β-lactams are shown in Figure 1.1. 
1.2.1.2 Fluoroquinolones 
Fluoroquinolones are synthetic antibiotics derived from 3-quinolinecarboxylic acid. The 
main difference between older classic quinolones and the recently introduced fluoroquinolones is 
that the latter contain a fluorine atom at the C-6 position and a piperazinyl group at the C-7 
position. These two structural differences increase antibacterial activity against Gram-positive and 
Gram-negative bacteria, respectively, endowing fluoroquinolones with a broad spectrum of 
antibacterial activity.38 Fluoroquinolones are widely used in human and veterinary medicine for 
the treatment of a variety of illnesses, and are largely prescribed to treat gastrointestinal and 
respiratory infections.39,41 Their widespread use in food-producing animals is of great concern due 
to recent evidence linking increased bacterial resistance in humans to the use of these antibiotics 
in food-producing animals.42,43 Representative fluoroquinolones, namely ciprofloxacin, 
enrofloxacin, and sarafloxacin, are shown in Figure 1.2. 
Figure 1.2 Molecular structures of ciprofloxacin, danofloxacin, and enrofloxacin. Structures were 




1.2.1.3 Macrolides and lincosamides 
Macrolides are basic macrocyclic compounds that have a common 14-, 16-, or 17- membered 
macrocyclic lactone ring linked by glycoside bonding to one or more molecules of deoxy 
sugars.38,39 They are widely used in veterinary medicine to treat respiratory diseases, as well as 
feed additives to promote growth.40 Erythromycin, shown in Figure 1.3, is an example of a 14-
membered ring. Macrolides are reported to be unstable in both acidic and basic aqueous solutions. 
Lincosamides constitute a small group of antibiotics that includes compounds such as lincomycin 
and clindamycin, shown in Figure 1.3. Lincomycin was the first member of the lincosamide class 
that was reported in the literature.44 They mainly consist of three components: an amino acid and 
a sugar (lincosamine), that are connected by an amide bond.45 Both macrolides and lincosamides 
target the bacterial ribosome and inhibit protein synthesis.38 
Figure 1.3 Molecular structures of lincomycin, erythromycin, and clindamycin. Structures were 
obtained from chemspider.com  
1.2.1.4 Phenicols 
Phenicols such as chloramphenicol, florfenicol, and thiamphenicol, shown in Figure 1.4, are 




active against a variety of pathogens through interaction with their ribosomes, resulting in 
inhibition of protein synthesis.38,39 The p-nitro group attached to the benzene ring in 
chloramphenicol has been associated with the causation of irreversible dose-independent aplastic 
anemia in some humans, and as a result, chloramphenicol use in food-producing animals has been 
banned in Canada, USA, and the EU.16,46,47 Thiamphenicol and florfenicol, which are structurally 
similar but lack the p-nitro group, have been introduced as substitutes for chloramphenicol.38 
Because they lack the p-nitro moiety, neither thiamphenicol nor florfenicol are associated with 
dose-independent aplastic anemia in humans or any other species, but both are associated with 
dose-dependent bone marrow suppression in humans.19 
Figure 1.4 Molecular structures of thiamphenicol, chloramphenicol, and florfenicol. Structures were 
obtained from chemspider.com 
1.2.1.5 Sulfonamides 
While much of the credit is given to penicillin as the first antibiotic, the first commercially 
available synthetic antibiotic belongs to the sulfonamide group,48 which is comprised of broad-
spectrum synthetic antibiotics that are active against gram-positive and gram-negative bacteria.2,49 




structural requirements for antibacterial activity. The sulfonamides of this group differ in the 
radical attached to the amido group, or occasionally, in the substituent on the amino group.50 
Representative compounds are presented in Figure 1.5. Sulfonamides have amphoteric properties 
imparted by the weak basic anilinic nitrogen and the weakly acidic sulfonamide group present in 
their structure.38,39 Several sulfonamides are usually combined in one preparation and administered 
to animals to reduce toxicity and cover a wider activity range. Sulfonamides are potentially 
carcinogenic and highly susceptible to antibiotic resistance in humans. Their antibacterial activity 
has been greatly diminished due to the extensive resistance that has developed throughout their 
over 70 years of use.40 
Figure 1.5 Molecular structures of sulfachloropyridazine, sulfanitran, and sulfadoxine. Structures 
were obtained from chemspider.com 
1.2.1.6 Tetracyclines  
Tetracyclines are broad-spectrum antibiotics that are widely used in veterinary medicine 
against both Gram-positive and Gram-negative bacteria by inhibiting their protein biosynthesis. 
Because tetracyclines are relatively inexpensive, they are also widely used for cost-effective 





From an analytical perspective, tetracyclines are not stable in bases, and they can decompose 
rapidly under the influence of light and atmospheric oxygen. They are also susceptible to 
configurational degradation to their 4-epimers in aqueous solutions and during sample preparation. 
They also have the ability to chelate with metal ions and interact with silanol groups.52,53 
Representative tetracyclines are shown in Figure 1.6. 
Figure 1.6 Molecular structures of chlortetracycline, doxycycline, and tetracycline. Structures were 
obtained from chemspider.com 
1.2.2 Anthelmintics 
The term anthelmintic is derived from the Greek words anti - ‘against’, and helminth – 
‘intestinal worm’; therefore, anthelmintics are a group of antiparasitic drugs that are active against 
internal parasites without causing significant damage to the host.39 However, they have also been 
exploited for other uses due to their ability to increases milk yield in lactating animals.13 
Levamisole, albendazole, cambendazole, fenbendazole, oxfendazole, thiabendazole, and 
ivermectin are the most frequently used of these drugs.54 One of the main concerns arising from 
the use of anthelmintics in food-producing animals is the emergence of resistance in humans, 
particularly as most anthelmintics are thermally stable and can withstand conventional cooking 




Figure 1.7 Molecular structures of Albendazole, cambendazole, and levamisole. Structures were 
obtained from chemspider.com 
1.2.3 Non-steroidal anti-inflammatories  
Non-steroidal anti-inflammatory drugs (NSAIDs) have analgesic and fever-reducing effects 
at low dosages, and anti-inflammatory effects at higher doses.55 The term “non-steroidal” is used 
to distinguish these drugs from steroids, which are also prescribed for their anti-inflammatory 
effects. While NSAIDS are often chemically unrelated, most of them are organic acids consisting 
of a carboxylic and/or phenolic functional group.13,39,55 While a wide variety of NSAIDs are 
available for human and veterinary use, only a few are licensed or commonly used in food-
producing animals due to concerns over animal safety, lack of efficacy, or drug residues. The most 
common NSAIDs administered to food producing animals include ketoprofen, flunixin, and 
meloxicam, which are shown in Fig 1.8. 






β-Agonists are synthetically produced phenethanolamines that have been used in medicine 
for more than three decades as bronchodilating agents for the treatment of asthma and chronic 
obstructive pulmonary diseases due to their relaxing effect on muscles.12 Their ability to increase 
lean body mass in animals by increasing meat-to-fat ratios has been demonstrated in several 
studies.12,39 This characteristic has led to the illicit exploitation of these compounds to enhance 
leanness in livestock. 
Serious concerns over the misuse of β-agonists began to emerge in the early 1990s after 
reports of several human intoxication incidents worldwide. The first outbreak was reported in 
France, where 22 people were poisoned as a result of consumption of veal liver contaminated with 
clenbuterol residues. Within the next two years, 232 cases were reported in Spain, where people 
complained of a variety of symptoms, including racing heart, dizziness, nausea, headaches, and 
peripheral tremors following ingestion of veal liver and possibly veal tongue.16,56 Similar incidents 
were also reported in Italy, Hong Kong, and Portugal.16 As a result, an absolute ban was placed on 
β-agonists in food-producing animals in the EU, Russia, and China.57–59 However, two β-agonists 
are still approved for use for this purpose in food-producing animals within the US and Canada. 
They are administered to enhance feed efficiency and produce leaner meat, namely ractopamine 
for use in swine, turkeys and cattle, and zilpaterol for use in cattle only.3,60,61 The beef hormone 
dispute between the EU and the USA and Canada is considered one of the longest-standing trade 
disputes due to the use of β-agonists and hormones, ractopamine in particular.58,62 In Canada, the 




zilpaterol removed it from the Canadian market due to animal welfare problems.3 The molecular 
structures of clenbuterol, ractopamine, and salbutamol are shown in Fig 1.9. 
Figure 1.9 Molecular structures of clenbuterol, salbutamol, and ractopamine. Structures were obtained 
from chemspider.com 
1.2.5 Coccidiostats 
Coccidiostats or anticoccidial agents are used to treat coccidiosis, a highly contagious 
infection caused by single-cell protozoan parasites that affect the intestinal tract.63 These parasites 
are prevalent in the warm humid conditions normally observed in high density rearing 
environments in which animals such as pigs and poultry are intensively reared.39,64,65 Coccidiosis 
costs the Canadian poultry industry in excess of $50 million annually despite an annual 
expenditure of more than $85 million on preventive drugs.66 To counteract this threat, most 
intensively reared animals are given coccidiostats as feeds additives for the whole or the majority 
of their growing periods, with a withdrawal of medication time of 1–5 days prior to slaughtering.39 
Whilst acute toxicity in humans has never been reported, coccidiostats such as 5-nitroimidazoles 
have been found to display mutagenic and carcinogenic properties, and as a result have been 




nitroimidazole compounds, namely dimetridazole, ronidazole, and ipronidazole, are shown in 
Figure 1.10.  
 
Figure 1.10 Molecular structures of dimetridazole, ipronidazole, and ronidazole. Structures were 
obtained from chemspider.com 
1.2.6 Sedatives and Tranquilizers 
Food animals raised in intensive farming units are prone to stress due to overcrowding, 
especially during loading and transportation to the slaughterhouse. Stress in food-producing 
animals reduces the quality of their meat and may even lead to death of animals as a result of a 
heart attack.39,40,54 Sedatives and tranquilizers are often used to induce calmness and reduce anxiety 
as a means to manage stress and minimize death and injury of food animals. It has also been 
reported that tranquilizers have been used as feed additives to enhance growth rates and improve 
milk yield due to their ability to slow down metabolic processes and reduce animal activity.70 On 
the basis of their chemical structure, sedatives and tranquilizers are classified into four families: 
butyrophenones, phenothiazines, benzodiazepines, and imidazopyridines. Major members of the 




chlorpromazine, and butyrophenone-type drugs such as azaperone. The molecular structures of 
these compounds are presented in Figure.1.11. 
 
Figure 1.11 Molecular structures of acepromazine, azaperone, and Chlorpromazine. Structures were 
obtained from chemspider.com 
1.2.7 Thyreostats 
Thyreostatics or antithyroid agents inhibit the synthesis of thyroid hormones, which regulate 
metabolism and as a result moderate animal weight.12,39 The use of these drugs also result in 
considerable animal weight gain due to increased water retention in edible tissues and 
accumulation in the gastrointestinal tract.71,72 This class of drugs can be exploited as growth 
promoters as well as utilized fraudulently to fatten animals prior to slaughter. In addition to the 
negative effects on the quality of meat, thyreostats are potentially harmful to humans due to their 
teratogenic and carcinogenic properties.73 The most powerful and most frequently abused 
thyreostatic agents in cattle are thiouracil and its analogues, methylthiouracil, propyl thiouracil, 




analysis of these molecules pose a challenge due to their high polarity which affects their retention 
in reverse phase LC and their small molecular weight that makes them susceptible to chemical 
noise in the mass spectrum.74 
Figure 1.12 Molecular structures of methylthiouracil, propylthiouracil, and 6-phenyl-2-thiouracil. 
Structures were obtained from chemspider.com 
1.2.8 Others 
Veterinary drugs listed in the FSIS-USDA method that do not fall into any of the previous 
categories include carbadox and its metabolite 2-quinoxalinecarboxylic acid, bacitracin, 
novobiocin, virginiamycin, and melengesterol acetate. 
Carbadox is an antimicrobial agent used to control swine dysentery and bacterial swine 
enteritis. Due to its growth promotion effects, it has been exploited as an animal feed additive.39 
Since carbadox is a suspected carcinogen, it has been banned in Canada and the EU; however, the 
use of carbadox is still approved in pigs in the US for up to 42 days before slaughter.75,76 
Bacitracin is a cyclic polypeptide antibiotic that is active against Gram-positive bacteria by 
affecting protein synthesis.77 Since it has growth promotion effects, it is considered as an AGP that 




frequently used in combination with penicillin for treatment of bovine mastitis.39 Virginiamycin is 
a mixture of macrocyclic lactones with a peptide part, collectively called peptolides. It is also 
considered an AGP, and has been reported to increase egg production in laying hens.39 Canada and 
the US are required to certify that meat products intended for export to the EU are free from 
AGPs.77 Melengesterol acetate is a synthetic steroidal hormone administered as a feed additive to 
heifers intended for slaughter. While it is widely used in the US, it is not approved for use in the 
EU. In Canada, similar to all hormones and growth promoters, the only approved use for this drug 
is in the production of beef cattle. It is illegal to administer melengesterol acetate to dairy cows to 
increase milk production, or to any other food animal species.78,79  
Figure 1.13 Molecular structures of carbadox, melengestrol acetate, and virginiamycin. Structures 
were obtained from chemspider.com 
1.3 Regulatory framework 
Since the use of veterinary drugs in food producing animals is essential to the maintenance 
of a sustainable animal food industry, developed countries have established several measures and 
extensive regulatory controls to prevent veterinary drug exploitation in the food-animal industry 
and safeguard consumer health. In Canada, Health Canada through the Veterinary Drugs 




assessments of veterinary drugs under the Food and Drugs Act (R.S.C., 1985, c. F-27).80 Risk 
assessments are conducted by performing the following six steps:81 
1. Review of metabolism studies of veterinary drugs conducted in food-producing 
animals to determine the length of time it takes for a given drug and its metabolites to 
be excreted, as well as their amounts.  
2. Review of comparative metabolism studies conducted in laboratory test animals to 
ensure that similar patterns of metabolism exist in these animals. 
3. Toxicity of the substance is determined by toxicity/carcinogenicity testing. This 
information allows VDD scientists to determine the Acceptable Daily Intake (ADI) 
quantity, which is defined as the safe quantity of a given substance that can be 
consumed by humans on a daily basis over a lifetime without posing a threat to their 
health. 
4. After determining the ADI, safe concentrations for total residue levels are established 
by ensuring that consumption of edible tissues does not exceed the ADI. A maximum 
residue limit (MRL) is then set for the concentration of the marker residue that will 
ensure that humans are not exposed to residues levels above the safe concentrations 
for the total residues. MRL is defined by Health Canada as the maximum amount of 
residue that could safely remain in the edible tissue of the treated animal.82 At its MRL 
level or below, a residue is considered to pose no adverse health effects if ingested 




5. The analytical methodology developed for the marker residue in food is evaluated. 
6. A withdrawal period is then established based on residue depletion data for the specific 
residue in the target tissue. 
Similarly, in the U.S.A., the Food and Drug Administration’s (FDA) Center for Veterinary 
Medicine (CVM) establishes tolerances for veterinary drugs under the Federal Food, Drug, and 
Cosmetic Act (FFDCA).83,84 In the EU, the use of veterinary drugs is regulated through Council 
Regulation 2377/90/EC, which also describes the procedure for the establishment of MRLs.54 In 
China, the ministry of agriculture  issues maximum residue levels for veterinary drugs in food of 
animal origin.22 
At the international level, MRLs are established by the Codex Alimentarius Commission 
(Codex), a joint initiative between the Food and Agricultural Organization and the World Health 
Organization.85 MRLs for veterinary drugs developed by Codex play an important role as trading 
standards to facilitate fair practices and ensure the quality of imported and exported meat.13,18,86 
Consumers rely on regulatory authorities to ensure that foods derived from animals treated 
with veterinary drug products are safe for consumption. 
Monitoring of veterinary drug residues in foodstuffs is necessary to ensure that MRLs are 
not breached, and that only approved drugs are used. In Canada and the USA, the Canadian Food 
Inspection Agency (CFIA) and FSIS  are respectively responsible for monitoring residues of drugs 




ensure that food derived from animals treated with veterinary drugs does not contain residues that 
pose a health hazard to consumers.2,18,83,84 
1.4 Analytical approaches for multi-residue veterinary drugs 
Analysis of veterinary drug residues in animal-tissue samples is a challenging task due to a 
variety of factors, including the complexity of the matrix, the large number of analytes with a wide 
range of physico-chemical properties that must be taken into consideration, the often very low 
concentration levels of said compounds that the method must be able to detect, and the large 
number of samples that must be analyzed. As a result, high-throughput multi-residue multi-class 
methods (MMM) i.e., methods capable of analyzing residues of multiple compounds belonging to 
different classes in a single run, are preferred by regulatory agencies and food testing laboratories 
due to their time-saving abilities and cost-effectiveness.32,38,84,87,88 
In Canada and the EU there is no obligation to use standardized methods for residue analysis, 
as long as established performance characteristics are met by the methods used. This approach 
offers a significant advantage in that it allows development and introduction of new analytical 
methods.73 
In 2012, the FSIS started employing MMMs as a means to analyze more compounds per 
sample and reduce the overall amount of required samples. Despite the continual increase of VD 
residues, the use of MMMs has helped expand the total number of samples per animal population 




violation to 99% if the violation rate is equal to or greater than 1% of the population of animals 
being sampled.83 
Development of MMMs has been facilitated by the recent major advances in both liquid 
chromatography (LC) and mass spectrometry (MS) technologies.89,90 The introduction of ultra-
high performance liquid chromatography (UHPLC), featuring sub-2 μm stationary phase particles, 
and fast MS/MS scanning (<10 ms), has enabled detection of larger numbers of compounds within 
one run.6,90 Narrower peaks and consistent retention times afforded by UHPLC enable narrower 
multiple reaction monitoring (MRM) windows and longer MS/MS dwell times per analyte, and 
therefore, notable improvements in quantitative and qualitative analytical performance.5,91 
Currently, LC coupled with electrospray ionization (ESI)-tandem mass spectrometry 
(MS/MS) in selected reaction monitoring (SRM) acquisition mode is the main analytical platform 
for MMMs.92 High resolution MS (HRMS) instruments such as time-of-flight (ToF-MS) and 
orbitrap have also been successfully used for multi-residue analysis, mainly for screening 
purposes.9 Berendsen et al. comprehensively evaluated the use of LC-MS/MS in SRM mode and 
high-resolution HRMS with respect to the selectivity of 100 veterinary drugs in liver, muscle, and 
urine extracts, and concluded that MS/MS using SRM mode is more selective than single stage 
full-scan HRMS monitoring only the molecular ion and allowing a ±5 ppm mass tolerance. The 
authors concluded that full scan alone is insufficient for confirmatory analysis.93 However, HRMS 
can be fit for the purpose for confirmatory analysis when monitoring the molecular ion in full scan 
and one fragment ion after precursor ion selection.93 In terms of detectability, Hou et al. compared 




The results demonstrated that MS/MS in SRM mode has higher detectability for low amounts of 
residues (<1 µg·kg−1), whereas QTOF-MS provided comparable results to MS/MS for higher 
residue concentrations (>10 μg·kg−1).94 Accordingly, acquisition in SRM mode isolating one 
precursor ion while monitoring two product ions is considered the benchmark for any reliable 
confirmation of target analytes and the gold standard for both quantification and screening of 
veterinary drug residues.1,5,13,17,22,95 
With that said, and considering the old adage, “you can only find what you are looking for”, 
a major limitation of the MS/MS approach is that it is only capable of detecting targeted drugs, 
while HRMS have the clear advantage of retrospective data analysis.93 Moreover, HRMS allows 
for screening of a theoretically unlimited number of residues, and thus, detection of unknown drugs 
and low dose cocktails.73 
1.5 Sample preparation approaches for multi-residue veterinary drugs 
Quantification of veterinary drugs in animal tissue samples can be daunting due to the high 
contents of protein, fat and phospholipids present in this type of complex matrix.96 The major 
components of a typical meat sample are water (up to 70%), protein (15–25%), fat (5–25%) and 
phospholipids (1–3%).97 Improper sample preparation and clean-up can lead to the presence of 
interferences from co-eluting components, which adversely affect the signal and compromise the 
analytical outcome.40,92,98 Accordingly, a successful outcome for an MMM depends mostly on 
adopting a sample preparation workflow that minimize interferences from proteins and 




spectrometric analysis.84 While the modern UHPLC–MS/MS platform is very powerful in terms 
of detectability and selectivity, it simply cannot replace proper sample preparation.99–101 
Conventional sample preparation is considered to be the Achilles’ heel of any analytical 
workflow, as it typically takes more than 70% of the total analysis time.98 Considering the high 
throughput requirements imposed by MMMs, sample preparation time must be minimized 
sufficiently so as to render the MMM applicable to fast, high-throughput analysis of extensive 
quantities of samples within very short timeframes.  
Further, an ideal sample preparation procedure for an MMM must be able to not only address 
an increasing number of analytes with a wide range of physical and chemical properties, but must 
also be applicable to different types of matrices.96,102 Therefore, sample preparation procedures 
that are very generic, non-selective, and allow for sufficient recovery of as many analytes as 
possible from different matrices are ideally suited for this type of application.22,90  
In this context, and since this thesis is mainly focused on multi-class multi-residue veterinary 
drug methods in animal tissue, the scope of the following sub-sections will only discuss generic 
sample preparation procedures for LC-MS based analysis. 
1.5.1 Solvent extraction without clean-up 
Solvent extraction (SE) or liquid extraction of homogenized tissues is the first and most 
essential sample preparation step in conventional LC-MS based analysis of VD residue in tissue 
samples. Prior to extraction of residues from tissue samples, a homogenization step is carried out 




residues. Cryogenic sample comminution with dry ice or under liquid nitrogen has been 
demonstrated to achieve much better sample homogeneity as it transforms the sample to a uniform 
fine powder and also reduces the degradation of labile analytes.103 
SE only, i.e., without any further clean-up steps, is considered the fastest, simplest, and most 
economic extraction method among conventional methods.13 Accordingly, it is frequently reported 
in the literature as a method of choice.91,104 An ideal generic extraction solvent for this method 
should offer efficient extraction of as many target analytes as possible while minimizing the 
extraction of matrix constituents so as to prevent excessive matrix effects (MEs).90 The selection 
of a suitable solvent therefore depends not only on the analytes under study, but also on the matrix. 
SE is often performed with organic solvents such as acetonitrile, methanol, acetone, or ethyl 
acetate, since such solvents allow simultaneous precipitation of proteins and extraction of a wide 
range of target analytes.91,104 Mol et al. investigated the performance of acetonitrile (MeCN), 
methanol (MeOH) and acetone (ACE) as extraction solvents for extraction of 86 veterinary drug 
residues belonging to several drug classes in milk, muscle, egg, honey, and feed matrices.102 The 
authors found that MeOH performed worst in term of MEs, which led to ion suppression during 
detection, probably due to inadequate protein precipitation. While acetone was found to yield the 
highest recoveries across all tested matrices, it delivered a sub-optimal performance compared to 
MeCN in terms of MEs. Further, the authors determined that solvent suitability was mostly 
dependent on the matrix under study, and MeCN was selected as the solvent of choice for 




Similarly, Chen et al. performed a comparison of three organic solvents, MeCN, MeOH, and 
ethyl acetate, using ultrasound-assisted extraction (UAE) for screening of multi-residue veterinary 
drugs in food-animal tissue, milk, and eggs.88 The authors reached a similar conclusion to Mol et 
al. that MeCN offered the best extraction efficiency of analytes and least MEs compared to MeOH 
and ethyl acetate, as the latter solvents tend to extract too many matrix components, complicating 
analysis or any further clean-up procedures.88,99 MeCN in general is the most common generic 
extraction solvent used in tissue analysis due to its ability to precipitate proteins which is 
considered the first clean-up step for tissue analysis.90,99,105 However, MeCN does not sufficiently 
extract polar analytes such as tetracyclines and penicillins.32,88,91,106 To enhance extraction of polar 
analytes, a mixture of MeCN and water is usually employed as extraction solvent. Higher MeCN 
fractions decreases the extraction efficiency of the more polar analytes, while higher fractions of 
water lead to higher co-extraction of the matrix components.106,107 Chen at al. tested different ratios 
of MeCN:water (90:10, 80:20, and 70:30), and found (90:10, v/v) to provide the highest recovery 
rate of analytes under investigation. Yet, scientists from the USDA selected 4:1 MeCN/water as 
their extraction solvent for the current MMM used for extraction of bovine muscle after testing 
different ratios.9,32,84,91 
Following SE and prior to instrumental analysis, centrifugation and sometimes ultra-
filtration are applied to assist in separating the supernatant from the tissue and protein 
precipitates.96,102 However, many reports established that ultra-filtration tends to not only 
selectively adsorb certain analytes and affect recoveries, but also has the potential to introduce 




protein interferences present in animal tissue, fat and phospholipids, which can introduce matrix 
effects, remain dissolved in MeCN extracts. To address this drawback, defatting of the extracted 
solvent with hexane has been utilized in different works.84,89,109 However, the use of hexane was 
found to cause losses of less hydrophilic compounds. Furthermore, final extracts were found to 
contain trace amounts of hexane, which could adversely impact chromatography.32 
To increase the detectability of MMM and enhance chromatography, sample extracts are 
often evaporated to near dryness and then reconstituted with a solvent compatible with the mobile 
phase used in the LC method.84,104,109 
Assisted SE techniques such as pressurized liquid extraction (PLE) or supercritical fluids, 
which utilize high pressure to heat water above its atmospheric boiling point instead of utilizing 
an organic solvent, have been applied to improve extraction efficiency and reduce the use of 
organic solvents.90,96,110 However, the high temperatures used in PLE render such techniques 
incompatible with analytes with low thermal stability. For example, degradation of macrolides has 
been observed with PLE at temperatures above 100 °C. 
While SE is a simple and cost-effective sample preparation technique, one of the main 
disadvantages is the use of large amounts of organic solvents and generation of organic waste due 
to the use of large amounts of organic solvents. Another evident drawback of SE is the occurrence 
of abundant matrix effects, which compromise detection limits, quantitative aspects, and method 
selectivity, in addition to increasing instrument maintenance frequency and accordingly, the 




1.5.2 Solvent extraction followed with sorbent clean-up 
1.5.2.1 Solid Phase Extraction (SPE) in cartridge format 
SPE is frequently used in its conventional packed cartridge or column format as a clean-up 
technique in the analysis of veterinary drugs in animal tissue.90,96 There are two modes of SPE 
clean-up: 
1. Conventional SPE mode, in which the solvent extract is applied to the sorbent to 
selectively adsorb and retain the analytes of interest, while allowing matrix components 
to pass through and be discarded, followed by a weak solvent wash step to remove matrix 
interferences and subsequent elution of the analytes of interest from the cartridge with a 
stronger solvent.88,111,112 
2. Flow-through mode SPE, in which the sample extract is applied to a sorbent in a highly 
organic solvent, in such a way that the analytes remain dissolved in the solvent. The 
eluent is immediately collected for further analysis while the matrix components are 
retained by sorbent.106,112 
While conventional SPE clean-up is suitable for single compound methods where selective 
wash and elution steps can be used effectively to separate the target compounds from matrix 
interferences, its application is not suitable in multi-class methods due to the diverse range of  
physico-chemical properties of target analytes. For example, reverse phase (RP) sorbents such as 
C18 and C8, are not suitable for polar compounds due to their selective affinity for hydrophobic 




and concluded that conventional SPE lead to significant losses of many analytes. The authors 
concluded that the conventional SPE method was not suitable for simultaneous extraction of 
several classes of veterinary drugs.112 A similar conclusion was made by Zhao et al.113 Moreover, 
Souverain et al found that SPE tends to concentrate not only the analyte but also matrix 
components, which may significantly increase ionization suppression.114 
Regardless of the SPE mode used, silica-based sorbents are susceptible to the binding of 
tetracyclines to free silanol groups, which can lead to significant losses of these analytes during 
the clean-up step.115,116 In efforts to eliminate silanol group interactions and extend the scope of 
SPE sorbents for a broad range of compounds with different physico-chemical properties, 
polymeric sorbents with both polar and non-polar affinities, such as hydrophilic-lipophilic balance 
(HLB), were introduced as alternatives to silica-based sorbents. The HLB sorbent consists of a 
copolymer of the hydrophilic N-vinylpyrrolidone to increase water wettability, and lipophilic 
divinylbenzenes, which assist in the reversed-phase retention of analytes. Frenich at al. compared 
C18 and HLB sorbents in the flow-through SPE method and found poor recoveries for tetracyclines 
with C18.
112 
While SPE in flow-through mode might be more suitable for MMM than conventional SPE, 
both modes share certain limitations, such as loss of analytes due to blocking of sorption sites by 
fatty components originating from lipid-rich samples, difficulties in achieving consistent flow, and 




1.5.2.2 Dispersive SPE/QuEChERS 
Dispersive SPE (d-SPE) is a sorbent based clean-up approach that involves the use of solid 
sorbents in dispersed form to bind to matrix components in the sample extracts.96 It is best known 
for its use in the QuEChERS (quick, easy, cheap, effective, rugged, and safe) method. To separate 
the purified solvent extracts from the sorbent material, centrifugation and sometimes filtration 
prior to instrumental analysis are needed. The QuEChERS approach found popularity over the 
well-established conventional SPE method due to its quick and easy extractions, which eliminate 
clogging concerns while maintaining the clean-up advantage.13,89 For samples of animal origin, 
which have higher lipid contents, the selected sorbent material is usually a reverse-phase material 
such as C18. The original QuEChERS method achieves phase separation via addition of inorganic 
salts; however, use of salt may cause loss of sensitive or polar analytes due to metal chelation, 
degradation, or limited solubility of polar compounds in MeCN.113 Scientists from the USDA 
evaluated several materials for use as clean-up sorbents, including end-capped C18, graphitized 
carbon black, Z-Sep, and Z-Sep+ (zirconium oxide-based materials from Supelco), a polymeric 
ENV+ from Biotage, and enhanced-matrix removal of lipids (EMR-L), a new material from 
Agilent. While the structures of these sorbents were not disclosed, in the case of EMR-L, it is 
mentioned that the mechanism involves size exclusion and hydrophobic interactions.9,32,84,109 As a 
compromise between sample throughput, recovery, and cleanliness of sample extracts, the authors 
selected C18 as the clean-up sorbent for their final method. The authors determined that while the 
E-MRL method provided cleaner extracts than C18, it was not suitable in terms of throughput and 




sorbent, consequently adding cost and time to the already lengthy sample preparation step.9 
However, the authors did not include in their studies an assessment of increased instrument 
maintenance requirements due to the introduction of dirtier extracts, which in the long run impact 
downtime and cost. Nevertheless, following further investigation of matrix effects in their latest 
MMM evaluation, the authors concluded that the sample extract clean-up provided by the d-SPE 
method step does not merit the extra time and effort, nor the reduction of analytical scope that is 
incurred. Instead, the authors opted for injecting a small sample equivalent by using a large dilution 
factor.91 Similarly, Robert et al., after investigating several SPE clean-up methods and sorbents, 
skipped the sorbent clean-up step due to the loss of certain analytes and the added time, effort, and 
cost associated with this step.104 While large dilution factors were demonstrated to be more 
efficient than d-SPE in minimizing matrix effects, it can complicate the method’s limit 
detectability.12 
While the QuEChERS/d-SPE approach offers several advantages over conventional SPE, it 
is obvious from the abovementioned studies that it does not provide efficient clean-up and thus 
higher matrix effects in addition to partial loss of the analytes.9,13,104 
Similar to SE only, both SPE and d-SPE require the use of large sample volumes of toxic 
organic solvents resulting in large volume of hazardous waste, which make these techniques not 
only time-consuming, but also environmentally harmful.13 
Given the challenges and limitations associated with the conventional methods described 
above, an alternative sample preparation approach is required to address the pressing analytical 




residue drug analysis in tissue samples should be non-selective, as well as able to isolate and enrich 
a wide range of analytes from matrix components while using a minimum amount of analytical 
steps, and generating minimum amounts of solvent waste. Moreover, it should be suitable for 
automation and high-throughput analysis. 
1.6 Solid phase microextraction (SPME) 
1.6.1 Theoretical aspects of SPME 
Solid-phase microextraction (SPME) is a versatile sample preparation technique developed 
in 1989 by Pawliszyn and co-workers at the University of Waterloo.118 SPME was originally 
designed as a fused silica fiber coated with a thin polymeric extraction phase for equilibrium based 
extraction of volatile and semi-volatile organic compounds from air and water for analysis with 
gas chromatography (GC).118,119 In the last three decades, the applicability of SPME has 
substantially expanded to offer numerous geometrical configurations with different substrates and 
coating chemistries that allow direct extraction of a wide range of analytes from a broad variety of 
complex liquid and solid matrices, for both GC and LC applications. For volatile and semi-volatile 
analytes, the extraction process can be carried out either by exposing the SPME extractive phase 




sample matrix, as shown in Figure 1.14, whereas successful extraction of low volatility compounds 
is carried out using direct immersion mode only. 
Figure 1.14 SPME modes of extraction 
After the extraction process with SPME is complete, the extracted analytes are desorbed 
from the extractive phase either thermally using high-temperatures, or by using a solvent with 
strong affinity for the target analytes. The desorption step is generally followed by instrumental 
analysis in GC or LC platforms.120,121 
An in-depth understanding of SPME theory is crucial for successful development of SPME 
methods, as analysts must be able to identify, control, and exploit the various parameters that 
influence SPME extraction in order to develop and optimize a method for a given application.122 
First and foremost, unlike SE and SPE, SPME is based on the non-exhaustive extraction of 
quantities of analytes that are proportional to the concentrations of said analytes in a sample matrix. 










∞       Equation 1.1 
where 𝐶𝑒
∞ and 𝐶𝑠
∞ are the analyte equilibrium concentrations in the extractive phase and the 
sample, respectively. 𝐾𝑒𝑠 is mainly dependent on the physico-chemical properties of the analyte 
of interest and the extractive phase used. Extraction conditions that affect 𝐾𝑒𝑠 are temperature, 
ionic strength, pH, and organic solvent content. At equilibrium, in the case of direct immersion 
extraction using a liquid-based extractive coating, where the analyte diffuses within the complete 
volume of the extractive phase during the extraction process, the amount of analyte extracted by 
the extractive phase (𝑛𝑒) is given by Equation 1.2:
123,124 




       Equation 1.2 
where 𝐶𝑠
0 is the initial sample concentration, 𝑉𝑠 is the sample volume, and 𝑉𝑒 is the volume 
of the extractive phase. When the sample volume, 𝑉𝑠 , is much larger than 𝐾𝑒𝑠𝑉𝑒, Equation 1.2 can 
be reduced to: 
𝑛𝑒 = 𝐾𝑒𝑠𝑉𝑒𝐶𝑠
0       Equation 1.3 
Therefore, according to SPME fundamental principles, as shown in equations 1.2 and 1.3, 




In case of solid adsorptive coatings, where the volume of surface-active sites should be taken 
into consideration, 𝑛𝑒 can be calculated using Equation 1.4:  






      Equation 1.4 
where 𝐶𝑓 𝑚𝑎𝑥 is the maximum concentration of active sites in the solid coating, 𝐶𝑓
∞ is the 
equilibrium concentration of the analyte in the extractive phase, and 𝐾𝐴𝑓𝑠 represents the analyte’s 
adsorption constant, which is the ratio of the surface concentration of the adsorbed analyte on the 
porous solid extractive phase (𝑆𝐴𝑓




When extraction is performed from a heterogeneous sample, such as biological fluids or 
tissue, the amount of analyte extracted by SPME is directly proportional to the unbound 
concentration of the drug present in the sample system, and can be calculated by modifying 
Equation 1.2 to the following equation: 







       Equation 1.5 
Where 𝐾𝑖𝑠 = 𝐶𝑖
∞/𝐶𝑠
∞ is the distribution constant of the analyte between the ith phase and the 
matrix of interest with a volume of 𝑉𝑖. All other terms are defined as in the previous equations. 
1.6.2 Balanced Analyte Coverage 
According to equation 1.5, in case of heterogeneous samples (such as biological fluids or 




(unbound) concentration of the analyte under study.123 This unique characteristic of SPME enables 
it to achieve balanced coverage of analytes with a wide range of physico-chemical properties in 
the presence of matrix components without manifestation of saturation or displacement 
effects.125,126 Essentially, due to the presence of binding matrix components, analytes that usually 
exhibit strong affinities for SPME coatings tend to bind heavily to matrix components, which limits 
their availability in their free form for extraction by SPME. As a result, adsorptive coatings are 
unlikely to become saturated by these compounds within a reasonable extraction time. In contrast, 
compounds with low affinity for SPME extraction phases, such as polar compounds, typically 
demonstrate low protein binding affinity, resulting in a high proportion of these chemicals 
becoming freely available in the sample in comparison to hydrophobic compounds. Yet, due to the 
lower affinity of these compounds to SPME coatings, saturation from these compounds is also 
unlikely to take place.127 This phenomenon of balanced analyte coverage, which has been 
demonstrated by experimental data as well as mathematical models by Alam et al., additionally 
leads to minimal extraction of phospholipids, resulting in significant reduction of matrix effects 




1.6.3 Kinetics of solid phase microextraction 
The SPME extraction process generally follows the profile shown in Figure 1.15, where the 
x-axis represents extraction time whereas the y-axis represents the amount of analyte extracted.128 
When the extractive phase is first exposed to the sample, an almost linear mass uptake process 
ensues until extraction time t50, which is defined as the time needed for 50% of the equilibrium 
amount of analyte to be extracted from the sample. Afterwards, the rate of extraction slows down 
until it reaches equilibrium. 
Figure 1.15 Typical extraction time profile for SPME 
A kinetic regime is defined by a steady increase in the amount of analyte extracted. 




that the experimental error is typically about 5%, equilibration time is assumed to be achieved 
when 95% of the equilibrium amount of an analyte is extracted from the sample. Thus, for all 
intents and purposes, t95 is assumed to be the equilibrium time. In a practical agitated system, the 
main factors that influence the time required to achieve equilibrium can be expressed using the 
following equation: 
𝑡95 =
3 𝐾𝑒𝑠 𝑏 𝛿
𝐷𝑠
       Equation 1.6 
where 𝑏 is the fiber coating’s thickness, 𝛿 is the boundary layer, and 𝐷𝑠  is the analyte’s 
diffusion coefficient in the sample fluid. From equation 1.6, we can conclude that the time required 
to reach equilibrium can be very long for analytes that have either very high affinity for the coating, 
δ is too large (e.g. no agitation); or the extractive phase is too thick. 
When time is of importance, and in cases where it takes a long time for all analytes to reach 
equilibrium, a kinetic or pre-equilibrium calibration approach can be employed instead. At such 
conditions, the amount extracted is calculated by using Equation 1.7, where 𝑎 is a time constant 
that represents a measure of how fast adsorption equilibrium can be reached in the SPME process, 
while 𝑡 is extraction time.130 




      Equation 1.7 
It is of course obvious from figure 1.15 that maximum detectability and better reproducibility 
can be achieved through equilibrium extraction. However, for applications where rapid analysis is 




made. Nevertheless, with recent advances in MS capabilities, pre-equilibrium extraction is still 
capable of achieving low limits of quantitation. In addition, as will be discussed in the following 
sections, full automation of the extraction step permits implementation of pre-equilibrium 
extraction without compromising the reproducibility of the method.131 
1.6.4 Thin Film SPME (TFME) 
The low regulatory level requirements that must be met by methods for residue analysis in 
complex sample matrices are one of the key challenges in the development of said methodologies, 
as such methods must have superior detectability, often at trace level, for a large number of 
compounds consisted of a wide range of physico-chemical properties. 
According to SPME fundamental principles, as shown in Equation 1.3, the amount of analyte 
extracted by SPME is proportional to the volume of the extractive phase (𝑉𝑒); thus, SPME 
detectability can be improved with the use of larger extractive phase volumes. While this can be 
accomplished by simply increasing the thickness of the extractive phase, this approach, as 
specified in equation 1.6, would obviously also lead to longer equilibration times, and thus longer 
extraction times and lower sample throughput.132 An alternative approach to increasing the volume 
of the extractive phase that does not compromise extraction time is to increase the surface area of 
the coating. This can be achieved either by increasing the diameter of the SPME fiber, or by using 
a thin-film geometry. It has also been demonstrated that the initial uptake rate of SPME extraction 











where n is the mass of analyte extracted over sampling time t, and A is the surface area of 
the extraction phase. Therefore, the best way to increase the volume of the extraction phase, and 
thus the detectability of the method, is to use a thin extraction phase with a large surface area, as 
this configuration would also additionally improve the uptake rate of the method. This theory 
formed the basis for the development of thin-film SPME (TFME). Another advantage of the TFME 
geometry as compared to a rod geometry with a larger diameter is the higher surface area-to-
volume ratios provided by TFME, which enable configuration of smaller probes that occupy 
significantly less space than the rod geometry. If made sufficiently large, the rod geometry can 
cause displacement of the sample solution and limit the maximum sample volume that could be 
placed in the wells, although smaller sample volumes can also be compensated for by using less 
desorption solvent volumes. 
Although the term TFME may cause some confusion since the extraction phase of traditional 
SPME fibers is essentially a thin film, TFME in this context refers to a thin rectangular flat surface 
geometry with relatively larger surface areas and larger volumes of extraction phase compared to 
traditional fibers.120,134 The most common format of TFME for LC-MS based analysis consist of 
a stainless steel blade coated with an extraction phase.132 
1.6.5 Automated high-throughput SPME 
In modern food safety analysis, increased pressure to produce results in the shortest possible 
turnaround time continues to create high demand for the development of rapid and high-throughput 
methodologies.96,134 Within the SPME context, sample throughput can be significantly increased 




of a multi-well-plate format, resulting in a significant reduction in sample preparation time per 
sample. This type of high-throughput was successfully introduced in 2008 with the use of the 
Concept 96 autosampler.135–137 The Concept 96 autosampler is a fully automated, software-
operated, off-line robotic sample-preparation station designed by Professional Analytical Systems 
(PAS) Technology (Magdala, Germany) to facilitate the simultaneous extraction of up to 96 
samples. While the first application of this automated system was aimed at accommodating SPME 
in its traditional fiber format, the platform has since evolved to accommodate different geometries 
and coating chemistries. 
Figure 1.16 Thin Film SPME (TFME)  
The mechanical robustness afforded by the rigid metal nature of the TFME blades (shown 
in figure 1.16) makes it an ideal format for the Concept 96 autosampler.137 
Combining the advantages of simultaneous extraction of 96 individual samples with larger 




of high-throughput analysis methods that cover a wide range of analytes, including various food, 
environmental, and bioanalytical applications.123,131,145,146,132,138–144 
Figure 1.17 Concept 96 autosampler, Professional Analytical Systems (PAS) Technology  
Some of the major advantages of this system for analysis of tissue samples are its open-bed 
configuration and its ability to perform direct extraction from complex matrices such as dense 
fluids and colloidal suspensions without any need for sample pretreatment or concerns regarding 
clogging, which is a common concern in SPE systems.138 
1.6.6 Biocompatible SPME coatings 
Certainty, one of the main concerns when selecting an SPME coating for open-bed extraction 
from tissue homogenate is the potential adhesion of proteins and other macromolecules to the 




kinetics of analyte uptake and reduce the efficiency of extraction. One of the solutions to minimize 
the attachment of macromolecules to the coating surface is the use of biocompatible coatings. In 
the context of SPME, biocompatible coatings serve two purposes: (i) they prevent adverse and/or 
toxic reactions in living systems and, (ii) they prevent adhesion of macromolecules, such as 
proteins, to the surface of the coating.123 The development of biocompatible SPME coatings can 
be achieved by either direct application of biocompatible extractive phases such as PDMS, or by 
utilizing biocompatible polymers to immobilize non-biocompatible extractive particles onto 
SPME substrates. For instance, while Polyacrylonitrile (PAN), considered one of the best polymers 
in terms of biocompatibility, is not appropriate in itself as an extractive phase for drugs, and 
whereas good extractive materials are generally not biocompatible, as demonstrated by Musteata 
and co-workers, PAN can be used as a binder to immobilize these extractive materials onto SPME 
substrates to form a biocompatible extractive phase.147 The hydrophilic and negatively charged 
polyacrylonitrile minimizes the binding of macromolecules such as proteins and allows for 
selective permeation of small molecules to the extraction phase.120,126,148 Over the last decade, the 
emergence of biocompatible coating chemistries for SPME devices, which hinder fouling of the 
coating by protein adsorption, has enabled employment of direct immersion SPME for analysis of 
complex samples in many applications.148–151 
While PAN as a binder offers the desired biocompatibility characteristic, the selection of 
suitable extractive particles is key to achieving maximum SPME detectability. An ideal coating 
for multi-class multi-residue analysis would offer extraction efficiency for a large number of 




extractive phase consists of a universal sorbent with affinity for both polar and non-polar 
compounds. One example of such a sorbent is Hydrophilic-Lipophilic Balance (HLB) particles. 
HLB particle sorbents are second-generation mesoporous polymers characterized by a high surface 
area that were specifically designed for extraction of low-molecular-weight polar and non-polar 
compounds.152 Due to the respective presence of aromatic rings in divinylbenzene and polar groups 
in the lactam ring of N-vinylpyrrolidone, as can be seen in Figure 1.18, HLB provides balance 
between hydrophobic and hydrophilic interactions. 
 
Figure 1.18 HLB copolymer and PAN structures 
Another advantage of selecting HLB as an extractive phase is its characteristic wettability: 
the hydrophilic N-vinylpyrrolidone increases the water wettability of the polymer, which 
facilitates its interaction with aqueous matrices. 
1.6.7 SPME applications in biological tissue analysis 
Biocompatible SPME probes have facilitated a growing number of studies for the 




offered by SPME in tissue analysis is its tuning capabilities in terms of both the geometry of the 
device and the coating chemistry. The geometry of the device can be customized and miniaturized 
to target specific sampling sites with minimal invasiveness, while the coating chemistry can be 
either selective to target specific analytes or generic to cover a very wide range of analytes. The 
suitability of DI-SPME methodology has been demonstrated and validated successfully for both 
ex vivo and in vivo sampling for targeted and untargeted studies for many different types of tissue 
samples from different matrices, such as fish, as well as muscle, lung, liver, and brain.154 It has 
also been applied successfully for monitoring and sampling tumors and other tissues in humans. 
For instance, SPME fibers were successfully utilized to measure changes in the concentrations of 
selected neurotransmitters, namely, dopamine, serotonin, gamma amino-butyric acid, and glutamic 
acid, in rats brains after fluoxetine administration.155 Another application by Togunde et al. 
employed in vivo non-lethal SPME sampling coupled with LC-MS/MS to quantify drugs such as 
fluoxetine, venlafaxine, sertraline, paroxetine, and carbamazepine in rainbow trout and fathead 
minnow.156 Recently, Roszkowska and colleagues have developed an in vivo SPME-LC-MS/MS 
method for the quantitation of the anticancer drug, doxorubicin in pig lung tissues.157 Preliminary 
experiments were performed using the ex vivo SPME approach, using lamb's lungs as a surrogate 
matrix to optimize the extraction conditions and for ex vivo calibration for doxorubicin. As 
evidenced in the literature, the biocompatibility of SPME together with its flexible tuning 




1.7 Research objective 
In the field of food safety, the perishable nature of food commodities such as meat demands 
accurate and fast decisions regarding potential human health risks. Therefore, food safety 
investigations require the use of fast, efficient, and reliable analytical methods. In addition, due to 
the large number of samples to be analyzed, high-throughput methods are favored by regulatory 
agencies and food safety laboratories to save cost and time. However, due to the tedious nature of 
conventional sample preparation approaches and the large number of steps involved, the possibility 
of error is very high. Accordingly, automation of the sample preparation step plays a major role in 
improving efficiency and analytical outcomes. 
The main objective of this thesis was to develop a fully automated high-throughput sample 
preparation method for quantitative analysis of multi-class multi-residue veterinary drugs in 
animal tissue using the Concept 96-blade SPME robotic system and LC-MS/MS. Chapter 2 is 
mainly focused on method development, optimization of parameters influencing SPME extraction, 
and the validation of a fully automated, high-throughput multi-class multi-residue method for 
quantitative analysis of 77 veterinary drugs using SPME and LC-MS/MS. In chapter 3, the scope 
of the method developed in chapter 2 was extended to cover more than 100 veterinary drugs in 
two different matrices: chicken and beef muscle. Moreover, chapter 3 also encompassed a 
thorough comparison between the developed SPME method and two well-documented generic 
sample preparation procedures, namely solvent extraction (SE) and QuEChERS. With aims to 
overcome lengthy chromatographic runs, and reduce sample turnaround time, chapters 4 and 5 




main findings and contribution of this work and proposes future directions with regards to the 






Development and Validation of a Fully Automated Solid Phase 
Microextraction High-throughput Method for Quantitative Analysis of 
Multi-residue Veterinary Drugs in Chicken Tissue 
2.1 Preamble  
The materials in this chapter have been published as a research article: Khaled, A.; 
Gionfriddo, E.; Acquaro, V.; Singh, V.; Pawliszyn, J. Development and Validation of a Fully 
Automated Solid Phase Microextraction High Throughput Method for Quantitative Analysis of 
Multi-residue Veterinary Drugs in Chicken Tissue. Anal. Chim. Acta 2019, 1056, 34–46. Materials 
for all sections of this current chapter are reprinted from this research article with the permission 
of Elsevier, (Copyright 2018). Copyright for this work remains the property of Elsevier 
publications and any further request for re-use of this information should be requested directly 




The contribution of co-author Emanuela Gionfriddo to the work described in this chapter 
was technical advice at the early stage of method development and assistance in preparing stock 
solutions. The contribution of Varoon Singh was in preparation of 5 µm HLB particles for the 
SPME coating. Vinicius Acquaro Jr. assisted in the use of the Statistica software for statistical 
analysis for the lack of fit and the simplex-lattice mixture design (SLMD). All of the experimental 
work, experimental planning and design conducted in the laboratory, data processing, analysis, 
interpretation, and writing were performed by the author of the thesis. 
I, Emanuela Gionfriddo, authorize Abir Khaled to use the material for her thesis. 
I, Vinicius Acquaro Jr., authorize Abir Khaled to use the material for her thesis. 
I, Varoon Singh, authorize Abir Khaled to use the material for her thesis. 
2.2 Introduction 
As per current agricultural practices, animals raised for food are often housed and transported 
in high densities, which makes them more prone to increased levels of stress and disease. Aiming 
to minimize livestock losses and increase production, veterinary drugs (VDs) are thus frequently 
used to prevent and treat diseases, as well as promote weight gain.158,159. In this regard, illegal or 
improper dosage of VDs as well as failure to comply with stipulated withdrawal dates may lead to 
the presence of drug residues in the edible tissue of the treated animal. These residues, even at low 
concentrations, may in turn pose a risk to human health.159 In this respect, one of the main concerns 




Aiming to protect human health, most governments and associated agencies have established 
monitoring and regulation laws, standards, and procedures with respect to veterinary drug residues 
in the edible tissues of food-producing animals.109,160 To this end, maximum residue levels 
(MRLs), defined as the maximum concentration of residue that can safely remain in the edible 
tissue of an animal that has been treated with a veterinary drug, are established to set and enforce 
these regulatory standards.81 In Canada, VD residues are regulated by MRLs established by the 
Veterinary Drugs Directorate of Health Canada. Likewise, in the USA, regulatory tolerances of 
registered veterinary drugs are set by the Food and Drug Administration (FDA) Center for 
Veterinary Medicine.84 In the European Union (EU), the use of veterinary drugs is also strictly 
regulated through EU Council Regulation 2377/90/EC.161 At the international level, MRLs are 
established by Codex Alimentarius, a joint initiative between the Food and Agricultural 
Organization and the World Health Organization.85 MRLs are also employed in the establishment 
and monitoring of trading standards so as to ensure the quality of imported and exported meat.13,86 
Given the growing public interest and concern regarding food safety and taking into account 
the importance of the meat industry to the global economy, the demand for simple, automated 
high-throughput analytical procedures for monitoring of drug residues in meat is expected to 
continue growing. Within this same context, cost-effectiveness plays a large role in analytical 
method selection, particularly for laboratories that provide regulatory testing for VD residues. In 
this respect, one approach to increase the efficiency and cost-effectiveness of an assay is to increase 




residue, multi-class analytical methods have been gaining popularity as cost-effective methods for 
screening, identification, and quantification of drug residues in food.32 
Despite the high selectivity and detectability afforded by LC-MS/MS platforms, analysis of 
VDs at trace levels in complex matrices, such as animal tissues, still requires extensive sample 
preparation procedures aimed at isolating target analytes from complex matrix constituents, and 
minimizing interferences and matrix effects.90 In this respect, multi-residue sample preparation 
poses a large challenge to analysts due to two main factors: the large quantity and variety of 
analytes under consideration, and the complexity of the matrix under study. A suitable sample 
preparation method must enable the detection and quantification of a large quantity of analytes, 
encompassing a wide range of physico-chemical properties, while offering sufficient sample clean-
up so as to minimize interferences and matrix effects - a challenging prospect, given that the 
studied matrix is characterized by the presence of endogenous compounds as well as 
macromolecules such as proteins and lipids. One of the first and most commonly employed sample 
preparation techniques for analysis of tissues is solvent extraction (SE), which involves liquid 
extraction of analytes from homogenized animal tissue.85 While this method offers a quick and 
simple workflow, it also involves the co-extraction of a high number of endogenous sample 
compounds, which may cause matrix effects in LC-MS/MS analysis. Other disadvantages include 
the possibility of emulsion formation and the use of large volumes of toxic organic solvents.162 To 
minimize interferences and matrix effects, solid phase extraction (SPE) is commonly used for 
further sample pre-treatment.98 Another extraction method that offers purification of sample 




QuEChERS (Quick, Easy, Cheap, Effective, Rugged, and Safe) method.163–165 However, while 
SPE and d-SPE techniques are widely employed for sample preparation, such approaches do not 
always effectively eliminate matrix effects, and may sometimes retain target analytes, thus leading 
to analyte loss.90,91 Further, owing to the multiple steps often involved in such methods, 
employment of such sample preparation strategy may involve long analysis times, the introduction 
of errors, as well as large costs.7 
As a well-established and environmentally friendly sample preparation technique, solid 
SPME enables the attainment of clean sample extracts while minimizing matrix interferences from 
biological samples.123,137,166 Matrix-compatible SPME coatings offer adequate robustness for 
direct immersion in complex matrices and balanced extraction coverage of compounds with a wide 
range of polarities.126,167,168 Matrix-compatible coatings, when combined with the open-bed 
configuration of SPME, facilitate extraction of multi-residue compounds from complex matrices 
without being burdened by the clogging issues typical of conventional SPE packed bed systems.120 
Boyaci et al. recently developed a fully automated high-throughput thin-film solid phase 
microextraction (TF-SPME) method where TF-SPME blades coated with C18 particles/PAN were 
utilized to extract 110 doping compounds banned by the World Anti-Doping Agency (WADA) 
from urine.131 Among the many configurations offered by SPME, SPME thin films are consisted 
of a higher surface area as compared to the conventional SPME fiber format, and a comparable or 
lower thickness.132 Further, as thin-film SPME offers high-throughput compatibility, use of thin-
film SPME offers enhanced throughput of the extraction process due to the simultaneous extraction 




surface area and enhance recovery is the use of round SPME devices with larger outer 
diameters.149,169 The purpose of the presented work entailed the development of a simple, green, 
automated, high throughput sample preparation method for determination of a wide range of 
veterinary drugs at regulatory levels in chicken muscle. Automated sample preparation improves 
precision and reproducibility due to the elimination of human error from the procedure. Thus, an 
automated high throughput DI-SPME LC-MS/MS method is presented in this chapter for analysis 
of 77 veterinary drug compounds in homogenized tissue from chicken. 
2.3 Experimental 
2.3.1 Chemicals and materials 
The veterinary drugs under study were selected from the list of standards specified in the 
official method for screening and confirmation of animal drug residues developed by the United 
States Department of Agriculture (CLG-MRM1.08)31 and referred to by Schneider et al.32 
Depending on availability of standards, we aimed to include as many analytes from the list which 
cover a wide range of polarities representing at least 12 classes. Standards were obtained from 
suppliers listed in Table 2.1. The corresponding class of each target analyte is presented in Table 
2.2. LC-MS grade acetonitrile (MeCN), methanol (MeOH), isopropyl alcohol (IPA), water, and 
formic acid (FA) were purchased from Fisher Scientific (Mississauga, ON, Canada). 
Polyacrylonitrile (PAN), Dimethyl sulfoxide (DMSO), and N, N-dimethylformamide (DMF), 
divinylbenzene (DVB), N-vinylpyrrolidone (N-VP), and 2,2’-azobisisobutyronitrile (AIBN) were 
obtained from Sigma Aldrich (Oakville, ON, Canada). Nunc U96 Deep Well 2 mL and 1 mL plates 




Polypropylene inserts (600 μL) for the 1 mL plates were purchased from Analytical Sales and 
Services (NJ, USA). For preparation of SPME coatings, C8-benzenesulfonic acid (Mix-mode) was 
obtained from Supelco (Bellefonte, PA, USA), PS-DVB was purchased from Chromabond, 
Germany, and HLB particles were synthesized in-house as per the protocol discussed in section 
2.3. High-tolerance 304 stainless steel rods (1/16” diameter) were obtained from McMaster-Carr 
(Aurora, OH, USA) for use as SPME pins. 
Table 2.1 Physico-chemical properties and supplier information for all studied compounds. 




2-Aminoflubendazole Sigma-Aldrich C14H10FN3O 255.2 1.96 
5-Hydroxythiabendazole Sigma-Aldrich C10H7N3OS 217.3 1.73 
6-Phenyl-2-thiouracil Sigma-Aldrich C10H8N2OS 204.3 -0.10 
Acepromazine Maleate Sigma-Aldrich C19H22N2OS 326.5 4.08 
Albendazole Sigma-Aldrich C12H15N3O2S 265.3 3.07 
Albendazole-2-Aminosulfone Sigma-Aldrich C10H13N3O2S 239.3 0.12 
Albendazole Sulfone Sigma-Aldrich C12H15N3O4S 297.1 0.86 
Albendazole Sulfoxide Sigma-Aldrich C12H15N3O3S 281.3 0.91 
Azaperone Sigma-Aldrich C19H22FN3O 327.4 2.50 
Betamethasone Sigma-Aldrich C22H29FO5 392.2 1.87 
Cambendazole Sigma-Aldrich C14H14N4O2S 302.4 2.90 
Carbadox Sigma-Aldrich C11H10N4O4 262.2 -1.22 
Chlorpromazine HCl Sigma-Aldrich C17H20Cl2N2S 355.3 5.20 
Chlortetracycline HCl Sigma-Aldrich C22H24Cl2N2O8 515.3 1.11 
Clenbuterol HCl Sigma-Aldrich C12H19Cl3N2O 313.7 2.61 
Clindamycin HCl Sigma-Aldrich C18H34Cl2N2O5S 461.4 1.83 
Cloxacillin Sodium Salt Sigma-Aldrich C19H17ClN3NaO5S 457.9 2.53 
Danofloxacin Sigma-Aldrich C19H20FN3O3 357.1 1.20 
Desethylene Ciprofloxacin HCl TRC2 C15H17ClFN3O3 341.8 -0.14 





Table 2.1 continued 




Dicloxacillin Sodium Salt Hydrate Sigma-Aldrich C19H16Cl2N3NaO5S.xH2O 492.3 3.02 
Difloxacin HCl Sigma-Aldrich C21H20ClF2N3O3 435.9 2.78 
Dimetridazole Sigma-Aldrich C5H7N3O2 141.1 0.31 
Doxycycline HCl Sigma-Aldrich C22H25ClN2O8 480.9 -0.54 
Emamectin Benzoate Sigma-Aldrich C56H81NO15 1008.2 6.84 
Enrofloxacin Sigma-Aldrich C19H22FN3O3 359.4 1.88 
Erythromycin Sigma-Aldrich C37H67NO13 733.9 2.83 
Erythromycin Sigma-Aldrich C37H67NO13 733.9 2.83 
Fenbendazole Sigma-Aldrich C15H13N3O2S 299.3 3.75 
Fenbendazole Sulfone Sigma-Aldrich C15H13N3O4S 331.3 1.70 
Florfenicol amine Sigma-Aldrich C10H14FNO3S 247.3 -0.80 
Flubendazole Sigma-Aldrich C16H12FN3O3 313.3 3.05 
Flunixin Sigma-Aldrich C14H11F3N2O2 296.2 5.40 
Haloperidol Sigma-Aldrich C21H23ClFNO2 375.9 3.01 
Haloxon CedarLane C14H14Cl3O6P 415.6 2.81 
Hydroxy dimetridazole TRC2 C5H7N3O3 157.1 -0.49 
Hydroxy ipronidazole Sigma-Aldrich C7H11N3O3 185.2 0.21 
Hydroxy metronidazole Sigma-Aldrich C6H9N3O4 187.15 -0.81 
Ipronidazole Sigma-Aldrich C7H11N3O2 169.2 1.18 
Ketoprofen Sigma-Aldrich C16H14O3 254.3 2.81 
Levamisole HCl Sigma-Aldrich C11H13ClN2S 240.8 1.85 
Lincomycin HCl Monohydrate Sigma-Aldrich C18H37ClN2O7S 461.0 0.91 
Mebendazole Sigma-Aldrich C16H13N3O3 295.3 2.83 
Mebendazole-amine Sigma-Aldrich C14H11N3O 237.3 1.74 
Melengestrol Acetate Sigma-Aldrich C25H32O4 396.5 4.21 
Metronidazole Sigma-Aldrich C6H9N3O3 171.2 -0.01 
Morantel Tartrate Hydrate Sigma-Aldrich C16H22N2O6S xH2O 370.4 1.97 
Norfloxacin Sigma-Aldrich C16H18FN3O3 319.3 0.82 
Orbifloxacin Sigma-Aldrich C19H20F3N3O3 395.4 2.37 
Oxacillin Sodium Salt Monohydrate Sigma-Aldrich C19H18N3O5SNa H2O 441.4 2.05 
Oxfendazole Sigma-Aldrich C15H13N3O3S 315.3 1.36 




Table 2.1 continued 




Oxyphenylbutazone Sigma-Aldrich C19H20N2O3 324.4 2.72 
Oxytetracycline HCl Sigma-Aldrich C22H25ClN2O9 496.9 -1.50 
Phenylbutazone Sigma-Aldrich C19H20N2O2 308.4 3.16 
Pirlimycin HCl TRC2 C17H32Cl2N2O5S 447.4 1.47 
Prednisone Sigma-Aldrich C21H26O5 358.4 1.57 
Promethazine HCl Sigma-Aldrich C17H21ClN2S 320.9 4.78 
Propionylpromazine HCl Sigma-Aldrich C20H25ClN2OS 376.9 4.61 
Ractopamine HCl Sigma-Aldrich C18H24ClNO3 337.8 1.65 
Sarafloxacin HCl Hydrate  Sigma-Aldrich C20H17F2N3O3 HCl xH2O 421.8 2.09 
Sulfachloropyridazine Sigma-Aldrich C10H9ClN4O2S 284.7 1.02 
Sulfadimethoxine Sigma-Aldrich C12H14N4O4S 310.3 1.48 
Sulfadoxine Sigma-Aldrich C12H14N4O4S 310.3 0.34 
Sulfaethoxypyridazine Sigma-Aldrich C12H14N4O3S 294.3 0.85 
Sulfamerazin Sigma-Aldrich C11H12N4O2S 264.3 0.34 
Sulfamethazine Sigma-Aldrich C12H14N4O2S 278.33 0.80 
Sulfamethizole Sigma-Aldrich C9H10N4O2S2 270.3 0.51 
Sulfamethoxazole Sigma-Aldrich C10H11N3O3S 253.3 0.89 
Sulfamethoxypyridazine Sigma-Aldrich C11H12N4O3S 280.3 0.32 
Sulfapyridine Sigma-Aldrich C11H11N3O2S 249.3 0.03 
Sulfaquinoxaline Sigma-Aldrich C14H12N4O2S 300.3 1.30 
Sulfathiazole Sigma-Aldrich C9H9N3O2S2 255.3 0.05 
Tetracycline HCl Sigma-Aldrich C22H25ClN2O8 480.9 -1.47 
Tolfenamic Acid Sigma-Aldrich C14H12ClNO2 261.7 5.76 
Triclabendazole Sigma-Aldrich C14H9Cl3N2OS 359.7 5.97 
Triclabendazole Sulfoxide Sigma-Aldrich C14H9Cl3N2O2S 375.7 4.12 
Triflupromazine HCl Sigma-Aldrich C18H20ClF3N2S 388.9 5.70 
Tylosin TRC2 C46H77NO17 916.1 3.27 
Virginiamycin M1 Sigma-Aldrich C28H35N3O7 525.6 -0.66 
Xylazine HCl Sigma-Aldrich C12H17ClN2S 256.8 2.37 
1 Data taken from www.chemspider.com, accessed April 2018, LogP data taken from 
computational predictions ACD/LogP  





Stock solutions of veterinary drugs and deuterated internal standard were prepared by 
weighing approximately 5 mg of each individual standard, and dissolving individual quantities in 
5 mL of either MeCN, MeOH, water, or 10% DMSO in MeCN, in accordance with the solubility 
of each compound. An internal standard (IS) solution, containing flunixin-d3 at 1 µg mL
−1, was 
prepared by appropriate dilution of IS stock solution in MeCN. All target analytes were mixed in 
a composite solution and diluted to 100X, where X represents the MRLs listed in Table 2.6 with 
MeCN, with the exception of the β-lactams/cephalosporins composite solution, which was 
prepared and diluted in water at a concentration of 200X. All stock and composite solutions were 
stored at −30 °C. Spiking solutions and their dilutions were prepared daily for validation 
experiments. With the exception of β-lactams/cephalosporins solutions, which were stored in 
plastic, all other standard and composite solutions were stored in amber glass vials closed with 
fitted PTFE caps.  
The MRL values displayed in Table 2.6 were based primarily on Canadian MRL values81 in 
poultry, or US tolerance levels170 in cases where MRL values corresponding to certain analytes 
were not available in the Canadian database. In cases where MRL values were unavailable for 
poultry in either database, values in other tissues, such as bovine tissue, were selected instead. In 
cases where Canadian MRLs were higher than US tolerance levels, such as that established for 
Ketoprofen, the US regulatory value was selected. 
Antibiotic free chicken breast, thighs, and liver from five different sources were purchased 
from local grocery stores to serve as matrix. Chicken thighs and liver tissue were used only for 




Vitamix blender to obtain a uniform powder. All samples were then combined and ground again 
with dry ice to produce a pooled matrix. All homogenized samples were first stored in glass jars 
covered by loose lids overnight at −30 °C to allow for sublimation of dry ice to occur, then 
subsequently stored at −80 °C until analysis. 
2.3.2 LC-MS/MS method 
Experiments were performed with the use of a Thermo Accela 1250 pump with an on-line 
vacuum degasser liquid chromatography system coupled to a triple quadrupole mass spectrometer 
TSQ Vantage (Thermo Scientific, San Jose, USA). Further instrumental details and optimized LC 
and MS/MS parameters are provided in Tables 2.2, 2.3, and 2.4. The autosampler, thermostated at 
5 °C, was used for high throughput, 10 μL sample injections in full loop mode. A Waters 
(Mississauga, ON, Canada) Acquity UPLC HSS T3 (100 × 2.1 mm, 1.7 μm) analytical column 
connected to a guard column (HSS T3, 2.1 × 5 mm, 1.7 μm) was used for separation of the targeted 
analytes. The column compartment was maintained at 40 °C, and the flow rate was 0.3 mL/min. 
MeCN/water (70:30, v/v) was used to clean the injection system (flush and wash volumes were 





Table 2.2 MS/MS optimized parameters, (m/z), and retention times (RT) of compounds, ions used for 














2-Aminoflubendazole Anthelmintics 256 123, 95, 75 27, 38, 56 5.7 131 + 
5-Hydroxythiabendazole Anthelmintics 218 191, 147, 81 26, 33, 40 4.2 50 + 
6-Phenyl-2-thiouracil Thyreostats 205 188, 103, 146 19, 20, 28 5.7 47 + 
Acepromazine Maleate Tranquilizers 327 86, 58, 222 20, 35, 37 6.7 66 + 
Albendazole Anthelmintics 266 234, 191, 159 19, 33, 38 6.9 62 + 
Albendazole sulfone Anthelmintics 298 266,159, 224 36, 20, 28 6.0 70 + 
Albendazole sulfoxide Anthelmintics 282 240, 207, 159  13, 24, 39 5.3 71 + 
Albendazole-2-
aminosulfone 
Anthelmintics 240 133,198,106 29,19,42 4.4 63 + 
Azaperone Tranquilizers 328 165,123, 121 36, 21, 23 5.2 113 + 
Betamethasone Anti-inflammatories 393 325, 373, 347 11, 6, 29 7.2 57 + 
Cambendazole Anthelmintics 303 217, 261, 190 28, 18, 190 5.8 110 + 
Carbadox Other 263 231, 130, 102 13, 20, 46 5.0 63 + 
Chlorpromazine HCl Tranquilizers 319 86, 58, 214 20, 34, 40 7.3 102 + 
Chlortetracycline HCl Tetracyclines 479 462,444, 154 20, 16, 28 5.3 121 + 
Clenbuterol HCl β-Agonists 277 203, 259, 132 16, 10, 30 5.4 56 + 
Clindamycin HCl Macrolides/lincosamides 425 126, 377, 83 30, 19, 53 5.7 114 + 
Cloxacillin Sodium Salt β-Lactams/cephalosporins 436 277, 160, 114 14, 12, 31 8.0 61 + 
Danofloxacin Fluoroquinolones 358 340, 82,314 23, 41, 17 5 116 + 
Desethylene Ciprofloxacin Fluoroquinolones 306 288, 268, 217 19, 26, 38 4.7 61 + 
Diclofenac Sodium Anti-inflammatories 296 214, 250, 278 37, 13, 9 9.3 56 + 
Dicloxacillin  β-Lactams/cephalosporins 470 452, 310, 114 13, 13, 39 8.5 87 + 
Difloxacin HCl Fluoroquinolones 400 382, 298, 356,  28, 18, 2 5.4 116 + 
Dimetridazole Coccidiostats 142 96, 81, 54 16, 28, 34 4.2 47 + 
Doxycycline HCl Tetracyclines 445 428, 267, 321 17, 37, 30 5.8 107 + 
Emamectin Benzoate Anthelmintics 887 158, 82, 126 35, 48, 37 9.3 231 + 
Enrofloxacin Fluoroquinolones 360 342,316, 245  19, 27, 22 5.1 120 + 
Erythromycin Macrolides/lincosamides 734 576,158, 116 30, 17, 36 6.5 94 + 
Fenbendazole Anthelmintics 300 268, 159,131 21, 34, 45 7.7 115 + 
Fenbendazole Sulfone Anthelmintics 332 300, 159, 131 23, 38, 49 6.8 102 + 
Florfenicol amine Phenicols 248 230, 130, 91 12, 25, 46 0.9 48 + 



















Flunixin Anti-inflammatories 297 279, 264, 236 23, 34, 42 8.5 127 + 
Haloperidol Tranquilizers 376 165,123, 95 37, 24, 95 6.7 118 + 
Hydroxy dimetridazole Coccidiostats 158 80,140, 55 12, 13, 19 3.5 32 + 
Hydroxy ipronidazole Coccidiostats 186 168, 122, 106 13, 20, 35 5.4 46 + 
Ipronidazole Coccidiostats 170 124, 109, 96 17, 25, 22 6.4 48 + 
Ketoprofen Anti-inflammatories 255 209, 77, 105 39, 22, 13 8.2 51 + 
Levamisole HCl Anthelmintics 205 178, 91, 123 22, 39, 29 4.4 51 + 
Lincomycin  Macrolides/lincosamides 407 126, 359, 389 30, 18,16 4.4 127 + 
Mebendazole Anthelmintics 296 264, 105, 77 21, 34, 43 6.9 115 + 
Mebendazole-amine Anthelmintics 238 105, 77, 133 25, 26, 37 5.5 58 + 
Melengestrol Acetate Other 397 279,337, 221 13, 20, 40 10.2 89 + 
Morantel Tartrate Hydrate Anthelmintics 221 123, 111, 164 35, 25, 27 5.6 53 + 
Norfloxacin Fluoroquinolones 320 302, 276, 233 16, 24, 21 4.8 53 + 
Orbifloxacin Fluoroquinolones 396 352, 295, 226 17, 24, 43 5.2 89 + 
Oxacillin Sodium  β-Lactams/cephalosporins 402 243, 160, 114 14, 14, 34 7.6 75 + 
Oxfendazole Anthelmintics 316 159, 284, 191 32, 18, 22 6.0 122 + 
Oxyclozanide Anthelmintics 402 186, 83, 144 22, 22, 44 9.9 62 + 
Oxyphenylbutazone Anti-inflammatories 325 204, 148, 232 16, 29, 13 8.2 89 + 
Oxytetracycline HCl Tetracyclines 461 426, 443, 201 18, 11, 39 4.9 98 + 
Phenylbutazone Anti-inflammatories 309 120, 188, 160 42, 19, 29 9.7 53 + 
Pirlimycin HCl Macrolides/lincosamides 411 363,112, 56 29, 17, 49 5.5 111 + 
Prednisone Anti-inflammatories 359 341, 313, 147 11, 10, 26 6.7 65 + 
Promethazine HCl Tranquilizers 285 86, 198, 71 17, 29, 36 6.7 52 + 
Propionylpromazine HCl Tranquilizers 341 86, 58, 236 20, 35, 37 7.1 113 + 
Ractopamine HCl β-Agonists 302 164, 284, 107 12, 16, 34 5.0 56 + 
Sarafloxacin HCl Hydrate  Fluoroquinolones 386 342,299, 368 26, 18, 22 5.4 66 + 
Sulfachloropyridazine Sulfonamides 285 156, 92, 108 15, 29, 26 5.9 59 + 
Sulfadimethoxine Sulfonamides 311 156, 92, 108 20, 33, 29 6.7 116 + 
Sulfadoxine Sulfonamides 311 156, 108, 65 18, 29, 45 6.1 107 + 
Sulfaethoxypyridazine Sulfonamides 295 156, 108,92 18, 28, 30 5.4 62 + 
Sulfamerazine Sulfonamides 265 156, 172, 108 16, 26, 30 4.9 59 + 
Sulfamethazine Sulfonamides 279 186, 156, 124 18, 20, 28 5.3 104 + 
Sulfamethizole Sulfonamides 271 156, 92, 108 15, 27, 25 5.3 60 + 



















Sulfamethoxazole Sulfonamides 254 108, 156, 92 28, 27, 41 6.1 67 + 
Sulfamethoxypyridazine Sulfonamides 281 156, 126, 108 17, 20, 46 6.1 105 + 
Sulfapyridine Sulfonamides 250 156, 92, 184 16, 28, 19 4.7 75 + 
Sulfaquinoxaline Sulfonamides 301 156, 92, 108 17, 30, 28 6.7 57 + 
Sulfathiazole Sulfonamides 256 156, 92, 65 15, 29, 39 4.6 100 + 
Tetracycline HCl Tetracyclines 445 410, 154, 427 19, 28, 12 5.1 107 + 
Tolfenamic Acid Anti-inflammatories 262 214, 180, 209 16, 41, 27 10.2 51 + 
Triclabendazole Anthelmintics 359 274, 344, 171 36, 25, 51 9.8 158 + 
Triclabendazole Sulfoxide Anthelmintics 375 357, 360, 242 20, 45, 22 9.0 122 + 
Triflupromazine HCl Tranquilizers 353 248, 86, 58  21, 35, 45 7.6 106 + 
Tylosin Macrolides/lincosamides 917 772, 174, 101 36, 27, 43 6.7 121 + 
Virginiamycin M1 Other 526 508, 337, 355 12, 20, 17 7.8 115 + 
Xylazine HCl Tranquilizers 221 90, 164, 72  23, 26, 37 5.6 51 + 






Table 2.3 Optimized LC conditions 
 Optimized LC conditions 
Column 
Acquity UPLC HSS T3 C18 Column 
2.1 x 100 mm, 1.7 µm particle size, Waters, Mississauga, ON, Canada 
Guard 
cartridge 
VanGuard Pre-Column HSS T3 
1.7μm, 2.1mm x 5mm  
Mobile phase 
A: water with 0.1% formic acid 
B: acetonitrile with 0.1% formic acid 










10 µL (full loop mode) 
Gradient 
Time (min) %A %B 
0 97 3 
1 97 3 
11 0 100 
13 0 100 
15 97 3 
18 97 3 
The mobile phases were water (solvent A) and MeCN (Solvent B), each containing 0.1% 
(v/v) formic acid. The gradient was run at 3% B for 1 min, ramped linearly to 100% B until 11 min, 
and then held at 100% B until 13 min. The column was then returned to 3% B over 2 min, where 
it was allowed to re-equilibrate for 3 min. MS data was processed using Xcalibur software v.2.1 
(Thermo Fisher Scientific, San Jose, USA). Mobile phases were degassed for 30 min in a VWR 




Table 2.4 Optimized MS/MS conditions 
MS parameters on TSQ Vantage 
Spray voltage 3.5 kV (positive)  
Vaporizer temperature 275 °C 
Sheet gas and flow N2, 30 AU 
Auxiliary gas and flow N2, 30 AU 
Transfer capillary temperature 275 °C 
Quadrupole resolution at FWHM 0.7 u 
Collision gas and pressure Argon, 1.5 mTorr 
Cycle time 0.4 s 
 
2.3.3 Synthesis of Hydrophilic-Lipophilic Balance (HLB) particles 
HLB particles were synthesized via precipitation polymerization by modifying the procedure 
described elsewhere;152,171 however it was scaled up and toluene was used as a porogen in order to 
prepare mesoporous particles. First, 450 mL MeCN and 150 mL toluene were added in a 2 L three-
necked round bottom flask equipped with a mechanical stirrer and an inlet for nitrogen gas purging, 
then purged with nitrogen for 30 min. Following, 42 mL of the monomer/cross linker (DVB) and 
18 mL of the functional monomer (N-VP) were added to the solvent mixture. AIBN (500 mg) was 
used as an initiator for the polymerization reaction. The reaction was thermally controlled at 70 °C 
for 24 hours. Particles were then rinsed and dried as per previous methods. 
HLB particles were characterized by UltraPlus field emission scanning electron microscopy 




Quantachrome (Boyton Beach, Florida)), for determinations of size and shape, and surface area, 
respectively. 
2.3.4 Automated concept 96-pin SPME system 
The Concept 96 robotic sample preparation station (Professional Analytical System (PAS) 
Technology, Magdala, Germany) used in this work for SPME sample preparation is a fully 
automated, software-operated, off-line bench top robotic station (Figure 2.1). The device executes 
all steps of the SPME protocol, including preconditioning of the sorbent, SPME extraction, rinsing, 
and solvent desorption. In addition, the system also contains an evaporation unit that allows for 
optional drying and reconstitution of extracts and/or preconcentration of analytes. The SPME 
brush is comprised of 96 SPME pins coated with extraction phase (Figure 2.1). The brush fits 
standard commercial 96-well-plates, which can be accommodated on the agitators used during 
subsequent steps of the method, and is compatible with most autosamplers available for standard 
LC systems. 
Stainless steel rods for the SPME brush were cut to a length of 50 mm at the University of 
Waterloo's Science Technical Services. The SPME coating was comprised of HLB particles 
suspended in PAN, and immobilized on the stainless steel rod surfaces of the 96-pin SPME brush 
by dip coating, as per the protocol developed by Gomez-Ríos at al.151 All prepared coatings had 





Figure 2.1 Concept 96-SPME device and SPME brush with 96 pins. Optimized conditions (time, 
agitation, solvent, and volume) for conditioning, extraction, rinsing, and desorption steps are shown, 
respectively, under each agitator-station. 
2.3.5 Automated SPME procedure for high-throughput analysis 
Spiked chicken samples were prepared by adding 100 μL of the working solution, containing 
all analytes under study at their respective designated concentrations, and 30 μL of the internal 
standard working solution to 2.0 g of homogenized chicken tissue. Samples were vortexed 
manually for 1 min, then placed on a benchtop agitator for 1 h. Samples were then placed in a 4 °C 




Following overnight refrigeration, chicken samples were placed on the benchtop agitator for 1 h 
prior to extraction so as to allow samples to reach room temperature. 6 mL of water were added to 
each individual spiked chicken sample; samples were then vortexed for 1 min in order to attain 
homogeneous consistency, and a viscosity suitable for pipetting of samples to wells of the 96 well-
plates. Next, 1.5 mL of the diluted chicken samples were transferred to 96 well plates. All final 
diluted spiked samples had an organic solvent content equivalent to less than 2%. 
The Concept 96 system was programmed to consecutively perform the preconditioning of 
fibers, SPME extraction, fiber rinsing, and solvent desorption. The SPME protocol was executed 
as follows: prior to extractions, SPME rods were conditioned for 30 min with 1 mL of 
methanol/water (50:50, v/v) in 96-well-plates with agitation (900 rpm). Next, static extractions 
were performed from 1.5 mL of diluted chicken tissue samples spiked with the target compounds. 
For coating and desorption solvent selection, sample matrix was 1 mL of PBS spiked with each 
target analyte at 50 ng mL−1. Chicken matrix was used for all subsequent steps of the study. The 
final optimized extraction parameters were static extraction for 60 min at 50 °C. In the fiber rinsing 
step, SPME pins were rinsed with 1 mL of water for 10 s with agitation (900 rpm). Following, 
desorption of analytes was carried out in 400 μL of desorption solvent (in the final method) for 
20 min with agitation (1200 rpm) in a new 96-well-plate containing desorption solvent. In order to 
evaluate carryover for each pair of sorbent and desorption solvents, second and third sequential 
desorption steps were carried out under the same conditions. Lastly, the 96-well-plate containing 
final extracts was covered with the 96-well-plate lid, and placed in the LC-MS/MS autosampler 




The final optimized SPME conditions for preconditioning, extraction, rinsing, and 
desorption steps are shown in Figure 2.1, while protocols for preparation of the used solutions as 
well as further details regarding the full analytical procedure can be found in figure 2.2 and 2.3. 











2.3.6 Optimization of the desorption solvent by experimental design 
The composition of the desorption solvent was optimized for effectiveness with respect to 
ratios of water, methanol, and acetonitrile. Experiments to optimize the desorption solvent were 
designed based on a simplex-lattice mixture design (SLMD) introduced by Scheffé.172 The design 
consists of a symmetrical arrangement of points, referred to as {k, m}-lattice, where k is the 
number of components, and m is the polynomial model degree. According to Scheffé, in order to 
better elucidate the shape of the response surface, the best design option comprises the use of a 
design where points are spread evenly over the whole simplex. The uniformly spaced distribution 
of points on a simplex is known as a lattice. In addition, the summation of the three portions 
(factors) in the SLMD must be equal to one. In cases where the optimization process involves 
multiple responses, it is not feasible to individually optimize each response, as such would 
necessitate the use of a large number of samples, equal to the dependent variable under study.173 
The Derringer & Suich approach presents an alternative to overcome this drawback, as it allows 
for the discovery of the best compromised conditions among all investigated responses through 
the desirability function.174,175 In total, 14 experiments in triplicate were performed as listed in 
Table 2.5. Solvent ratios were established through an SLMD with three components, and the 
polynomial model degree equal to three. Statistical evaluation of data from these experiments was 





Table 2.5 Proportion of desorption solvent in a simplex lattice mixture design. 
Experiment Order % H2O % MeCN % MeOH 
12 16.7 66.7 16.7 
6 0.0 33.3 66.7 
3 0.0 0.0 100.0 
11 66.7 16.7 16.7 
10 33.3 33.3 33.3 
1 100.0 0.0 0.0 
13 16.7 16.7 66.7 
2 0.0 100. 0.0 
4 33.3 66.7 0.0 
8 66.7 0. 0 33.3 
7 66.7 33.3 0.0 
14 33.3 33.3 33.3 
5 33.3 0.0 66.7 
9 0.0 66.7 33.3 
 
2.3.7 Validation of the method 
The developed method was validated following the guidelines established by the FDA for 
Method Validation for Drugs and Biologics.176 The developed method was validated in terms of 
selectivity, linearity, accuracy, intra- and inter-day precision, stability, and limits of quantification 
(LOQs). Calibration curves as well as statistical tests were attained with Origin 2018 software 
(OriginLab Corporation®, MA, USA). 
The first step in the validation procedure entailed an evaluation of the selectivity of the 




Matrix-matched calibration with internal standard (IS) correction was selected as a 
calibration method for the current work. The matrix-matched calibration curve was prepared by 
spiking analytes in one lot of blank pooled chicken. Flunixin-d3 was added to samples as internal 
standard to compensate for sample variations with respect to matrix, variations from pin to pin, as 
well as variations in desorption solvent loss due to evaporation during the desorption step. 
The linear dynamic range of the LC-MS/MS instrument was determined for each analyte by 
direct injection of the neat standards prepared in desorption solution. In order to determine the 
linearity of the method, calibration curve solutions were prepared in a range of 0.1X to 3X in 
pooled chicken, and analyzed with the proposed SPME-LC-MS/MS method in triplicate. For 
determinations of accuracy and precision, target analytes were spiked at low-, mid- and high 
concentration levels (0.3X, 0.9X and 2.5X) in pooled chicken matrix. Internal standard (Flunixin-
d3) was spiked in pooled chicken matrix at 30 ng mL
−1. These extractions were performed in six 
replicates for intra-day precision. Interday precision was evaluated by running three different 
experiments over three different days. 
The stability of the analytes in the desorption solvent for the duration of the analysis period 
was also assessed. Supposing that one run of the experiment utilizes every one of the 96 SPME 
pin spaces available in the Concept 96, and taking into account that a total chromatographic time 
of 18 min is needed per sample, an approximate period of 48 h was calculated as required to 
complete analysis for each dataset. In addition to the 48 h period, periods of 72 h and one week 




solvent, stored at 5 °C, and analyzed after 48 h, 72 h, and 1 week; the attained results were then 
compared with those of freshly prepared standards. 
2.4 Results and discussion 
2.4.1 LC-MS method 
The method was optimized with respect to run time, retention time stability, 
chromatographic separation, carryover, and sensitivity. Chromatographic separation is especially 
important in the presence of isobaric compounds such as sulfadoxine and sulfadimethoxine, 
tetracycline and doxycycline.177 To this end, different chromatographic columns with different 
chemistry from various suppliers were tested with respect to their performance for the analytes 
under study. Based on the results attained in this comparative study, a Waters Acquity T3 C18 HSS 
(100 × 2.1 mm, 1.7 μm) column was selected for further experiments, as it provided the best 
performance compared to the other evaluated columns in terms of retention of target analytes, as 
well as peak shapes and resolution. Quality control (QC) samples were run to verify retention time, 
reproducibility, and instrumental performance. QC samples constituted of extracted blank chicken 
matrix spiked at 0.5X. The criteria used for verification were: retention time to verify that all 
analytes fall in retention time windows, peak shape, as well as peak area of the internal standard 





2.4.2 Development of the SPME method 
Method optimization was carried out as per the protocol suggested by Risticevic et al.178 
Evaluated parameters included coating chemistry, desorption solvent, extraction and desorption 
times, agitation rates for extraction and desorption, extraction temperature, and sample and 
desorption solvent volumes. The first, and most important step in SPME method development 
entails the selection of a suitable coating in terms of extraction efficiency and carryover. Coating 
selection is especially important when targeting a large number of analytes with a wide range of 
polarities such as the ones targeted in this work, which present log P values ranging from −1.50 to 
8.67. For this purpose, different polymer chemistries characterized by both polar and nonpolar 
functional groups to facilitate extraction of compounds with a wide range of polarities were 
selected for evaluation. Evaluated polymer chemistries included Hydrophilic-Lipophilic Balance 
(HLB) particles synthesized in-house, commercially available SPE particles, a polar modified 
polystyrene-divinylbenzene copolymer (PS-DVB), a mix-mode (C8-SCX), and a 50:50 (w/w) 
HLB:PS-DVB. At the beginning of the study, preparation of the above listed SPME coatings was 
first attempted by spraying the particle slurry on the SPME blade's surface, as described in earlier 
work by Mirnaghi et al.138 However, due to the sharp edges of the blades and the roughness of the 
sprayed coating surface, attachment of matrix components, especially fatty residue was observed 
on the coating surface following extraction. To avoid coating fouling, the geometry of the SPME 
device was modified to include rounded rods, while smaller HLB particles (1–5 μm) were used to 
yield a smoother extraction phase surface, which prevented any further attachment of matrix 




biological matrices such as blood by Reyes-Garcés et al.149 and Vuckovic et al.135 In addition, static 
extraction was carried out to totally prevent any mechanical attachment of the sample to the SPME 
device. 
When performing SPME in complex matrices, a rinsing step is usually added after the 
extraction step and prior to desorption so as to avoid fouling on the sorbent surface. In the current 
work, water was selected as rinsing solvent. Agitation rate was set up at 900 rpm, and rinsing time 
was set at 10 s so as to avoid loss of polar analytes. 
Desorption-solvent effectiveness was assessed by evaluating desorption solutions with 
varied composition of the MeCN, MeOH, isopropanol, and water content. The effect of adding 
formic acid to the desorption solvent was also evaluated. Target analyte extraction amounts by 
each coating/desorption solvent pair are shown in Appendix A. These results were then compared 
with the aim of selecting the combination of extraction phase and desorption solvent composition 
that offers the highest extraction efficiency for most of the analytes, and the least carryover. The 
attained results, as summarized in Figure 2.4, showed that HLB provided the highest extraction 
recoveries for most of the target analytes, while mix-mode yielded the poorest recoveries. HLB 
yielded higher extraction recoveries for hydrophobic analytes, while PS-DVB yielded higher 
extraction recoveries for more polar compounds. 
Although the PS-DVB and 50:50 [w/w] HLB:PS-DVB coatings offered higher extraction 
efficiencies for polar compounds, they were also shown to be characterized by higher carryover 
effects for a number of compounds when submitted to second and third desorption cycles. As a 





Figure 2.4 Evaluation of 4 SPME coatings (HLB, mix-mode, PS-DVB and 50:50 HLB:PS-DVB) in 
different desorption solutions (Des 1: MeCN/H2O 50/50, Des 2: MeCN/MeOH/H2O/FA 40/40/20/0.1 
and Des 3: MeCN/IPA/H2O/FA 40/40/20/0.1). Extraction volume:1000 μL, extraction time:120 min, 
concentration of analytes: 50 ng mL−1, extraction matrix: 1X PBS. Desorption time: 120 min, 
desorption volume: 1000 μL. 
2.4.3 Synthesis of Hydrophilic-Lipophilic Balance (HLB) particles 
FE-SEM images of the prepared HLB particles show that the attained particles are 
characterized by a uniform spherical shape and are monodisperse in nature. Surface area analysis 
of the HLB particles revealed that the particles were microporous and mesoporous in nature, 
although most of the observed pores were in the mesoporous range (2–8 nm). The specific surface 
area of the HLB particles, calculated via the Brunauer–Emmett–Teller (BET) method with 
nitrogen gas used as adsorbate at 77.35 K, was measured at 816.78 m2g-1. The SEM images in 




SEM images show the obtained particles were spherical in shape and of a size between 1 and 5 μm. 
Although the HLB particles are embedded in PAN glue (Figure 2.5, C and D), pores present in 
PAN allow analytes to access the different layers of the HLB coating. These pores enable the 
diffusion of analytes of interest into the coating but restrict access of macromolecules such as 
proteins and lipids, resulting in satisfactory extraction of compounds of interest and minimal 
background interferences. At the same time, the smooth layer of PAN hinders attachment of matrix 




Figure 2.5 FE-SEM images of (A and B) HLB particles and (C and D) HLB particles in PAN glue on 
stainless steel rod. 
2.4.4 Optimization of the desorption solvent by experimental design 
In order to optimize the desorption of the analytes under study, which are characterized by a 
wide range of polarities and physico-chemical properties, after extraction by the HLB coating, 
optimum desorption solvent composition was investigated via experimental design. In total, 14 
experiments in triplicate were performed, and the solvents portions were established through an 




for optimization of desorption solvent composition enables a much more efficient optimization 
process as compared to sequential testing, particularly when the goal of analysis is detection of a 
wide range of analytes. Figure 2.6 demonstrates the attained results for the tested compositions 
with respect to the HLB coating. In this work, the optimum desorption composition was selected 
as 25:37.5:37.5, v/v/v water: MeCN: MeOH. The optimum desorption solvent composition was in 
agreement with expected results; considering the wide range of Log P values studied, a 
considerable amount of water would be required to desorb polar compounds from the fiber coating, 
while a sufficient amount of organic solvent would be needed to desorb non-polar compounds 
(Figure 2.6A). The same experimental design was used to assess carryover values; not surprisingly, 
the attained results converged with the above discussed results. The best conditions to minimize 
carryover were water (25%), MeCN (75%), and MeOH (0%) (Figure 2.6B). As this test was 
performed by using the inverse of values obtained for carryover, the maximum point denotes the 
lowest carryover obtained. Although the attained carryover percentage (less than 3% for all 
analytes, except for Phenylbutazone and Tolfenamic acid, at 5 and 8%, respectively) in the final 
desorption solution is considered acceptable in terms of quantitative analysis requirements, 
potential false positive results should be kept in mind in cases where extractions from samples 
characterized by high concentrations of target compounds are followed by extractions from low 
concentration samples or blanks. Therefore, it is recommended that an additional desorption step 
is performed prior to the next SPME cycle. This additional desorption step, when combined with 




While addition of formic acid to the desorption solvent was found to improve overall 
desorption efficiency for most compounds, certain compounds, including lactams and 
fluoroquinolones, failed to present enough stability under such acidic conditions. Erythromycin, 
in particular, was observed to be very unstable under acidic conditions.179 Thus, formic acid was 
not added to the final desorption solution selected in the developed method. 
Figure 2.6 Optimum contour plot for special cubic model to fit experimental data for all compounds 
under study. (A: Desorption, B: Carryover). 
2.4.5 Time profiles 
Extraction time profiles were determined by extracting spiked chicken samples at 1 MRL 
level at different time points, within the range of 10–60 min, under optimized conditions. 
According to the attained results, most polar compounds reached equilibrium within 60 min, while 
the majority of the hydrophobic compounds under study did not reach equilibrium within this time 
period. As a compromise between extraction efficiency and overall analysis time, 60 min was 
selected as the final extraction time. Figure 2.7 presents the extraction time profiles of 




conditions, extraction of most hydrophobic compounds would occur under the pre-equilibrium 
regime. 
However, owing to the automation of the method, which enables precise control over 
extraction time, carrying out pre-equilibrium extractions will not affect the precision of the 
method. Desorption time profiles were determined by extracting spiked PBS samples at the 1 MRL 
level at various times (10–120 min). Although the results showed that most compounds reached 
quantitative desorption within only 15 min, 20 min were selected as desorption time in order to 
















The final optimized SPME parameters presented in Figure 2.1 yielded sufficient extraction 
efficiency, minimum carryover, and minimum use of organic solvents, while affording minimum 
manual handling during the sample preparation steps. A total time of 1 h 21 m is needed to achieve 
SPME extraction and desorption; supposing the 96-pin system is fully utilized within a run of the 
proposed workflow (i.e., 96 samples per run), the proposed method thus offers a time per sample 
of less than 1 min. 
2.4.6 Matrix effect 
The presence of matrix effects (MEs) is considered one of the main challenges in the multi-
residue determination of drugs in tissue by LC-MS due to the complexity of the matrix under study. 
Matrix effects were calculated by the equation: ME% = (slope of matrix-matched calibration 
curve − slope of reagent-only calibration curve) × 100%/slope of reagent-only calibration curve.32 
Matrix effects were evaluated for three different types of chicken tissues; breast, liver, and thighs. 
Figure 2.8 shows the matrix effects for the analytes studied versus their retention time. 
Absolute matrix effects were determined by the ratio of the peak areas of analytes spiked at 
three levels, low (0.3X), medium (0.9X), and high (2.5X), with extracts from the pooled matrix 
and neat standards at the same concentrations, as described by Matuszewski et al.180 Absolute 
matrix effects values are presented in Table 2.6 and Figure 2.9. Absolute matrix effect values for 
the majority of compounds were within the range of 80–120%. Only florfenicol amine displayed 
significant signal suppression (31%, 45% and 56% at 0.3X, 0.9X and 2.5X respectively), while six 





Figure 2.8 Matrix effects (%) of the final method for target analytes in three types of chicken tissue 
(breast, liver, and thigh) plotted vs. retention time. 




No significant differences were observed when the results were calculated without 
normalization with internal standard. This is mainly due to the use of matrix-matched calibration 
and minimal matrix effects offered by SPME which is capable of isolating and enriching target 
analytes with effective and efficient sample clean-up. However, we selected to use one internal 
standard in this method in order to compensate in case of variations from pin to pin, as well as 
variations in desorption solvent loss due to evaporation during the desorption step. The results 
confirm that SPME provides clean sample extracts, thus offering reliable results while minimizing 
analytical instrument maintenance requirements.120,131 
2.4.7 Validation of the method 
The target analytes in this work were selected to represent more than 12 classes of veterinary 
drugs varying in physiochemical properties. The developed method was validated following FDA 
guidelines for methods validation for drugs and biologics.176 The selectivity of the method was 
evaluated via an analysis of blank chicken samples (n = 10). No background peaks, above a signal-
to-noise ratio of 3, were present at the same elution time as the target analytes, showing that the 
method is free of endogenous interferences. Figure 2.10 displays an example of obtained total ion 





Figure 2.10 Total ion chromatogram.(A and B) Pooled blank chicken sample. (C) Pooled blank 
chicken spiked with all target analytes at 0.1X level. (D) Pooled blank chicken spiked with all target 
analytes at 1X level. All chromatograms are normalized to the highest peak except for B which is 
normalized to the same scale as (C). 
Method linearity was evaluated for each compound through the establishment of matrix-
matched calibration curves, which were prepared in a range of 0.1–3X in pooled chicken, and 
analyzed with the proposed SPME-LC-MS/MS method in triplicate. Pearson's coefficient (R) 
values ranged from 0.9956 to 0.9999 for all analytes under study, indicating good correlation 




compounds, and a lack of fit (LOF) test performed at the 5% level presented no significance 
difference (p > 0.05), indicating that well-adjusted models were obtained for all target compounds. 
Linear ranges, limits of quantitation, determination coefficients (R2), and lack of fit test 
results are presented in Table 2.6. 
The accuracy and precision of the method were calculated using six replicates per 
concentration (n = 6) at three levels; low, mid, and high (0.3X, 0.9X and 2.5X). To evaluate the 
accuracy of the method, the mean relative recovery of the analyte was calculated by fortifying 
blank chicken samples at the three concentration levels mentioned above. The spiked samples were 
quantified using the matrix matched calibration curves. Accuracy of the method as presented in 
Table 2.6 and Figure 2.11 was within 80–120% for all analytes except for Desethylene 
Ciprofloxacin (73%) Sulfadimethoxine (74%) and Tetracycline (63%) at low level concentration 
(0.3X), Oxyclozanide (60%) at mid level concentration (0.9X), 6-phenylthiouracil (134%), 
Albendazole (121%), and Oxytetracycline (121%) at high concentration level (2.5X). Intra-day 
and inter-day precision are presented in Figure 2.12. 
LOQs were calculated as the lowest point of the matrix matched calibration curves with RSD 
≤20%. LOQs equal to 0.1X were achieved for all analytes with the exceptions of 6-
Phenylthiouracil, Danofloxacin, Desethylene Ciprofloxacin, Norfloxacin, and Triclabendazole 
with LOQ of 0.25X and Oxyclozanide 0.9X. This could be attributed to the low affinity of these 




Figure 2.11 Accuracy of the final method for target analytes. 





Stability results were evaluated by calculating the percentage decrease in calculated 
concentrations of analytes after 48 h, 72 h, and one week of storage in the desorption solvent 
relative to the concentration results from the first day of preparation. A statistically significant 
decrease was only observed after 1 week of storage for tetracyclines and lactams. All other analytes 
were found to be stable within the studied conditions. 
2.4.8 Application of final method towards analysis of chicken samples 
The final developed method was used to analyze chicken samples purchased from five local 
grocery stores. Three different types of chicken tissues were selected: breast, liver, and thighs. 
Most of the samples analyzed were free from the target analytes, except for chicken samples from 
one supplier, where the following analytes were present at levels below established MRLs: 
sulfapyridine, sulfamerazine, enrofloxacin, orbifloxacin, sulfamethizole, sulfamethazine, 
sulfamethoxypyridazine, sulfachloropyridazine, doxycycline, sulfadoxine, sulfamethoxazole, 
sulfaethoxypyridazine, sulfadimethoxine. Although the amounts detected were below limits of 
quantification, chicken thigh tissue was observed to present consistently higher values of the 
detected analytes in comparison to the other tested tissues.
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Table 2.6 Validation of the developed method under optimized conditions (conditioning: 1.0 mL, 50/50 (MeOH/H2O, v/v) 30 min; extraction: 1.5mL diluted homogenized chicken, 60 min 
extraction time; rinsing: 1.0 mL H2O, 10 sec with agitation; desorption: 0.4 mL 37. 
Compound 
MRL (X) Linearity Accuracy (%) Intra-day precision (%) Inter-day precision (%) 
Absolute matrix effect 
(%) 
ng g-1 Range LOQ R2 LOF 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 
2-Amino flubendazole 10 0.1 – 3X 0.1X 0.9968 0.1668 105 91 92 10 8 7 9 6 9 107 105 100 
5-HydroxyThiabendazole 100 0.1 – 3X 0.1X 0.9996 0.6585 90 98 107 3 3 4 5 6 8 102 100 102 
6-Phenylthiouracil 400 0.25 – 3X 0.25X 0.9991 0.7475 102 102 134 15 15 6 12 15 9 96 100 102 
Acepromazine 10 0.1 – 3X 0.1X 0.9993 0.9666 97 91 93 12 6 6 8 6 10 111 113 107 
Albendazole 50 0.1 – 1X 0.1X 0.9963 0.3941 91 94 121 4 6 3 11 16 17 86 93 96 
Albendazole 2 aminosulfone 50 0.1 – 3X 0.1X 0.9986 0.313 98 98 110 9 2 2 9 6 10 95 98 100 
Albendazole Sulfone 50 0.1 – 3X 0.1X 0.9996 0.9327 96 97 101 4 2 4 5 4 7 100 101 101 
Albendazole Sulfoxide 50 0.1 – 3X 0.1X 0.9997 0.9808 99 99 106 5 3 3 8 5 7 97 97 101 
Azaperone 10 0.1 – 3X 0.1X 0.9995 0.9611 90 88 96 6 1 5 6 5 8 105 92 99 
Betamethasone 100 0.1 – 3X 0.1X 0.9987 0.2617 103 103 98 3 3 4 6 4 10 111 110 109 
Cambendazole 10 0.1 – 3X 0.1X 0.9996 0.5943 97 98 102 3 2 3 6 6 4 111 104 101 
Carbadox 30 0.1 – 3X 0.1X 0.9994 0.888 90 93 105 3 5 6 6 8 11 93 104 102 
Chlorpromazine 10 0.1 – 3X 0.1X 0.9984 0.2482 94 95 114 11 7 2 10 11 8 110 107 104 
Chlortetracycline 200 0.1 – 3X 0.1X 0.9989 0.7779 104 94 94 10 9 6 11 7 10 106 108 111 
Clenbuterol 10 0.1 – 3X 0.1X 0.9981 0.17 95 101 101 4 8 8 6 9 8 106 103 106 
Clindamycin 100 0.1 – 3X 0.1X 0.9993 0.071 102 101 106 6 4 9 7 6 10 103 103 102 
Cloxacillin 10 0.1 – 3X 0.1X 0.9995 0.9664 100 96 102 6 4 4 9 7 10 119 98 100 
Danofloxacin 70 0.25 – 3X 0.25X 0.9971 0.0611 85 96 115 10 7 6 13 10 7 131 116 109 
Desethylene ciproflaxin 100 0.25 – 3X 0.25X 0.9973 0.6129 73 98 114 26 8 3 31 13 10 130 130 106 




Table 2.6 Continued 
Compound 
MRL (X) Linearity Accuracy (%) Intra-day precision (%) Inter-day precision (%) 
Absolute matrix effect 
(%) 
ng g-1 Range LOQ R2 LOF 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 
Dicloxacillin 100 0.1 – 3X 0.1X 0.9998 0.9945 102 99 109 9 6 6 7 6 8 131 100 100 
Difloxacin 50 0.1 – 3X 0.1X 0.9994 0.8808 103 97 100 8 5 6 7 6 7 104 106 108 
Dimetridazole 10 0.1 – 3X 0.1X 0.9982 0.4102 96 97 104 4 6 9 8 7 11 98 97 98 
Doxycycline 100 0.1 – 3X 0.1X 0.9993 0.7341 97 96 100 6 9 4 9 8 8 116 107 106 
Emamectin 10 0.1 – 3X 0.1X 0.9922 0.3439 110 105 107 4 5 6 13 12 9 101 99 102 
Enrofloxacin 20 0.1 – 3X 0.1X 0.9996 0.9574 97 99 114 7 6 4 8 6 9 114 106 105 
Erythromycin 125 0.1 – 3X 0.1X 0.9987 0.7575 90 94 98 11 8 7 9 6 10 109 113 109 
Fenbendazole 100 0.1 – 3X 0.1X 0.9934 0.0541 100 94 99 8 8 7 11 12 12 82 95 97 
Fenbendazole Sulfone 400 0.1 – 3X 0.1X 0.9991 0.8673 102 96 106 8 3 3 14 6 5 77 93 95 
Florfenicol amine 100 0.1 – 3X 0.1X 0.9966 0.5284 89 101 100 6 7 9 9 9 10 31 45 56 
Flubendazole 10 0.1 – 3X 0.1X 0.9993 0.4049 101 94 104 6 2 2 7 5 4 98 99 98 
Flunixin 10 0.1 – 2X 0.1X 0.9993 0.1371 102 94 103 2 1 2 8 8 8 97 97 99 
Haloperidol 10 0.1 – 3X 0.1X 0.9974 0.1244 106 92 106 6 8 8 9 6 9 105 105 104 
Hydroxy dimetridazole 50 0.1 – 3X 0.1X 0.9991 0.6471 100 95 104 6 3 9 10 5 11 97 101 101 
Hydroxy Ipronidazole 10 0.1 – 3X 0.1X 0.9995 0.6841 95 97 92 6 8 5 7 8 8 102 103 101 
Ipronidazole 10 0.1 – 3X 0.1X 0.9958 0.8951 102 97 105 3 7 11 9 7 10 99 98 101 
Ketoprofen 10 0.1 – 3X 0.1X 0.9996 0.7832 100 98 107 4 1 3 8 7 8 98 99 99 
Levamisole 100 0.1 – 3X 0.1X 0.9985 0.1678 92 96 106 3 3 5 4 6 9 99 102 101 
Lincomycin 100 0.1 – 2X 0.1X 0.9989 0.885 93 95 112 9 6 3 9 8 4 103 102 102 




Table 2.6 Continued 
Compound 
MRL (X) Linearity Accuracy (%) Intra-day precision (%) Inter-day precision (%) 
Absolute matrix effect 
(%) 
ng g-1 Range LOQ R2 LOF 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 
Mebendazole amine 10 0.1 – 3X 0.1X 0.9996 0.7758 92 91 104 5 4 6 8 8 7 107 107 110 
Melengestrol Acetate 25 0.1 – 3X 0.1X 0.999 0.4051 108 90 98 3 2 5 11 9 9 94 93 92 
Morantel 150 0.1 – 3X 0.1X 0.9988 0.3643 94 94 98 4 7 6 5 6 8 103 105 111 
Norfloxacin 50 0.25 – 3X 0.25X 0.9972 0.1145 89 96 114 13 6 5 25 9 8 119 107 100 
Orbifloxacin 50 0.1 – 3X 0.1X 0.9997 0.9792 106 101 109 7 9 3 8 8 8 111 105 103 
Oxacillin 100 0.1 – 3X 0.1X 0.9969 0.1026 98 100 103 6 4 2 7 5 8 130 101 101 
Oxfendazole 800 0.1 – 3X 0.1X 0.9996 0.958 100 98 108 5 2 3 6 4 5 98 99 96 
Oxyclozanide 10 0.9 – 3X 0.9X 0.9912 0.267 - 60 86 - 15 13 - 51 30 98 95 96 
Oxyphenylbutazone 100 0.1 – 3X 0.1X 0.9981 0.6933 102 101 109 6 7 2 9 8 5 96 97 98 
Oxytetracycline 200 0.1 – 3X 0.1X 0.994 0.349 88 104 121 9 12 7 14 12 12 120 118 114 
Phenylbutazone 100 0.1 – 3X 0.1X 0.9987 0.5731 92 101 114 4 10 3 8 8 5 97 99 97 
Pirlimycin 300 0.1 – 3X 0.1X 0.9992 0.4285 100 97 107 5 2 6 8 5 11 100 101 98 
Prednisone 100 0.1 – 3X 0.1X 0.998 0.9244 92 102 101 3 4 3 8 7 8 95 92 97 
Promethazine 10 0.1 – 3X 0.1X 0.9988 0.1956 98 97 110 10 9 6 9 8 8 112 112 108 
Propionylpromazine 10 0.1 – 3X 0.1X 0.9998 0.9644 94 94 115 7 9 5 6 9 8 107 106 100 
Ractopamine 30 0.1 – 3X 0.1X 0.9984 0.0569 94 97 107 4 4 5 6 7 8 98 101 104 
Sarafloxacin 50 0.1 – 3X 0.1X 0.9987 0.0651 90 107 100 6 6 7 20 8 13 114 111 104 
Sulfachloropyridazine 100 0.1 – 3X 0.1X 0.9986 0.2934 96 99 103 6 3 2 6 5 8 101 100 101 
Sulfadimethoxine 100 0.1 – 3X 0.1X 0.9927 0.583 126 96 113 24 15 12 34 16 17 126 114 106 




Table 2.6 Continued 
Compound 
MRL (X) Linearity Accuracy (%) Intra-day precision (%) Inter-day precision (%) 
Absolute matrix effect 
(%) 
ng g-1 Range LOQ R2 LOF 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 0.3X 0.9X 2.5X 
Sulfaethoxypyridazine 100 0.1 – 3X 0.1X 0.9998 0.7936 92 96 98 3 4 3 4 4 6 101 101 102 
Sulfamerazine 100 0.1 – 3X 0.1X 0.9991 0.5314 98 97 108 7 3 4 7 5 9 99 103 103 
Sulfamethazine 100 0.1 – 3X 0.1X 0.9986 0.2373 108 99 106 4 6 2 6 4 6 106 102 102 
Sulfamethizole 100 0.1 – 3X 0.1X 0.9977 0.1043 96 102 111 7 4 2 7 7 8 99 103 102 
Sulfamethoxazole 100 0.1 – 3X 0.1X 0.9987 0.7362 91 99 104 6 3 2 6 7 8 101 102 100 
Sulfamethoxypyridazine 100 0.1 – 3X 0.1X 0.9988 0.6857 103 99 100 5 3 1 6 5 5 107 107 104 
Sulfapyridine 100 0.1 – 3X 0.1X 0.9993 0.5457 94 99 108 4 4 3 5 6 7 101 100 101 
Sulfaquinoxaline 100 0.1 – 3X 0.1X 0.9998 0.9357 96 101 109 4 2 3 5 4 4 98 100 100 
Sulfathiazole 100 0.1 – 3X 0.1X 0.9992 0.0588 99 96 105 4 3 8 8 6 10 102 99 103 
Tetracycline 200 0.1 – 3X 0.1X 0.9952 0.6236 63 92 107 20 7 8 21 7 7 123 119 118 
Tolfenamic Acid 200 0.1 – 2X 0.1X 0.9993 0.2278 103 90 98 3 2 2 5 7 6 99 99 100 
Triclabendazole  50 0.25 – 2X 0.25X 0.9972 0.0772 106 84 97 4 4 6 8 12 10 96 96 97 
Triclabendazole Sulfoxide 50 0.1 – 2X 0.1X 0.9952 0.0621 103 88 103 9 6 4 18 12 9 97 98 99 
Trifluropromazine 10 0.1 – 3X 0.1X 0.9986 0.5501 101 93 110 8 7 7 10 9 8 100 103 100 
Tylosin 200 0.1 – 3X 0.1X 0.9962 0.0558 105 94 105 9 5 7 11 7 8 111 107 103 
Virginiamycin 100 0.1 – 3X 0.1X 0.9953 0.118 103 98 100 3 2 3 7 5 9 100 103 102 




The developed method is the first and most comprehensive SPME approach to date for 
analysis of multi-residue veterinary drugs in meat in terms of the number of analytes tested as well 
as with respect to the range of physical and chemical properties covered. The method is fully 
automated, allowing for simultaneous analysis of up to 96 samples. Therefore, it offers a cost-
effective alternative for analysis of veterinary drug residues in meat, additionally offering 
improved precision and shorter analysis times as compared to traditional sampling procedures. 
Given the growing public interest and concern regarding food safety, and taking into account 
the importance of the meat industry to the global economy, the demand for sophisticated, 
automated high-throughput analytical procedures for monitoring of drug residues in meat is 
expected to continue growing. The method is ideal for large-scale monitoring of multi-residue 
drugs, and is thus proposed as a valuable tool for regulatory monitoring and enforcement of MRLs. 
In addition to its superior performance and wide coverage, it is environmentally friendly due to 
the minimum amount of organic solvents needed as compared to traditional methods. Furthermore, 
it can be potentially adopted for other high-throughput analyses in biological, pharmaceutical, food 
science, and metabolomics applications. The proposed SPME method for analysis of multi-residue 
veterinary drugs in meat offers many advantages in comparison to currently adopted approaches. 
Notably, it offers fully automated and high-throughput monitoring, thus allowing for shorter 
analysis times per sample as compared to traditional sampling procedures. Further, the range of 
compounds detectable by the method include analytes from several drug classes, and of varying 
physical and chemical properties. The validation results and minimal matrix effects demonstrate 




It is expected that the developed method will be tested in the near future in different food matrices 
and for ultra-fast screening of multi-class multi-residue drugs via direct interface to MS 
technologies. Furthermore, studies to compare results of this method to other established methods 






Comparison of Solid-Phase Microextraction to Solvent Extraction and 
QuEChERS for Quantitative Analysis of Veterinary Drug Residues in 
Chicken and Beef Matrices 
 
3.1 Preamble 
The materials in this chapter have been published as a research article: Khaled, A.; Singh, 
V.; Pawliszyn, J. Comparison of Solid-Phase Microextraction to Solvent Extraction and 
QuEChERS for Quantitative Analysis of Veterinary Drug Residues in Chicken and Beef Matrices. 
J. Agric. Food Chem. 2019, 67, 12663–12669. The article is part of the 55th North American 
Chemical Residue Workshop special issue. Materials for all sections of this current chapter are 
reprinted from this research article with the permission of Journal of Agricultural and Food 




property of ACS publications and any further request for re-use of this information should be 
requested directly from them (DOI: https://doi.org/10.1021/acs.jafc.9b01570). 
The contribution of co-author Varoon Singh was in preparation of HLB particles used to 
prepare the SPME coating used in this work. All of the experimental design, planning, and work 
conducted in the laboratory, data processing, analysis, interpretation, and writing were performed 
by the author of the thesis. 
I, Varoon Singh, authorize Abir Khaled to use the material for her thesis. 
3.2 Introduction 
Veterinary drugs are widely used in food-producing animals to prevent diseases and promote 
growth.84,109,181 It is estimated that nearly 80% of the world production of antibiotics is used on 
animals and that 80% of all antibiotics sales in the U.S. stem from the sale of antibiotics used to 
protect food-producing animals from infection and promote their growth.182,183 To ensure that 
veterinary drugs are used responsibly and that any possible residues left in the edible tissues of 
animals do not pose health risks to consumers, regulatory agencies worldwide have established 
maximum residue limits (MRLs) for veterinary drugs in animal-derived foodstuffs.10,13,82 
MRL compliance assessments demand robust and reliable analytical methods capable of 
detecting a wide range of potential residues. With recent advancements in liquid chromatography 
(LC) coupled to mass spectrometry (MS) and tandem mass spectrometry (MS/MS), analytical 
methods for monitoring veterinary drug residues have expanded from simple procedures only 




analytes of concern as possible.96 Unfortunately, MS/MS detection is highly vulnerable to matrix 
effects as a result of the complexity of animal tissue composition.184 Co-eluting matrix components 
can sometimes affect the ionization efficiency of target analytes, leading to either suppression or 
enhancement of signals. These matrix effects, consequently, may affect the qualitative and 
quantitative performance of the method.185 As such, sample extraction procedures capable of 
isolating analytes of interest while removing interfering matrix compounds are essential in 
achieving reliable results and maintaining instrument performance.117 On the other hand, 
simultaneous extraction and analysis of a wide variety of veterinary drugs with a wide range of 
physico-chemical properties require employment of non-selective, generic sample preparation 
procedures.186 
Among sample preparation procedures used for multi-residue methods, the most frequently 
reported generic sample preparation procedures are solvent extraction (SE),13,91 and quick, easy, 
cheap, effective, rugged, and safe (QuEChERS), a hybrid method combining SE and dispersive 
solid-phase extraction (d-SPE).186,187 Both procedures have been widely assessed and validated in 
the literature and are accepted for routine analysis by many accredited laboratories and 
governmental organizations.9,31,32,84,91,185,188 
Recently, a fully automated and high-throughput method using direct immersion solid phase 
microextraction (DI-SPME) was developed and validated for quantitative analysis of 77 veterinary 
drugs in chicken tissue.189 In this work, a SPME phase prepared with a matrix-compatible coating 




demonstrated as capable of extracting a broad range of analytes with a wide range of 
physiochemical properties from chicken tissue, with minimal matrix effects observed.189 
The aims of the current study were to expand the scope of the previously developed and 
validated SPME method189 by testing its applicability for other matrices of interest (beef tissue) 
and 25 additional analytes of interest. In addition, this work encompassed a comparison of the 
developed method to two “gold standard” methods developed and implemented by the United 
States Department of Agriculture (USDA) for quantitation of multi-residue veterinary drugs in 
meat, namely, a modified QuEChERS method and a SE method.9,32,91 This comparison took into 
consideration factors of impact, such as matrix effects, linearity, limit of quantitation (LOQ), 
accuracy, repeatability, sample throughput, and environmental footprint. 
3.3 Experimental Section 
3.3.1 Chemicals and Materials 
To expand the applicability of the method, beef muscle tissue was additionally selected as 
the target matrix and 25 new veterinary drugs not included in the previous study were considered 
herein for analysis. Standards of these additional veterinary drugs and their suppliers are listed in 
Table 3.1. The corresponding class of each drug is presented in Table 3.2. The veterinary drugs 
under study were selected from the list of standards specified in the official method for screening 
and confirmation of animal drug residues developed by the USDA (CLG-MRM1.08).31 LC–MS-
grade acetonitrile (MeCN), methanol (MeOH), water, and formic acid (FA) were purchased from 




dimethylformamide (DMF), and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich 
(Oakville, Ontario, Canada). Nunc U96 Deep Well 2 and 1 mL plates made of polypropylene (PP) 
were purchased from VWR International (Mississauga, Ontario, Canada). PP inserts (600 μL) used 
in the 1 mL 96-well plates used during the desorption step were purchased from Analytical Sales 
and Services (Flanders, NJ, U.S.A.). The end-capped C18 sorbent used for d-SPE was obtained 
from UCT (Bristol, PA, U.S.A.). High-tolerance 304 stainless-steel rods (1/16 in. diameter) used 
for SPME pins were purchased from McMaster-Carr (Aurora, OH, U.S.A.). HLB particles were 
synthesized in-house as previously described.189 
Stock solutions, deuterated internal standard, and mixed standards were prepared as 
described previously in chapter 2.189 Organic beef and chicken muscle tissue samples, five samples 
of each, were obtained from five different local grocery stores to serve as the pooled matrix. Five 
distinct samples of non-organic chicken and three non-organic beef were purchased from different 





Table 3.1 Physico-chemical properties and supplier information for additional 25 analytes 




6-Propyl-2-thiouracil Sigma-Aldrich C7H10N 170.232 1.37 
Amoxicillin Sigma-Aldrich C16H19N3O5S 365.404 0.61 
Ampicillin Sigma-Aldrich C16H19N3O4S 349.4048 1.35 
Bacitracin Sigma-Aldrich C66H103N17O16S 1422.69 -2.21 
Carazolol Sigma-Aldrich C18H22N2O2 298.379 3.59 
Cefazolin Sigma-Aldrich C14H14N8O4S3 454.507 1.13 
Ciprofloxacin Sigma-Aldrich C17H18FN3O3 331.341 0.65 
Desacetyl cephapirin TRC2 C15H15N3O5S2 381.427 0.32 
Desethylene ciprofloxacin HCl TRC2 C15H17ClFN3O3 341.8 -0.14 
Dimetridazole Sigma-Aldrich C5H7N3O2 141.0 0.31 
Florfenicol Sigma-Aldrich C12H14Cl2FNO4S 357.0 -0.12 
Gamithromycin Sigma-Aldrich C40H76N2O12 776.5 3.89 
Meloxicam Sigma-Aldrich C14H13N3O4S2 351.0 2.71 
Metamizole Sigma-Aldrich C13H17N3O4S 311.0 -0.74 
Nafcillin Sigma-Aldrich C21H22N2O5S 414.1 3.52 
Norfloxacin Sigma-Aldrich C16H18FN3O3 319.3 0.82 
Novobiocin Sigma-Aldrich C31H36N2O11 612.2 2.86 
Penicillin G TRC2 C16H18N2O4S 334.0 1.67 
Ronidazole Sigma-Aldrich C6H8N4O4 200.0 -0.45 
Salbutamol Sigma-Aldrich C13H21NO3 239.1 0.01 
Sulfadiazine Sigma-Aldrich C10H10N4O2S 250.277 -0.12 
Thiabendazole Sigma-Aldrich C10H7N3S 201.0 2.47 
Tildipirosin Sigma-Aldrich C41H71N3O8 733.5 4.70 
Tilmicosin Sigma-Aldrich  C46H80N2O13 868.5 4.95 
Tulathromycin TRC2 C41H79N3O12 805.5 4.07 
1 Data taken from www.chemspider.com, accessed March 2019, LogP data taken from computational 
predictions ACD/LogP  




3.3.2 LC–MS/MS Method 
All experiments were carried out using an UltiMate 3000RS HPLC system coupled to a TSQ 
Quantiva triple quadrupole mass spectrometer (Thermo Fisher Scientific, San Jose, CA, U.S.A.). 
MS/MS analysis was performed in positive ionization mode under selected reaction monitoring 
(SRM) conditions. Data acquisition and processing were performed using Xcalibur 4.0 and Trace 
Finder 3.3 software (Thermo Fisher Scientific, San Jose, CA, U.S.A.). Chromatographic 
conditions and analytical column specifications were set as previously described in chapter 2.189 
A Waters (Mississauga, Ontario, Canada) Acquity UPLC C18 HSS T3 (100 × 2.1 mm, 1.7 μm) 
analytical column connected to a guard column (HSS T3, 2.1 × 5 mm, 1.7 μm) was used for 
separation of targeted analytes. The column compartment was maintained at 40 °C, and the flow 
rate was 0.3 mL/min. MeCN/water (70:30, v/v) was used to clean the injection system (flush and 
wash volumes were 1000 and 200 μL, respectively). The mobile phases were water (solvent A) 
and MeCN (solvent B), each containing 0.1% (v/v) formic acid. The gradient was run at 3% B for 
1 min, ramped linearly to 100% B until 11 min, and then held at 100% B until 13 min. The column 
was then returned to 3% B over a 2 min period, whereupon it was allowed to re-equilibrate for 3 
min. The injection volume was 10 μL, and the autosampler was thermostated at 5 °C. MS data 
were processed using Xcalibur software version 4.0 (Thermo Fisher Scientific, San Jose, CA, 
U.S.A.). Mobile phases were degassed for 30 min in a VWR Scientific Aquasonic model 75HT 
(West Chester, PA, U.S.A.) ultrasonic bath before use. Further instrumental details, LC and 





Table 3.2 MS/MS optimized parameters, (m/z), and retention times (RT) of compounds, ions used for 
















2-Aminoflubendazole Anthelmintics 256 123, 95 37, 27 6.19 93 + 
2-Amino mebendazole Anthelmintics 238 105, 77 25, 34 5.03 88 + 
2-Quinoxalinecarboxylic 
acid 
Others 175 131, 104 22, 29 6.15 191 + 
5-Hydroxythiabendazole Anthelmintics 218 191, 147 26, 32 4.69 85 + 
6-Phenyl-2-thiouracil Thyreostats 205 188, 103 17, 26 6.12 69 + 
6-Propyl-2-thiouracil Thyreostats 171 154, 112 17, 19 5.29 57 + 
Acepromazine Maleate Tranquilizers 327 86, 254 19, 23 7.21 65 + 
Albendazole Anthelmintics 266 234, 191 19, 32 7.35 71 + 
Albendazole sulfone Anthelmintics 298 266,159 19, 36 4.94 70 + 
Albendazole sulfoxide Anthelmintics 282 240, 208  10, 23 6.50 75 + 
Albendazole-2-
aminosulfone 
Anthelmintics 240 133,198 28,19 5.68 63 + 
Amoxicillin β-Lactams/cephalosporins 366 349, 114 10, 20 4.18 48 + 
Ampicillin β-Lactams/cephalosporins 350 106, 160 18, 10 5.08 54 + 
Azaperone Tranquilizers 328 165,123 20, 29 5.68 66 + 
Bacitracin Others 475 199, 669 24, 10 6.17 74 + 
Betamethasone Anti-inflammatories 393 325, 347 14, 12 6.17 59 + 
Cambendazole Anthelmintics 303 217, 261 27, 17 6.27 66 + 
Carazolol Tranquilizers 299 116, 222 19, 19 6.38 63 + 
Carbadox Other 263 231, 245 10, 16 5.10 67 + 
Cephapirin β-Lactams/cephalosporins 424 292, 152  14, 22 4.45 66 + 
Cefazolin β-Lactams/cephalosporins 455 323, 333 10, 19 5.71 72 + 
Chlortetracycline HCl Tetracyclines 479 462,444 17, 19 5.80 70 + 
Chlorpromazine HCl Tranquilizers 319 86, 58 19, 30 7.85 63 + 
Ciprofloxacin Fluoroquinolones 332 288, 314 17, 19 5.34 72 + 
Clenbuterol HCl β-Agonists 277 203, 259 16, 10 5.89 47 + 
Clindamycin HCl Macrolides/lincosamides 425 126, 377 27, 18 6.24 78 + 
Cloxacillin Sodium Salt β-Lactams/cephalosporins 436 277, 160 12, 10 8.40 56 + 
Danofloxacin Fluoroquinolones 358 340, 255 21, 18 5.40 80 + 
Desacetyl cephapirin β-Lactams/cephalosporins 382 292, 226 10, 17 3.50 73 + 
Desethylene Ciprofloxacin Fluoroquinolones 306 288, 268 17, 24 4.93 67 + 
Diclofenac Sodium Anti-inflammatories 296 214, 215 33, 19 9.66 112 + 
Dicloxacillin  β-Lactams/cephalosporins 470 452, 212 16, 26 8.90 124 + 



















Dimetridazole Coccidiostats 142 96, 101 16, 10 4.66 38 + 
Doxycycline HCl Tetracyclines 445 267, 321 35, 30 5.54 66 + 
Emamectin Benzoate Anthelmintics 887 158, 868 33, 21 9.73 122 + 
Enrofloxacin Fluoroquinolones 360 342,316  20, 18 5.56 79 + 
Erythromycin Macrolides/lincosamides 734 576,158 17, 27 7.00 85 + 
Fenbendazole Anthelmintics 300 268, 159 20, 34 8.20 77 + 
Fenbendazole Sulfone Anthelmintics 332 300, 159 21, 37 7.30 81 + 
Florfenicol Phenicols 357 198, 182 14, 16 7.40 73 + 
Florfenicol amine Phenicols 248 230, 130 10, 24 1.00 50 + 
Flubendazole Anthelmintics 314 282, 123 22, 35 7.60 80 + 
Flunixin Anti-inflammatories 297 279, 264 22, 33 9.00 75 + 
Gamithromycin Macrolides/lincosamides 778 619, 601 28, 31 6.30 121 + 
Haloperidol Tranquilizers 376 165,123 22, 36 7.22 78 + 
Hydroxy dimetridazole Coccidiostats 158 80,140 10, 10 4.20 30 + 
Hydroxy ipronidazole Coccidiostats 186 168, 122 10, 19 5.90 37 + 
Hydroxy metronidazole Coccidiostats 188 123, 126 10, 17 3.77 47 + 
Ipronidazole Coccidiostats 170 124, 109 17, 24 6.87 54 + 
Ketoprofen Anti-inflammatories 255 209, 105 14, 23 8.60 59 + 
Levamisole HCl Anthelmintics 205 178, 123 21, 28 4.90 66 + 
Lincomycin  Macrolides/lincosamides 407 126, 359 26, 18 4.90 76 + 
Mebendazole Anthelmintics 296 264, 105 20, 33 7.35 75 + 
Melengestrol Acetate Others 397 279,337 20, 13 10.50 88 + 
Meloxicam Anthelmintics 352 115, 141 19, 20 8.87 67 + 
Metamizole Anti-inflammatories 218 56, 97 17, 12 4.53 47 + 
Metronidazole Anthelmintics 172 128, 82 14, 23 4.30 48 + 
Morantel Tartrate Hydrate Anthelmintics 221 123, 111 35, 25 6.03 73 + 
Nafcillin β-Lactams/cephalosporins 415 199, 171 14, 34 8.60 78 + 
Norfloxacin Fluoroquinolones 320 302, 276 20, 17 5.26 76 + 
Novobiocin Others 613 189, 133 27, 51 10.15 80 + 
Orbifloxacin Fluoroquinolones 396 352, 295 17, 23 5.68 83 + 
Oxacillin  β-Lactams/cephalosporins 402 243, 160 13, 11 8.10 68 + 
Oxfendazole Anthelmintics 316 159, 191 32, 20 6.44 68 + 
Oxyclozanide Anthelmintics 403 186, 83 22, 20 6.60 30 + 
Oxyphenylbutazone Anti-inflammatories 325 160, 162 20, 19 8.68 69 + 
Oxytetracycline HCl Tetracyclines 461 426, 443 18, 10 5.34 67 + 



















Phenylbutazone Anti-inflammatories 309 120, 160 42, 19 10.08 71 + 
Pirlimycin HCl Macrolides/lincosamides 411 363,112 16, 25 6.04 77 + 
Prednisone Anti-inflammatories 359 341, 295 10, 14 7.20 65 + 
Promethazine HCl Tranquilizers 285 86, 198 17, 25 7.26 46 + 
Propionylpromazine HCl Tranquilizers 341 86, 58 19, 30 7.70 68 + 
Ractopamine HCl β-Agonists 302 164, 284 15, 10 5.44 53 + 
Ronidazole Anthelmintics 201 140, 55 10, 21 4.75 30 + 
Salbutamol β-Agonists 240 148, 222 17, 10 4.22 42 + 
Sarafloxacin HCl Hydrate  Fluoroquinolones 386 299, 368 26, 21 5.83 85 + 
Sulfachloropyridazine Sulfonamides 285 156, 108 16, 24 4.90 57 + 
Sulfadiazin Sulfonamides 251 156, 108 14, 22 7.10 48 + 
Sulfadimethoxine Sulfonamides 311 156, 108 20, 27 6.53 72 + 
Sulfadoxine Sulfonamides 311 108, 154 25, 27 6.60 68 + 
Sulfaethoxypyridazine Sulfonamides 295 156, 108 17, 25 5.35 64 + 
Sulfamerazine Sulfonamides 265 172, 108 16, 24 5.74 59 + 
Sulfamethazine Sulfonamides 279 186, 156 17, 18 5.70 65 + 
Sulfamethizole Sulfonamides 271 92, 108 24, 22 6.48 47 + 
Sulfamethoxazole Sulfonamides 254 108, 156 23, 15 5.76 154 + 
Sulfamethoxypyridazine Sulfonamides 281 156, 108 16, 24 5.20 63 + 
Sulfapyridine Sulfonamides 250 156, 108 16, 24 7.08 57 + 
Sulfaquinoxaline Sulfonamides 301 156, 108 17, 25 5.05 69 + 
Sulfathiazole Sulfonamides 256 156, 108 15, 22 5.54 52 + 
Tetracycline HCl Tetracyclines 445 410, 427 18, 10 5.08 67 + 
Thiabendazole Anthelmintics 202 175, 131 25, 32 4.74 74 + 
Tildipirosin Macrolides/lincosamides 368 98, 637 19, 10 6.45 64 + 
Tilmicosin Macrolides/lincosamides 435 174, 99 23, 18 8.10 75 + 
Tolfenamic Acid Anti-inflammatories 262 244, 209 15, 27 10.43 47 + 
Triclabendazole Anthelmintics 359 274, 344 37, 25, 51 10.20 101 + 
Triclabendazole Sulfoxide Anthelmintics 375 357, 360 17, 21 9.39 79 + 
Triflupromazine HCl Tranquilizers 353 248, 86  42, 20 8.14 68 + 
Tulathromycin Macrolides/lincosamides 404 72, 158 19, 21 5.25 62 + 
Tylosin Macrolides/lincosamides 917 772, 174 27, 35 7.22 134 + 
Virginiamycin M1 Others 526 508, 355 12, 17 8.25 72 + 
Xylazine HCl Tranquilizers 221 90, 147  22, 23 5.86 68 + 





3.3.3 Sample Preparation 
Each tissue sample was homogenized under liquid nitrogen using a Freezer/Mill cryogenic 
grinder (SPEX SamplePrep, LLC, Metuchen, NJ, U.S.A.) to produce a fine uniform powder. All 
samples were then combined in equal weights and mixed to produce a pooled matrix. All 
homogenized samples were stored in glass jars at −30 °C until analysis. Spiked tissue samples 
were prepared by weighing 2.0 g of homogenized tissue into a 50 mL PP tube. Each sample was 
then spiked with 200 μL of a working solution containing all analytes under study at their 
respective designated concentrations and 50 μL of an internal standard working solution containing 
flunixin-d3 at 1 ng μL
–1. Samples were vortexed for 1 min and then placed on a benchtop agitator 
for 1 h. Subsequently, samples were stored in a 4 °C fridge overnight to allow for proper 
equilibration and matrix binding of target analytes prior to extraction. Following overnight 
refrigeration, samples were placed on the benchtop agitator for 1 h prior to extraction to allow 
samples to reach room temperature. 
3.3.3.1 Automated SPME Protocol 
The SPME procedure was carried out in accordance with the previously described high-
throughput extraction protocol in chapter 2,189 using the Concept 96 robotic sample preparation 
station [Professional Analytical System (PAS) Technology, Magdala, Germany].137 The Concept 
96 robotic station uses a 96 SPME pin device shown in Figure 2.1, which is compatible with 
commercially available 96-well plates. The main steps of automated SPME are summarized in 




stainless-steel rods, which were cut to 50 mm length. The HLB/PAN coating was deposited on the 
stainless-steel rod surfaces by dip coating as previously reported by Gómez-Ríos et al.190 The 
coating length and thickness was 20 mm and 60 μm, respectively. To prepare the samples for 
SPME extraction, 6 mL of water was added to each individual spiked tissue sample and vortexed 
for 1 min. Next, 1.5 mL of the diluted tissue samples were transferred to the 96-well plate. The 96-
well plate was then placed on the extraction plate of the Concept 96 station, which was 
programmed to consecutively execute the preconditioning of the SPME-coated pins, extraction, 
rinsing, and solvent desorption. While the SPME protocol normally permits direct transfer of the 
96-well plates to the LC autosampler for analysis, for the purpose of maintaining consistency 
among all methods, in the current work, 300 μL of each sample extract was transferred to PP 
autosampler vials and 10 μL was injected into the LC system. 
3.3.3.2 SE 
The SE protocol used in this study was adapted from the USDA multi-class, multi-residue 
method (MMM) described by Lehotay et al.91 In brief, each sample was extracted with 10 mL of 
MeCN/water (4:1, v/v) by vortex shaking (5 min and 1500 rpm in pulse mode) in a multitube 
vortexer, BenchMixer Multi-Tube Vortexer (Benchmark Scientific, Edison, NJ, U.S.A.). Each 
sample was then centrifuged for 3 min at 5000 rpm (Jouan B4i centrifuge, Thermo Electron 
Corporation, Waltham, MA, U.S.A.). A total of 300 μL of the supernatant was transferred to PP 
autosampler vials, and 10 μL was injected into the LC system. No dilution of the sample was 





The QuEChERS method followed in this study is a modified version of the USDA 
QuEChERS/d-SPE method using C18 as the cleanup sorbent as previously described in the 
literature.9 In brief, the QuEChERS procedure was carried out using the same described parameters 
as the SE method above, followed by transfer of full extracts into another 50 mL PP centrifuge 
tube containing a 500 mg end-capped C18 sorbent. The total volume of the extracts is 
approximately 11.5 mL, taking into account 1.5 mL of water in the 2 g tissue samples. Samples 
were then shaken in the multitube vortexer for 30 s and centrifuged for 3 min. A total of 300 μL 
of the final supernatant was transferred to PP autosampler vials. For the purposes of the current 
work, no dilution was performed post-extraction and 10 μL of the final extract was injected into 
the LC system. 
3.4 Results and Discussion 
3.4.1 Matrix Effects 
Matrix effects have significant influence on analyte response, being considered one of the 
main drawbacks of electrospray ionization (ESI)–LC–MS/MS analysis as a result of the co-
extraction and co-elution of interfering matrix components.191,192 Given the complexity of tissue 
as a matrix, reliable data can thus only be attained by use of sample preparation methods that are 
designed to minimize matrix effects.184 In view of this, the degree of matrix effect generated by 
each method was evaluated by comparing the slope of matrix-matched calibration curves against 




effect percentage: ME (%) = (slope of matrix-matched calibration curve – slope of reagent-only 
calibration curve) × 100/slope of reagent-only calibration curve.32 No internal standards were used 
when calculating matrix effects because such results might also be affected by matrix effects, 
which could, in turn, lead to inaccurate results.193 Figure 3.1 shows the matrix effect results for the 
target analytes versus their retention time for the three methods under study in beef and chicken 
tissue. As demonstrated in Figure 3.1, the SPME protocol yielded the best results among all three 
methods in both beef and chicken matrices, where only two compounds, namely, florfenicol amine 
and tildipirosin, displayed signal suppression (−26%) and signal enhancement (55%), respectively, 
in beef, while only florfenicol amine displayed signal suppression (−31%) in the chicken matrix. 
The minimal matrix effects achieved by SPME are mainly attributed to the smooth biocompatible 
PAN layer, which acts as a barrier to prevent interfering matrix components and macromolecules, 
such as proteins and lipids, from adsorbing to the SPME coating120,194,195 while still allowing target 
analytes to adsorb on the HLB coating. In addition, because the extraction rate of analytes by 
SPME coatings is proportional to the free concentration of analytes present in the sample, only a 
small amount of phospholipids is extracted, resulting in very low chromatographic backgrounds 
and minimal suppressive matrix effects, which are usually caused by the highly abundant 




Figure 3.1 MEs (%) of selected drug analytes in (A) beef tissue and (B) chicken tissue versus their 
retention time for all three sample preparation methods under study. Points above or below the green 
lines indicate MEs (%) ± 20%. 
Measured matrix effects for SE and QuEChERS methods displayed similar trends in both 
matrices. In the beef matrix, 30 and 42% of analytes extracted by the QuEChERS and SE methods, 
respectively, displayed either signal enhancement or suppression compared to 30 and 39% in 
chicken tissue. Full results are listed in Table 3.3 for beef tissue and Table 3.4 for chicken tissue. 
Tetracyclines, in particular, such as tetracycline, doxycycline, and oxytetracycline, showed 
significant signal enhancement in both matrices, demonstrating the importance of using a specific 
tetracycline internal standard and matrix-matched calibration for better quantification of these 
compounds when using SE or QuEChERS, as previously suggested by Anumol et al.9 While 
abundant matrix effects are expected in SE, the obtained results for QuEChERS demonstrate that 
the d-SPE cleanup step did not yield sufficiently effective sample clean up given the extra time 
and effort involved in the execution of this extra step. Blasco et al. also observed significant MEs 
for analytes in beef tissue when using the QuEChERS method compared to pressurized liquid 




assert that the sample clean up provided by the d-SPE step does not merit the extra time and effort, 
especially when injecting a small sample equivalent or when a large dilution factor is used.91 While 
large dilution factors are commonly used in SE and QuEChERS methods to minimize matrix 
interferences, high sample dilutions increase limits of detection and reduce overall method 
sensitivity and, as a result, may require the use of newer and more expensive 
instrumentation.32,92,184 In addition, the dilution step introduces an additional step to the already 
tedious sample preparation process, thus increasing time, cost, and probability of error. While SE 
and QuEChERS offer a simple sample preparation procedure, the occurrence of abundant matrix 
effects is a clear drawback that compromises method performance and selectivity as a result of 
interfering peaks.90 Implementation of these methods also requires frequent preventive 
maintenance of expensive equipment, thus leading to significant down time in high-throughput 
laboratories.184 
3.4.2 Linearity and LOQs 
Linearity and LOQ were assessed using matrix-matched calibration curves at six 
concentration levels in the range of 0.1–3X, with three replicates at each level. The calibration 
range was selected to include concentration levels bracketing the MRL. The MRL values shown 
in Tables 3.3 and 3.4 were based primarily on Canadian MRL82 values and U.S. tolerances91,170 in 
both chicken and beef tissues. In general, Canadian MRLs are either equal or less than U.S. 
tolerances; however, in cases where Canadian MRLs were higher than U.S. tolerances, the U.S. 




LOQ was established as the lowest point of the matrix-matched calibration curve that 
produced a response that is both accurate when compared to the expected value (calculated via 
linear regression) with the range of deviation of ≤30% as well as precise [≤30% relative standard 
deviation (RSD)]. 
In terms of linearity, as shown in Figure 3.2, the SPME protocol achieved the best linearity 
results among all three methods, with determination coefficients (R2) higher than 0.99 for 99% of 
the compounds in both matrices compared to 87 and 80% in QuEChERS and SE in beef tissue and 
91 and 87% of compounds in chicken, respectively, achieving (R2) higher than 0.99. 
LOQs for all methods were equal or lower than MRL values for all target analytes under 
study, with the exception of those attained for amoxicillin in the beef matrix with all methods and 
cephapirin in the chicken matrix with the SPME protocol. It is worth noting here that the MRL 
value for amoxicillin used in this study is the Canadian value (10 ng g–1), which is 5 times lower 
than the U.S. value (50 ng g–1). Florfenicol amine could not be quantified adequately with 
QuEChERS and SE in beef tissue as a result of the high noise attained via these methods at the 




listed in Tables 3.3 and 3.4, the LOQs obtained with the SPME method were generally lower than 
those obtained by QuEChERS and SE methods. 
Figure 3.2 Linearity results for selected drug analytes in (A) beef tissue and (B) chicken tissue 
expressed as the number of compounds corresponding to R2 value ranges. 
Figure 3.3 Number of compounds corresponding to LOQ values in (A) beef tissue and (B) chicken 
tissue. 
While QuEChERS and SE are exhaustive methods, which allow for higher recoveries, the 
non-exhaustive extraction provided by SPME enables a lower background noise, resulting in a 




known to lead to the extraction of sample constituents, such as lipids, to LC–MS, which leads to a 
noisy background and, thus, compromises high recovery as well as the precision of the analysis.120 
Better LOQs with SPME can also be attributed to lower sample dilution, 1:3 in SPME compared 
to 1:5 QuEChERS and SE. Moreover, in SPME, the analytes are extracted from a 1500 μL sample 
volume and desorbed in a 400 μL desorption volume, which leads to the enrichment of the analytes. 
Individual LOQ values and determination coefficient values for all compounds under study 
are listed in Table 3.3 for beef tissue and Table 3.4 for chicken tissue. 
3.4.3 Accuracy and Precision 
To determine the accuracy and precision of the three methods under study with respect to 
their intra-day repeatability, pooled matrix blanks were spiked at two concentration levels 
bracketing the MRL, at concentrations corresponding to 0.75X and 1.5X for each analyte, using 
six replicates per concentration (n = 6). The accuracy of each method was calculated on the basis 
of estimated concentration values calculated from the linear regression equation of the matrix-
matched calibration curve. 
As shown in Figure 3.4, excellent accuracy and repeatability results were achieved with the 
SPME protocol, with more than 97 and 99% of analytes falling within the 70–120% range of the 
true concentrations of compounds and RSD of ≤25% at the 0.75X and 1.5X concentration level, 
respectively, in the beef matrix. In comparison, 86 and 92% of analytes could be quantified by 
QuEChERS and 90 and 96% by SE, respectively, under the same parameters. However, all 




concentration levels, with 97 and 99% in SPME, 96 and 97% in QuEChERS, and 91 and 98% in 
SE of analytes falling within the 70–120% range of their true concentrations and RSD of ≤25% at 
both the 0.75X and 1.5X concentration levels, respectively. The better results attained by 
QuEChERS and SE in the chicken matrix compared to beef could be attributed to the lower fat 
content of this matrix and less matrix effects.  
Figure 3.4 Accuracy and repeatability results of the three methods for the target analytes fortified at 
the 0.75X level in (A) beef tissue and (B) chicken tissue and at the 1.5X level in (C) beef tissue and (D) 




The results obtained by the QuEChERS and SE methods in beef tissue further demonstrate 
the importance of using of matrix-matched calibration with internal standards specific for 
compounds, such as tetracyclines and lactams. Accuracy and RSD (%) values are listed in Tables 
3.3 and 3.4 for each analyte under study in beef and chicken tissues, respectively. 
The superior repeatability results, expressed as RSD (%), obtained by SPME can be 
attributed to lower matrix effects and to the fully automated process of the SPME protocol, which 
allows for samples to be extracted simultaneously and under the same conditions with minimum 
random variations, thus reducing the possibility of error during sample preparation. In addition to 
the superior precision afforded by the SPME protocol, automation of the method allows analysts 
to perform other activities during the extraction process, thus enabling more efficient use of their 
time in the laboratory. Conversely, the comparative lower precision of the QuEChERS and SE 
methods could also be attributed to the pronounced matrix effects compared to SPME.
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Table 3.3 Limits of quantification (LOQ), Linearity (n=3 at each level), and average accuracy (ACC), n = 6 at each level, in beef tissue. * designates compounds which could not be quantified 
Compound 
  SPME   QuEChERS   SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X  1.5X 
(ng g-1) ME ACC (RSD) ACC (RSD)   ME ACC (RSD) ACC (RSD)   ME 
ACC 
(RSD) 
  ACC (RSD) 
2-Aminoflubendazole 10 -2 0.1X 0.9981 98 (5) 92 (2)  -5 0.1X 0.9993 104 (4) 105 (4)  27 0.1X 0.9999 101 (3)  105 (3) 
2-Quinoxalinecarboxylic acid 100 -6 0.1X 1.0000 95 (6) 93 (3)  58 0.25X 0.9947 97 (17) 93 (13)  126 0.25X 0.9778 102 (32)  89 (15) 
2-Amino mebendazole 10 -1 0.1X 0.9985 100 (3) 93 (2)  16 0.25X 0.9991 103 (19) 108 (4)  35 0.25X 0.9935 107 (3)  105 (16) 
5-Hydroxythiabendazole 100 -1 0.1X 0.9955 97 (5) 100 (2)  -3 0.1X 0.9971 102 (9) 99 (4)  59 0.1X 0.9952 102 (12)  93 (7) 
6-phenyl-thiouracil 400 1 0.1X 0.9990 95 (6) 92 (4)  -5 0.1X 0.9985 93 (4) 98 (4)  -11 0.1X 0.9981 89 (4)  113 (6) 
6-propyl-2-thiouracil 50 -2 0.25X 0.9987 99 (7) 100 (5)  5 0.5X 0.9983 96 (16) 102 (6)  23 0.5X 0.9989 97 (8)  101 (10) 
Acepromazine 10 -2 0.1X 0.9992 94 (6) 92 (2)  -10 0.1X 0.9994 104 (1) 98 (2)  -1 0.1X 0.9998 105 (3)  101 (1) 
Albendazole 50 -2 0.1X 0.9943 99 (4) 93 (1)  2 0.1X 0.9992 99 (11) 94 (8)  6 0.1X 0.9945 113 (8)  113 (3) 
Albendazole 2-aminosulfone 50 -7 0.1X 0.9999 97 (5) 94 (3)  2 0.1X 0.9896 97 (10) 111 (13)  18 0.1X 0.9967 110 (12)  113 (7) 
Albendazole sulfone 50 -2 0.1X 0.9991 102 (5) 97 (3)  2 0.1X 0.9992 106 (2) 108 (4)  8 0.1X 0.9998 105 (2)  105 (3) 
Albendazole sulfoxide 50 -2 0.25X 0.9971 105 (5) 98 (3)  1 0.1X 0.9925 108 (10) 119 (9)  6 0.1X 0.9966 98 (10)  101 (8) 
Amoxicillin 10 * * * * *  * * * * *  * * * * * * 
Ampicillin 10 -1 0.25X 0.9906 89 (19) 84 (10)  -26 0.5X 0.9942 109 (27) 123 (17)  -3 0.5X 0.9923 93 (25)  89 (14) 
Azaperone 10 -2 0.1X 0.9997 95 (5) 94 (2)  12 0.1X 0.9991 97 (13) 95 (7)  26 0.1X 0.9959 113 (14)  118 (5) 
Bacitracin 500 17 0.1X 0.9946 132 (17) 89 (8)  17 0.25X 0.9982 103 (28) 106 (12)  36 0.25X 0.9499 95 (41)  80 (26) 
Betamethasone 100 -2 0.1X 0.9946 108 (9) 98 (5)  -10 1X 0.9554 86 (0) 96 (22)  -3 1X 0.9923 119 (23)  116 (11) 
Cambendazole 10 -2 0.1X 0.9988 98 (3) 94 (1)  -5 0.1X 0.9969 99 (13) 95 (9)  5 0.1X 0.9961 112 (12)  116 (3) 
Carazolol 10 0 0.1X 0.9989 99 (6) 93 (3)  5 0.1X 0.9955 98 (7) 98 (7)  20 0.1X 0.9986 108 (9)  108 (9) 
Carbadox 30 -7 0.1X 0.9988 100 (7) 90 (5)  13 1X 0.9996 105 (18) 113 (12)  40 1X 0.9982 93 (20)  92 (13) 
Cefazolin 100 -5 0.1X 0.9991 99 (5) 93 (4)  -36 0.1X 0.9997 99 (15) 99 (6)  -48 0.1X 0.9725 98 (23)  89 (15) 




Table 3.3 continued 
Compound 
  SPME   QuEChERS   SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X  1.5X 
(ng g-1) ME ACC (RSD) ACC (RSD)   ME ACC (RSD) ACC (RSD)   ME ACC (RSD)   ACC (RSD) 
Chlortetracycline 200 -4 0.1X 0.9986 99 (7) 92 (4)  25 1X 0.9942 101 (17) 146 (21)  75 1X 0.9965 100 (32)  82 (18) 
Chlorpromazine 10 -3 0.1X 0.9988 91 (4) 92 (3)  -7 0.1X 0.9993 103 (7) 97 (4)  -10 0.1X 0.9968 111 (5)  106 (4) 
Ciprofloxacin 50 -6 0.1X 0.9989 100 (9) 94 (3)  -4 0.5X 0.9887 101 (14) 119 (14)  23 0.5X 0.9970 86 (14)  89 (12) 
Clenbuterol 10 -5 0.1X 0.9991 96 (4) 94 (3)  -9 0.1X 0.9998 101 (6) 99 (3)  16 0.1X 0.9980 101 (3)  102 (3) 
Clindamycin 100 -2 0.1X 0.9968 106 (7) 89 (3)  32 0.1X 0.9917 115 (20) 117 (14)  64 0.1X 0.9872 94 (19)  92 (10) 
Cloxacillin 10 -5 0.1X 0.9993 102 (5) 95 (4)  -9 0.1X 0.9934 110 (14) 119 (9)  -15 0.1X 0.9972 96 (10)  96 (7) 
Danofloxacin 70 -4 0.1X 0.9995 93 (8) 89 (3)  12 0.1X 0.9982 103 (6) 99 (6)  45 0.1X 0.9919 97 (23)  87 (10) 
Desacetyl cephapirin 100 -12 0.1X 0.9995 93 (12) 91 (0)  -9 0.1X 0.9891 100 (38) 109 (23)  -13 0.1X 0.9878 81 (41)  78 (28) 
Desethylene Ciprofloxacin 100 -3 0.1X 0.9985 100 (6) 89 (4)  28 0.1X 0.9996 106 (13) 108 (8)  68 0.1X 0.9914 91 (16)  91 (10) 
Diclofenac 200 2 0.1X 0.9979 102 (6) 94 (4)  -9 0.1X 0.9997 101 (5) 97 (4)  -24 0.1X 0.9994 101 (3)  100 (2) 
Dicloxacillin 100 -3 0.1X 0.9833 102 (28) 128 (31)  11 0.25X 0.9959 95 (26) 85 (19)  5 0.25X 0.9919 106 (14)  107 (9) 
Difloxacin 50 -7 0.1X 0.9974 100 (8) 95 (2)  10 0.1X 0.9998 96 (21) 106 (4)  17 0.1X 1.0000 100 (5)  106 (4) 
Dimetridazole 50 -4 0.1X 0.9995 103 (0) 94 (0)  1 0.1X 0.9933 82 (8) 110 (11)  6 0.1X 0.9980 94 (9)  98 (8) 
Doxycycline 100 -5 0.1X 0.9983 101 (11) 91 (6)  193 0.1X 0.9986 126 (26) 137 (11)  223 0.1X 0.9886 90 (18)  80 (6) 
Doxycycline 100 -5 0.1X 0.9983 101 (11) 91 (6)  193 0.1X 0.9986 126 (26) 137 (11)  223 0.1X 0.9886 90 (18)  80 (6) 
Emamectin 10 6 0.25X 0.9944 100 (11) 94 (6)  -12 0.25X 0.9989 101 (12) 97 (7)  -16 0.25X 0.9958 103 (10)  102 (2) 
Enrofloxacin 20 -5 0.1X 0.9994 99 (8) 95 (3)  -6 0.1X 0.9921 103 (18) 106 (13)  14 0.1X 0.9976 94 (19)  99 (17) 
Erythromycin 100 1 0.1X 0.9976 103 (6) 89 (2)  -8 0.1X 0.9993 104 (8) 106 (7)  8 0.1X 0.9941 92 (7)  94 (5) 
Fenbendazole 100 -3 0.1X 0.9988 99 (5) 88 (2)  6 0.1X 0.9996 99 (16) 94 (9)  4 0.1X 0.9947 113 (12)  112 (2) 
Fenbendazole Sulfone 400 0 0.1X 0.9977 100 (3) 96 (1)  1 0.1X 0.9998 100 (10) 98 (6)  1 0.1X 0.9983 110 (7)  112 (2) 




Table 3.3 continued 
Compound 
  SPME   QuEChERS   SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X  1.5X 
(ng g-1) ME ACC (RSD) ACC (RSD)   ME ACC (RSD) ACC (RSD)   ME 
ACC 
(RSD) 
  ACC (RSD) 
Florfenicol Amine 100 -26 0.1X 0.9993 96 (3) 97 (3)  -86 * * * *  -85 * * * * * 
Flubendazole 10 -3 0.1X 0.9969 99 (4) 94 (2)  1 0.1X 0.9987 97 (14) 95 (8)  -1 0.1X 0.9949 108 (10)  113 (2) 
Flunixin 20 -1 0.1X 0.9999 98 (1) 100 (1)  -7 0.1X 0.9999 102 (1) 101 (1)  -13 0.1X 0.9999 102 (2)  100 (1) 
Gamithromycin 20 0 0.1X 0.9967 104 (9) 91 (6)  58 0.1X 0.9949 115 (24) 117 (15)  129 0.1X 0.9843 87 (24)  86 (14) 
Haloperidol 10 -3 0.1X 0.9962 98 (4) 93 (2)  -6 0.1X 0.9991 99 (12) 97 (7)  -1 0.1X 0.9935 110 (10)  113 (2) 
Hydroxy dimetridazole 50 -1 0.25X 0.9996 99 (3) 97 (5)  -14 0.25X 0.9911 114 (18) 104 (11)  -17 0.25X 0.9962 94 (18)  100 (8) 
Hydroxy ipronidazole 10 -6 0.1X 0.9996 96 (4) 92 (5)  1 0.1X 0.9962 104 (12) 99 (3)  0 0.1X 0.9977 106 (5)  111 (3) 
Hydroxy metronidazole 10 1 0.25X 0.9998 98 (0) 96 (0)  -14 0.25X 0.9984 112 (5) 109 (5)  -4 0.25X 0.9977 112 (11)  98 (8) 
Ipronidazole 10 -4 0.1X 0.9993 98 (6) 94 (4)  -2 0.1X 0.9997 99 (7) 98 (5)  1 0.1X 0.9967 108 (5)  112 (2) 
Ketoprofen 10 -2 0.1X 0.9999 101 (3) 94 (4)  -2 0.1X 0.9991 105 (5) 106 (2)  -6 0.1X 0.9962 101 (5)  106 (5) 
Levamisole 100 0 0.1X 0.9999 95 (6) 92 (4)  9 0.1X 0.9950 96 (22) 100 (13)  46 0.1X 0.9976 96 (17)  97 (13) 
Lincomycin 100 -2 0.1X 0.9994 97 (6) 91 (5)  27 1X 0.9958 108 (29) 116 (15)  33 1X 0.9806 86 (35)  86 (19) 
Melengestrol Acetate 25 0 0.1X 0.9991 93 (5) 84 (3)  -43 1X 0.9972 98 (13) 91 (11)  -60 1X 0.9927 99 (17)  92 (5) 
Meloxicam 20 -2 0.1X 0.9994 97 (4) 93 (1)  12 0.1X 0.9997 98 (7) 99 (4)  -20 0.1X 0.9987 100 (6)  98 (1) 
Metamizole 200 -4 0.1X 0.9934 82 (8) 103 (7)  -29 1X 0.9686 106 (23) 121 (12)  -22 1X 0.9278 101 (15)  117 (16) 
Metronidazole 10 -1 0.1X 0.9999 96 (4) 95 (7)  -26 0.5X 0.9957 88 (7) 79 (22)  -13 0.5X 0.9933 96 (15)  110 (15) 
Morantel 100 2 0.1X 0.9993 96 (2) 95 (4)  -11 0.1X 0.9883 75 (43) 83 (44)  7 0.1X 0.9828 86 (22)  97 (28) 
Nafcillin 100 -3 0.1X 0.9999 102 (4) 95 (3)  1 0.1X 0.9983 107 (11) 110 (9)  -9 0.1X 0.9996 97 (10)  94 (7) 
Norfloxacin 50 -6 0.1X 0.9993 100 (7) 92 (4)  -3 0.5X 0.9676 116 (14) 125 (11)  8 0.5X 0.9886 94 (16)  95 (8) 
Novobiocin 1000 4 0.1X 0.9946 92 (4) 80 (2)  -23 0.25X 0.9934 105 (26) 94 (16)  -41 0.25X 0.9949 96 (3)  86 (3) 




Table 3.3 continued 
Compound 
  SPME   QuEChERS   SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X  1.5X 
(ng g-1) ME ACC (RSD) ACC (RSD)   ME ACC (RSD) ACC (RSD)   ME 
ACC 
(RSD) 
  ACC (RSD) 
Oxacillin 100 -4 0.1X 0.9995 103 (4) 91 (3)  -4 0.1X 0.9955 107 (15) 113 (11)  -10 0.1X 0.9953 94 (15)  97 (9) 
Oxfendazole 800 -2 0.1X 0.9984 102 (4) 95 (3)  -1 0.1X 0.9998 105 (3) 99 (2)  2 0.1X 0.9967 108 (3)  104 (2) 
Oxyclozanide 10 -8 0.1X 0.9945 100 (19) 102 (17)  -16 0.5X 0.9932 85 (26) 87 (17)  4 0.5X 0.9803 105 (15)  95 (9) 
Oxyphenylbutazone 100 1 0.1X 0.9995 100 (6) 98 (3)  -10 0.25X 0.9982 96 (13) 94 (9)  -32 0.25X 0.9899 102 (16)  94 (4) 
Oxytetracycline 200 -6 0.1X 0.9993 99 (9) 91 (3)  258 1X 0.9764 105 (26) 117 (24)  279 1X 0.9499 72 (47)  64 (25) 
Penicillin G 50 1 0.1X 0.9941 103 (28) 87 (14)  25 1X 0.9879 96 (27) 71 (24)  15 1X 0.9584 105 (21)  82 (11) 
Phenylbutazone 100 0 0.1X 0.9990 96 (7) 96 (3)  -63 0.25X 0.9952 113 (11) 110 (4)  -74 0.25X 0.9929 101 (7)  92 (1) 
Pirlimycin 300 -3 0.1X 0.9961 106 (9) 90 (3)  37 0.1X 0.9993 102 (19) 99 (9)  51 0.1X 0.9809 90 (25)  88 (14) 
Prednisone 100 -2 0.1X 0.9997 104 (8) 96 (4)  -9 0.1X 0.9995 100 (3) 98 (1)  -9 0.1X 0.9995 107 (3)  107 (2) 
Promethazine 10 2 0.1X 0.9999 96 (3) 93 (4)  -4 0.1X 0.9992 101 (5) 99 (2)  -3 0.1X 0.9994 108 (4)  108 (3) 
Propionylpromazine 10 0 0.1X 0.9999 93 (3) 93 (2)  -9 0.1X 0.9995 102 (5) 96 (3)  -4 0.1X 0.9981 107 (2)  106 (3) 
Ractopamine 30 -2 0.1X 0.9990 97 (6) 92 (4)  5 0.1X 0.9961 97 (18) 92 (12)  15 0.1X 0.9953 98 (18)  102 (15) 
Ronidazole 10 -3 0.1X 0.9998 99 (5) 93 (6)  -16 0.1X 0.9987 111 (21) 113 (10)  -10 0.1X 0.9926 69 (16)  108 (11) 
Salbutamol 10 -13 0.1X 0.9984 98 (12) 94 (5)  -15 0.25X 0.9975 107 (26) 114 (15)  0 0.25X 0.9951 93 (30)  89 (20) 
Oxyphenylbutazone 100 1 0.1X 0.9995 100 (6) 98 (3)  -10 0.25X 0.9982 96 (13) 94 (9)  -32 0.25X 0.9899 102 (16)  94 (4) 
Sarafloxacin 50 -6 0.1X 0.9961 102 (7) 93 (4)  -24 0.1X 0.9919 98 (21) 97 (14)  6 0.1X 0.9984 114 (13)  115 (4) 
Sulfadiazin 100 -3 0.1X 0.9996 97 (6) 95 (2)  -26 0.1X 0.9968 98 (10) 97 (8)  -24 0.1X 0.9985 114 (13)  115 (4) 
Sulfadimethoxine 100 0 0.1X 0.9974 100 (4) 95 (2)  0 0.1X 0.9997 101 (11) 97 (6)  0 0.1X 0.9971 113 (9)  112 (2) 
Sulfaethoxypyridazine 100 -1 0.1X 0.9977 101 (5) 97 (3)  3 0.1X 0.9988 101 (9) 96 (5)  -1 0.1X 0.9986 113 (10)  114 (2) 
Sulfamerazine 100 0 0.1X 0.9985 101 (6) 96 (3)  -22 0.1X 1.0000 102 (6) 98 (3)  -23 0.1X 0.9995 113 (10)  114 (2) 




Table 3.3 continued 
Compound 
  SPME   QuEChERS   SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X 1.5X  % 
LOQ R2 
0.75X  1.5X 
(ng g-1) ME ACC (RSD) ACC (RSD)   ME ACC (RSD) ACC (RSD)   ME 
ACC 
(RSD) 
  ACC (RSD) 
Sulfamethizole 100 -4 0.1X 0.9997 100 (5) 96 (3)  -25 0.1X 0.9988 113 (9) 105 (5)  -27 0.1X 0.9999 81 (24)  107 (2) 
Sulfamethoxazole 100 -3 0.1X 0.9967 108 (6) 100 (3)  1 0.1X 0.9995 105 (8) 95 (8)  3 0.1X 0.9963 117 (14)  114 (5) 
Sulfamethoxypyridazine 100 -1 0.1X 0.9960 102 (5) 100 (3)  -19 0.1X 0.9999 104 (12) 98 (5)  -21 0.1X 0.9987 114 (13)  116 (3) 
Sulfapyridine 100 4 0.1X 0.9995 99 (6) 97 (4)  -27 0.1X 0.9994 101 (9) 97 (5)  -19 0.1X 0.9988 113 (12)  114 (4) 
Sulfaquinoxaline 100 -1 0.1X 0.9970 100 (4) 94 (2)  -2 0.1X 0.9999 101 (8) 97 (5)  -4 0.1X 0.9986 111 (8)  111 (2) 
Sulfathiazole 100 2 0.1X 0.9995 100 (5) 97 (4)  -39 0.1X 0.9957 93 (12) 87 (8)  -37 0.1X 0.9956 113 (15)  114 (5) 
Tetracycline 200 -4 0.1X 0.9979 100 (9) 92 (4)  199 0.1X 0.9850 144 (36) 140 (21)  226 0.1X 0.9917 99 (25)  102 (19) 
Thiabendazole 100 -9 0.1X 0.9997 96 (4) 96 (3)  45 0.1X 0.9990 97 (16) 90 (12)  105 0.1X 0.9957 116 (17)  119 (5) 
Tildipirosin 400 55 0.1X 0.9956 94 (19) 90 (5)  31 0.25X 0.9926 110 (34) 116 (16)  60 0.25X 0.9826 92 (37)  87 (20) 
Tilmicosin 100 -1 0.1X 0.9942 108 (12) 83 (6)  -8 0.1X 0.9978 95 (18) 94 (10)  50 0.1X 0.9915 98 (4)  96 (2) 
Tolfenamic acid 200 -3 0.1X 0.9957 95 (5) 86 (4)  -17 0.1X 0.9997 103 (9) 100 (5)  -42 0.1X 0.9973 103 (9)  102 (3) 
Triclabendazole 50 6 0.1X 0.9995 94 (3) 83 (3)  -24 0.1X 0.9920 106 (17) 101 (12)  -23 0.1X 0.9797 106 (15)  105 (4) 
Triclabendazole Sulfoxide 50 2 0.1X 0.9988 98 (7) 90 (3)  -14 0.1X 0.9948 103 (14) 99 (11)  -25 0.1X 0.9943 103 (13)  105 (4) 
Trifluropromazine 10 -2 0.1X 0.9977 96 (4) 91 (3)  2 0.1X 0.9939 104 (11) 102 (7)  -2 0.1X 0.9912 105 (7)  100 (4) 
Tulathromycin 1000 11 0.1X 0.9956 99 (19) 90 (5)  35 0.25X 0.9843 115 (19) 114 (12)  83 0.25X 0.9804 92 (23)  88 (10) 
Tylosin 200 2 0.1X 0.9983 104 (5) 94 (3)  -14 0.1X 0.9994 109 (4) 114 (6)  6 0.1X 0.9961 99 (6)  100 (5) 
Virginiamycin 100 -2 0.1X 0.9993 101 (6) 95 (3)  19 0.1X 0.9998 98 (12) 100 (5)  20 0.1X 0.9981 104 (9)  106 (1) 





Table 3.4 Limits of quantification (LOQ), Linearity (n=3 at each level), and average accuracy (ACC), n = 6 at each level, in chicken tissue. * designates compounds which could not be 
quantified 
Compound 
 SPME   QuEChERS   SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ 
 0.75X 1.5X  % 
LOQ 
 0.75X 1.5X 















2-Aminoflubendazole 10 -3 0.1X 0.9998 97 (5) 95 (3)  -2 0.1X 0.9994 109 (13) 93 (2)  27 0.1X 0.9992 103 (7) 96 (2) 
2-Quinoxalinecarboxylic acid 100 -4 0.1X 0.9989 96 (7) 95 (7)  70 0.1X 0.9986 103 (15) 84 (3)  112 0.25X 0.9984 105 (16) 100 (4) 
2-Amino mebendazole 10 -1 0.1X 0.9997 95 (6) 95 (3)  20 0.1X 0.9992 112 (7) 95 (5)  40 0.1X 0.9953 103 (8) 96 (4) 
5-Hydroxythiabendazole 100 -3 0.1X 0.9990 98 (7) 96 (5)  6 0.1X 0.9949 120 (7) 104 (8)  35 0.1X 0.9882 90 (11) 101 (9) 
6-phenyl-thiouracil 400 3 0.1X 0.9995 91 (7) 88 (6)  -3 0.1X 0.9994 103 (8) 93 (3)  -3 0.1X 0.9997 109 (8) 103 (3) 
6-propyl-2-thiouracil 50 1 0.25X 0.9997 94 (9) 95 (22)  -2 0.25X 0.9960 101 (12) 96 (6)  7 0.25X 0.9974 114 (11) 105 (4) 
Acepromazine 10 -1 0.1X 0.9986 95 (4) 96 (3)  -2 0.1X 0.9969 107 (8) 105 (2)  3 0.1X 0.9999 100 (6) 98 (4) 
Albendazole 50 0 0.1X 0.9976 98 (5) 95 (5)  0 0.1X 0.9992 98 (11) 90 (5)  1 0.1X 0.9917 102 (23) 102 (10) 
Albendazole 2-aminosulfone 50 -1 0.1X 0.9997 97 (5) 95 (3)  7 0.1X 0.9985 119 (13) 104 (4)  19 0.1X 0.9995 109 (3) 102 (6) 
Albendazole sulfone 50 2 0.1X 0.9978 99 (4) 95 (4)  2 0.1X 0.9999 103 (7) 99 (3)  3 0.1X 0.9993 103 (12) 98 (3) 
Albendazole sulfoxide 50 -1 0.1X 0.9983 100 (5) 94 (3)  6 0.1X 0.9975 110 (4) 101 (5)  10 0.1X 0.9989 108 (4) 99 (5) 
Amoxicillin 10 4 1X 0.9938 120 (33) 97 (19)  -47 1X 0.9935 98 (1) 98 (9)  -30 0.1X 0.9981 88 (23) 87 (12) 
Ampicillin 10 -4 0.25X 0.9995 94 (11) 91 (15)  -38 0.25X 0.9973 105 (19) 99 (8)  -19 0.25X 0.9991 104 (22) 94 (16) 
Azaperone 10 -2 0.1X 1.0000 97 (6) 95 (4)  17 0.1X 0.9992 103 (10) 91 (3)  19 0.1X 0.9980 103 (18) 96 (6) 
Bacitracin 500 5 0.1X 0.9963 116 (10) 104 (5)  17 0.1X 0.9809 166 (22) 175 (6)  8 0.25X 0.9469 214 (24) 170 (21) 
Betamethasone 100 4 0.1X 0.9973 100 (1) 99 (7)  -2 0.1X 0.9959 88 (9) 84 (12)  -4 0.1X 0.9889 90 (1) 93 (1) 
Cambendazole 10 -2 0.1X 0.9993 96 (5) 96 (3)  -4 0.1X 0.9994 100 (11) 87 (1)  -6 0.1X 0.9975 101 (18) 98 (6) 
Carazolol 10 -1 0.1X 0.9998 97 (5) 94 (3)  7 0.1X 0.9989 102 (5) 93 (2)  9 0.1X 0.9988 104 (5) 97 (2) 




Table 3.4 continued 
Compound 
 SPME  QuEChERS  SE 
MRL % 
LOQ R2 
0.75X 1.5X  % 
LOQ 
 0.75X 1.5X  % 
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Cefazolin 100 -3 0.1X 0.9979 93 (9) 95 (5)  -27 0.1X 0.9978 101 (12) 90 (9)  -53 0.25X 0.9951 104 (16) 96 (12) 
Cephapirin 100 * * * * *  8 0.1X 0.9942 76 (23) 60 (6)  -10 0.25X 0.9802 76 (32) 71 (19) 
Chlortetracycline 200 0 0.1X 0.9987 93 (3) 92 (2)  31 0.1X 0.9943 104 (11) 97 (11)  42 0.25X 0.9996 94 (19) 94 (8) 
Chlorpromazine 10 -3 0.1X 0.9978 98 (6) 98 (3)  -5 0.1X 0.9960 103 (9) 97 (5)  -5 0.25X 0.9979 102 (14) 100 (4) 
Ciprofloxacin 50 0 0.1X 0.9993 97 (5) 97 (4)  0 0.1X 0.9874 113 (8) 104 (12)  12 0.1X 0.9825 117 (15) 102 (13) 
Clenbuterol 10 -2 0.1X 0.9995 99 (7) 97 (6)  2 0.1X 0.9983 108 (7) 92 (8)  18 0.1X 0.9986 107 (3) 97 (4) 
Clindamycin 100 0 0.25X 0.9978 100 (4) 98 (3)  30 0.25X 0.9935 112 (7) 99 (9)  55 0.25X 0.9923 111 (10) 97 (11) 
Cloxacillin 100 0 0.1X 0.9998 97 (4) 94 (4)  -2 0.1X 0.9977 104 (8) 105 (5)  -8 0.1X 0.9966 106 (11) 97 (10) 
Danofloxacin 70 6 0.1X 0.9976 90 (3) 89 (2)  15 0.1X 0.9958 111 (4) 95 (14)  41 0.1X 0.9958 111 (5) 101 (7) 
Desacetyl cephapirin 100 -3 0.1X 0.9994 101 (1) 102 (18)  -13 0.1X 0.9847 107 (10) 107 (14)  2 0.25X 0.9894 113 (23) 94 (23) 
Desethylene Ciprofloxacin 100 4 0.1X 0.9965 96 (3) 94 (3)  47 0.1X 0.9784 130 (20) 110 (19)  90 0.25X 0.9886 134 (12) 116 (11) 
Diclofenac 200 -2 0.1X 0.9995 99 (4) 96 (4)  -7 0.1X 0.9994 95 (13) 103 (3)  -17 0.1X 0.9990 103 (5) 97 (3) 
Dicloxacillin 100 -2 0.1X 0.9957 95 (1) 99 (6)  5 0.1X 0.9991 95 (10) 103 (2)  8 0.1X 0.9994 102 (11) 95 (7) 
Difloxacin 50 -3 0.1X 0.9995 98 (5) 97 (2)  24 0.1X 0.9962 105 (2) 96 (4)  44 0.1X 0.9965 107 (2) 97 (6) 
Dimetridazole 50 -1 0.1X 0.9993 97 (18) 92 (14)  2 0.1X 0.9991 100 (11) 103 (8)  -5 0.1X 0.9966 114 (5) 103 (3) 
Doxycycline 100 -2 0.1X 0.9960 95 (4) 89 (7)  185 0.1X 0.9893 110 (12) 105 (12)  231 0.25X 0.9991 95 (21) 96 (9) 
Emamectin 10 -3 0.25X 0.9877 99 (6) 91 (5)  -28 0.25X 0.9995 98 (10) 99 (5)  -24 0.1X 0.9908 90 (10) 96 (9) 
Enrofloxacin 20 -1 0.1X 0.9991 97 (3) 96 (3)  3 0.1X 0.9978 107 (4) 100 (6)  20 0.1X 0.9968 108 (6) 96 (7) 
Erythromycin 125 -2 0.1X 0.9990 108 (10) 100 (4)  -5 0.1X 0.9947 109 (7) 97 (7)  -1 0.1X 0.9976 106 (8) 101 (8) 
Fenbendazole 100 1 0.1X 0.9979 100 (4) 98 (4)  5 0.1X 0.9988 95 (13) 87 (6)  1 0.1X 0.9856 102 (31) 103 (12) 




Table 3.4 continued 
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Florfenicol 300 0 0.1X 0.9976 106 (8) 105 (5)  -13 0.1X 0.9978 89 (11) 87 (3)  -18 0.1X 0.9911 106 (13) 88 (14) 
Florfenicol Amine 100 -31 0.1X 0.9976 103 (8) 92 (10)  -88 0.1X 0.9953 108 (6) 105 (6)  -88 0.25X 0.9884 113 (11) 106 (6) 
Flubendazole 10 0 0.1X 0.9994 96 (6) 96 (3)  4 0.1X 0.9992 91 (10) 88 (7)  2 0.1X 0.9943 96 (23) 96 (8) 
Flunixin 20 1 0.1X 0.9992 98 (1) 98 (1)  -2 0.1X 0.9998 97 (1) 93 (1)  -11 0.1X 0.9998 97 (1) 94 (1) 
Gamithromycin 20 3 0.1X 0.9987 98 (4) 95 (7)  55 0.1X 0.9869 111 (12) 114 (7)  107 0.1X 0.9868 106 (17) 92 (14) 
Haloperidol 10 1 0.1X 0.9996 97 (4) 96 (2)  2 0.1X 0.9984 95 (10) 90 (5)  3 0.1X 0.9939 100 (20) 101 (9) 
Hydroxy dimetridazole 50 -1 0.25X 0.9993 100 (6) 96 (4)  -14 0.25X 0.9992 113 (7) 100 (5)  -26 0.1X 0.9979 88 (21) 89 (5) 
Hydroxy ipronidazole 10 -1 0.1X 0.9997 97 (6) 92 (4)  1 0.1X 0.9979 108 (6) 94 (4)  6 0.1X 0.9997 109 (3) 99 (3) 
Hydroxy metronidazole 10 7 0.25X 0.9967 106 (20) 106 (20)  -16 0.25X 0.9988 110 (1) 91 (7)  -17 0.25X 0.9994 75 (15) 93 (11) 
Ipronidazole 10 -1 0.1X 0.9992 96 (5) 95 (5)  0 0.1X 0.9997 108 (10) 94 (2)  -3 0.1X 0.9961 99 (14) 95 (5) 
Ketoprofen 10 1 0.1X 0.9997 98 (7) 98 (4)  -2 0.1X 0.9950 96 (16) 104 (5)  -2 0.25X 0.9937 107 (9) 97 (9) 
Levamisole 100 -3 0.1X 0.9994 100 (8) 96 (4)  4 0.1X 0.9990 110 (8) 96 (5)  36 0.1X 0.9984 107 (3) 98 (3) 
Lincomycin 100 1 0.1X 0.9992 97 (5) 97 (3)  25 0.1X 0.9944 99 (14) 99 (7)  38 0.25X 0.9984 106 (15) 96 (15) 
Mebendazole 10 1 0.1X 0.9996 97 (4) 97 (4)  7 0.1X 0.9997 95 (8) 93 (8)  1 0.1X 0.9968 100 (17) 96 (5) 
Melengestrol Acetate 25 -9 0.1X 0.9995 114 (3) 97 (5)  -34 0.1X 0.9984 91 (15) 83 (6)  -58 0.25X 0.9823 85 (21) 95 (14) 
Meloxicam 20 0 0.1X 0.9990 95 (4) 96 (4)  13 0.1X 0.9992 98 (5) 96 (2)  -7 0.1X 0.9989 93 (3) 92 (3) 
Metamizole 200 -2 0.1X 0.9999 98 (8) 95 (8)  -30 0.1X 0.9936 119 (12) 101 (11)  -23 0.1X 0.9997 108 (14) 88 (11) 
Metronidazole 10 -5 0.1X 0.9989 101 (7) 92 (11)  -21 0.1X 0.9966 107 (8) 101 (6)  -9 0.25X 0.9997 108 (7) 101 (5) 
Morantel 150 -4 0.1X 0.9993 97 (3) 96 (3)  -7 0.1X 0.9999 101 (6) 86 (4)  -1 0.1X 0.9989 96 (7) 90 (4) 
Nafcillin 100 0 0.1X 0.9997 103 (4) 102 (3)  3 0.1X 0.9991 104 (8) 106 (4)  -2 0.1X 0.9965 104 (11) 96 (10) 
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Novobiocin 1000 -1 0.25X 0.9952 149 (17) 99 (4)  -20 0.25X 0.9976 114 (13) 127 (5)  -37 0.25X 0.9941 86 (21) 93 (11) 
Orbifloxacin 50 -3 0.1X 0.9994 97 (4) 96 (2)  -7 0.1X 0.9962 107 (4) 94 (8)  17 0.1X 0.9946 109 (4) 95 (9) 
Oxacillin 100 -1 0.1X 0.9996 97 (4) 94 (4)  -2 0.1X 0.9953 107 (8) 106 (7)  -4 0.25X 0.9979 93 (21) 97 (10) 
Oxfendazole 800 -1 0.1X 0.9961 102 (7) 99 (4)  1 0.1X 0.9996 110 (5) 100 (2)  -2 0.1X 0.9940 94 (20) 96 (12) 
Oxyclozanide 10 -2 0.5X 0.9982 100 (10) 110 (35)  -5 0.5X 0.9960 95 (11) 87 (5)  -3 0.25X 0.9834 87 (28) 99 (10) 
Oxyphenylbutazone 100 -2 0.1X 0.9992 105 (5) 106 (3)  1 0.1X 0.9972 91 (11) 91 (2)  -16 0.1X 0.9991 95 (4) 93 (2) 
Oxytetracycline 200 1 0.1X 0.9987 93 (3) 93 (4)  244 0.1X 0.9971 105 (15) 108 (3)  261 0.1X 0.9957 106 (22) 105 (9) 
Penicillin G 50 -1 0.5X 0.9945 98 (21) 105 (17)  8 0.5X 0.9913 92 (20) 104 (3)  14 0.1X 0.9946 98 (16) 87 (12) 
Phenylbutazone 100 -3 0.1X 0.9999 102 (3) 101 (4)  -49 0.1X 0.9983 98 (11) 104 (4)  -62 0.1X 0.9981 90 (3) 92 (4) 
Pirlimycin 300 -1 0.1X 0.9984 96 (3) 95 (3)  41 0.1X 0.9924 110 (9) 102 (9)  57 0.25X 0.9990 97 (21) 96 (10) 
Prednisone 100 0 0.1X 0.9987 96 (6) 96 (3)  -5 0.1X 0.9998 99 (10) 91 (3)  -9 0.1X 0.9997 103 (7) 98 (3) 
Promethazine 10 -2 0.1X 0.9990 95 (6) 96 (3)  -5 0.1X 0.9973 109 (9) 101 (2)  -5 0.25X 0.9995 102 (6) 99 (5) 
Propionylpromazine 10 -1 0.1X 0.9990 97 (5) 97 (2)  -6 0.1X 0.9970 103 (8) 98 (5)  -2 0.25X 0.9990 104 (11) 99 (4) 
Ractopamine 30 -1 0.1X 0.9994 97 (7) 97 (4)  11 0.1X 0.9997 108 (6) 92 (6)  13 0.1X 0.9987 103 (14) 98 (3) 
Ronidazole 10 0 0.1X 0.9997 98 (10) 97 (10)  -15 0.1X 0.9997 101 (24) 94 (8)  -12 0.1X 0.9956 84 (19) 100 (12) 
Salbutamol 10 3 0.25X 0.9993 95 (4) 96 (4)  15 0.25X 0.9836 105 (12) 97 (13)  17 0.25X 0.9992 94 (26) 94 (18) 
Sarafloxacin 50 -2 0.1X 0.9970 97 (11) 95 (15)  -16 0.1X 0.9968 106 (6) 99 (7)  23 0.1X 0.9916 112 (8) 99 (10) 
Sulfadiazin 100 1 0.1X 0.9958 98 (14) 99 (19)  -26 0.1X 0.9988 103 (13) 89 (2)  -30 0.1X 0.9994 105 (15) 96 (3) 
Sulfadimethoxine 100 -2 0.1X 0.9980 104 (16) 101 (20)  7 0.1X 0.9998 102 (9) 94 (2)  0 0.1X 0.9951 106 (18) 104 (7) 
Sulfadoxine 100 -3 0.1X 0.9978 105 (15) 101 (19)  -2 0.1X 0.9999 106 (8) 95 (1)  -9 0.1X 0.9991 103 (19) 102 (7) 
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Sulfamerazine 100 0 0.1X 0.9976 101 (15) 99 (19)  -16 0.1X 0.9971 95 (10) 88 (5)  -22 0.1X 0.9989 108 (16) 98 (5) 
Sulfamethazine 100 -1 0.1X 0.9978 106 (14) 102 (18)  -10 0.1X 0.9999 110 (8) 97 (3)  -17 0.1X 0.9998 109 (13) 100 (4) 
Sulfamethizole 100 -1 0.1X 0.9969 100 (13) 99 (16)  -13 0.1X 0.9982 90 (13) 90 (5)  -24 0.1X 0.9963 109 (3) 99 (6) 
Sulfamethoxazole 100 1 0.1X 0.9971 105 (15) 104 (18)  4 0.1X 0.9998 101 (7) 95 (5)  -2 0.1X 0.9923 103 (21) 102 (6) 
Sulfamethoxypyridazine 100 -1 0.1X 0.9981 104 (14) 101 (18)  -4 0.1X 0.9999 107 (10) 92 (2)  -22 0.1X 0.9996 108 (16) 101 (4) 
Sulfapyridine 100 0 0.1X 0.9966 100 (15) 98 (19)  -13 0.1X 0.9995 105 (11) 91 (3)  -15 0.1X 0.9998 107 (12) 99 (4) 
Sulfaquinoxaline 100 0 0.1X 0.9984 102 (16) 99 (20)  5 0.1X 0.9997 98 (6) 95 (3)  -3 0.1X 0.9986 103 (14) 101 (4) 
Sulfathiazole 100 -4 0.1X 0.9986 101 (8) 100 (6)  -35 0.1X 0.9992 104 (14) 87 (2)  -40 0.1X 0.9991 105 (15) 97 (4) 
Tetracycline 200 -2 0.1X 0.9982 93 (4) 96 (4)  198 0.1X 0.9994 100 (16) 104 (3)  231 0.1X 0.9990 97 (20) 93 (9) 
Thiabendazole 100 -3 0.1X 0.9984 100 (8) 98 (7)  58 0.1X 0.9995 105 (15) 85 (2)  95 0.1X 0.9987 106 (17) 98 (5) 
Tildipirosin 400 -8 0.1X 0.9945 71 (14) 81 (18)  44 0.1X 0.9887 107 (15) 101 (13)  48 0.25X 0.9934 82 (27) 80 (14) 
Tilmicosin 100 -1 0.1X 0.9983 96 (4) 96 (6)  -2 0.1X 0.9997 95 (9) 86 (3)  48 0.1X 0.9918 111 (13) 92 (14) 
Tolfenamic acid 200 4 0.1X 0.9979 117 (1) 96 (0)  -20 0.1X 0.9992 98 (14) 108 (3)  -45 0.1X 0.9970 94 (10) 91 (5) 
Triclabendazole 50 2 0.1X 0.9968 101 (8) 99 (4)  -23 0.1X 0.9968 88 (18) 82 (6)  -26 0.25X 0.9596 71 (33) 85 (31) 
Triclabendazole Sulfoxide 50 -1 0.1X 0.9988 105 (6) 97 (4)  -13 0.1X 0.9980 92 (13) 84 (5)  -22 0.25X 0.9896 91 (17) 91 (9) 
Trifluropromazine 10 -2 0.1X 0.9979 99 (6) 103 (3)  1 0.1X 0.9970 99 (10) 93 (7)  1 0.25X 0.9942 101 (22) 99 (9) 
Tulathromycin 150 -4 0.1X 0.9845 84 (9) 97 (17)  49 0.1X 0.9889 129 (13) 115 (11)  79 0.25X 0.9937 99 (21) 81 (17) 
Tylosin 200 0 0.1X 0.9992 123 (12) 110 (9)  -46 0.1X 0.9711 109 (17) 86 (10)  -53 0.25X 0.9996 100 (9) 97 (6) 
Virginiamycin 100 -1 0.1X 0.9999 103 (5) 103 (4)  10 0.1X 0.9987 99 (8) 93 (3)  10 0.1X 0.9919 100 (17) 100 (7) 




3.4.4 Sample Throughput and Environmental Footprint 
In terms of time required to perform extraction, the SE method necessitated a total time of 9 
min, including 5 min for extraction and 4 min for centrifugation, while the QuEChERS required a 
total of 14 min as a result of the additional time needed to weigh the 500 mg of C18, followed by 
the 30 s shake on the vortexer, and another round of centrifugation. In our lab setup, while 15 
samples could be simultaneously processed on the multivortexer, the centrifuge was a limiting 
factor, because only four tubes could be processed at a time as a result of the centrifuge capacity. 
As a result, it took approximately 9 min to extract four samples using the SE protocol and 14 min 
using the QuEChERS protocol. Therefore, total sample extraction times per sample corresponded 
to over 2 min/sample for SE and over 3 min/sample for QuEChERS of active analyst time. While 
the QuEChERS and SE extraction methods offer a simple method for extraction, the manual nature 
of the extraction process, which has not been automated to date, renders the method as tedious and 
time-consuming while additionally introducing a significant source of variation. While the SPME 
protocol necessitates 80 min for extraction and desorption, up to 96 samples can be extracted 
simultaneously, thus affording total sample preparation times of less than 1 min per sample. 
Moreover, the automated nature of the protocol enables performance of other lab duties throughout 
the sample preparation procedure, given that the analyst is not actively engaged with the sample 
preparation process throughout the 80 min. 
In addition to high-throughput extraction, another main advantage of SPME is its minimal 
use of organic solvents compared to SE and QuEChERS. The SPME protocol used in this work 
requires only 0.3 mL of organic solvent per sample (0.15 mL MeOH + 0.15 mL MeCN) for the 




commercially. In contrast, SE and QuEChERS require a minimum of 8 mL of MeCN per sample. 
This clear advantage of SPME not only leads to obvious savings on reagent costs but also to a 
significant reduction in the environmental footprint as well as a decreased degree of exposure of 
analysts to organic solvents. 
Nonetheless, while SPME offers several advantages over SE and QuEChERS in terms of 
significantly cleaner sample extracts, excellent accuracy and precision, high-throughput, 
automation, and ease of use, applicability for onsite and in vivo extraction, and a much lower 
environmental footprint, SPME method development requires careful considerations, such as 
optimization of the extraction phase and extraction and desorption conditions, which require a 
fundamental understanding of the theory and principles of SPME. 
3.4.5 Analysis of Market Samples 
Five chicken tissue samples and three beef tissue samples obtained from different local 
grocery stores were submitted to analysis for determination of veterinary drugs, using the three 
methods described above. None of the veterinary drugs under study were found in any of the 
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The contribution of co-author Germán Augusto Gómez-Ríos to the work described in this 
chapter was technical advice at the early stage of method development. All of the experimental 
planning, design, and experimental work conducted in the laboratory, data processing, analysis, 
interpretation, and writing were performed by the author of the thesis. 
I, Germán Augusto Gómez-Ríos, authorize Abir Khaled to use the material for her thesis. 
4.2 Introduction 
A chief concern for human health nowadays is the presence of drug and chemical residues 
in the edible tissues of food animals.7,197,198 As the number of residues and contaminants found to 
present a risk to human health continues to expand, the demand for highly efficient analytical 
methods capable of monitoring a wide variety of analytes rapidly and simultaneously in one single 
run continues to grow around the globe.15,92 One approach to increase the efficiency and cost-
effectiveness of an analytical method is to increase the number of analytes that can be determined 
in a single run. Regulatory bodies and testing laboratories strive to increase the scope of their 
analytical methods as a means to analyze more compounds per sample, reduce the overall amount 
of required samples, and increase the probability of detecting residue violations. As a result, multi-
residue multi-class methods that are capable of analyzing as many analytes as possible in a single 
run are becoming very popular.32,38,84,87,88 Moreover, developing methods that are capable of 
screening in both negative and positive ionization modes in the same run can also help to increase 
the scope of analytical methods. Thanks to its selective and fast scanning capabilities, tandem Mass 
spectrometry (MS/MS) is arguably considered one of the most effective analytical techniques for 




However, matrices such as biological tissues can be extremely complex to analyze via MS due to 
their high fat and protein content, as such compounds are very likely to cause interferences in the 
MS.200 As such, the introduction of such matrices to the MS often requires multiple sample 
preparation steps and chromatographic separation to prevent interferences from matrix co-
extractives. Conventional sample preparation methods often include solvent extraction (SE) or 
protein precipitation (PP) followed by additional extract clean-up with either solid phase extraction 
(SPE) or dispersive SPE (d-SPE).92,96,201,202 These steps can be very time consuming and may not 
be suitable for the direct and high-throughput screening requirements of modern analysis of real 
samples.139,200 An alternative approach to this lengthy workflow is to simplify sample preparation 
and eliminate chromatographic separation by directly introducing the sample to the MS.200,203–205 
Direct-to-MS analysis techniques offer the advantages of obtaining analytical results in the order 
of seconds and screening hundreds of samples in a short period of time.96 However, in case of 
tissue samples, minimal sample preparation can introduce an abundance of matrix interferences to 
the MS. Solid phase microextraction (SPME) has consistently demonstrated its ability to isolate 
and enrich a wide variety of analytes from biological samples with minimal coextraction of 
proteins, salts, and other matrix macromolecules.147,189,206 SPME-based devices have also been 
successfully used to integrate sample preparation and direct sample introduction into the MS 
system in a single device.120,141,204,207,208 One of these devices is the coated blade spray (CBS), 
which has been widely and successfully applied for rapid qualitative and quantitative analysis of 
biological fluids such as blood, plasma, and urine.151,208–210 In addition to its direct-to-MS 




Several other direct-to-MS methods have been studied and demonstrated suitable for 
analysis of tissue samples, but none so far for multi-residue analysis of more than 100 analytes in 
both negative and positive mode in a single run.14,84,200,202,211 CBS has not been investigated yet 
for analysis of tissue samples as, unlike mere direct-sample-to-MS technologies, there is need to 
remove any tissue debris potentially adhered to the device prior to instrumental analysis. In 
previous CBS studies on biological fluids which are less challenging than homogenized tissue, 
loosely attached macromolecules and cellular debris were removed by rinsing with water, followed 
by a light wipe with a Kimwipe in the rare cases that the attachments were not dislodged by the 
quick rinse.146 However, in automated high-throughput workflows, using Kimwipe is not a 
practical approach. Thus, another coating design of the CBS device was needed to 
minimize/prevent any potential attachments to the device. In this study, we present the 
optimization of the CBS design to improve and maximize its performance for analysis of complex 
matrices such as biological tissue samples. In order to prevent adhesion of tissue debris and 
macromolecules to the uncoated part of the blade, we first applied a thin layer, approximately 5 
µm in thickness, of polyacrylonitrile (PAN) to the blade prior to the application of the HLB/PAN 
extraction phase. The length of the undercoat PAN layer, 20 mm, was 10 mm longer than that of 
the HLB coating so as to ensure no contact between the bare stainless-steel and the sample during 
the extraction step. PAN was selected in this study as the protective undercoating layer because it 
is one of the most commonly used polymers in the biomedical field in terms of biocompatibility.147 
In addition, it is compatible with the extractive phase as it is used in this study as the binder to 




undercoat layer served to seal the surface of the stainless steel that comes into contact with the 
sample during the extraction process, thus eliminating the adhesion of matrix debris and 
macromolecules onto the bare stainless-steel surface. It is worth noting that this protective layer 
was applied under the extraction phase and not on top of it so as to prevent changes in the thickness 
of the coating and the slowing of the extraction or elution kinetics. While the main purpose of the 
undercoat is to eliminate adhesion of matrix macromolecules onto the bare stainless-steel surface, 
it also serves the following purposes: 1) the sample is in contact with a biocompatible surface 
during extraction and 2) the undercoating serves as a primer binder layer where the extractive 
phase can better adhere to the stainless-steel support. This new device feature enabled the use of 
CBS-MS/MS for the analysis of 105 veterinary drugs in homogenized bovine tissue. Furthermore, 
the proposed analytical method allows for the first time screening in both negative and positive 
modes in a single run using a single sampling device. In addition, when 96 samples are submitted 
to extraction simultaneously, total analysis time drops to 1 min per sample. As part of the validation 
procedure, the method was evaluated with respect to matrix effects, selectivity, linearity, accuracy, 
intra-day repeatability, and limit of quantitation (LOQ). 
4.3 Experimental Section 
4.3.1 Target Analytes 
A total of 114 target analytes, comprising drugs with a wide range of physico-chemical 
properties (log P −1.85–9.36), were initially selected for this investigation. These analytes include 
103 veterinary drugs that were successfully quantified below the regulatory residue limits in a 




spectrometry (UHPLC-ESI-MS/MS) in positive ionization mode.206 An additional 11 new target 
analytes that ionize in negative mode were added to this study to evaluate the performance of CBS 
in negative mode. Further details pertaining to these compounds, including their physico-chemical 
properties, drug classes, supplier information, and ionization mode, can be found in Table 4.1 and 
4.2. Sulfadoxine was also not further investigated in this study as it is an isobar of 
sulfadimethoxine. All analytes were selected from the list of standards specified in the official 
method developed by the United States Department of Agriculture for screening and confirmation 
of animal drug residues (CLG-MRM1.08).31 A total of 9 analytes (bolded in Table 4.1) were 
excluded from validation studies following final optimization of the multi-residue method due to 
poor ionization efficiencies at the maximum residue limit (MRL). While the detection limit for 
these compounds could certainly be improved were they to be analyzed separately, optimized 
method conditions, including desorption solvent, were mainly targeted at optimizing negative 
mode compounds due to the complexity of negative ionization, leading to compromised 
performance of certain compounds with low MRL values. The MRL values, listed in Table 4.3, 
were based primarily on Canadian MRL values and US tolerances in beef tissues.82,91 In general, 
Canadian MRLs are either equal or lower than US tolerances; however, in cases where Canadian 
MRLs were higher than US tolerances, the US regulatory value was selected, as is the case for 
ketoprofen and morantel. Two isotopically labelled internal standards (IS), namely d5-
Enrofloxacin for positive mode analytes and d3-Thiamphenicol for negative mode analytes, were 




4.3.2 Materials and supplies 
LC/MS-grade methanol (MeOH), acetonitrile (MeCN), and water were purchased from 
Fisher Scientific (Mississauga, ON, Canada). Ammonium fluoride, polyacrylonitrile (PAN), 
HPLC grade Acetone, and Dimethyl Sulfoxide (DMSO) were purchased from Sigma Aldrich 
(Oakville, ON, Canada). Stainless steel blades were purchased from Shimifrez Incorporated 
(Concord, ON, CAN). The blades were first coated with a 20 mm layer of biocompatible PAN and 
then coated with a slurry of PAN and Hydrophilic-Lipophilic Balanced (HLB) particles. The HLB 
particles (~5 µm diameter) were synthesized in house and characterized as previously described.189 
The procedure used to coat the CBS devices was reported elsewhere.209 The extraction phase 
coating length used was 10 mm, and the thickness was 10 μm. Figure 4.1 shows a schematic of the 
optimized CBS design with the undercoat layer, as well as the positioning of the blade during 
extraction. Nunc U96 600 µL, 1 mL Deep, and 2mL well-plates made of polypropylene were 
purchased from VWR International (Mississauga, ON, Canada). Individual stock standard 
solutions were prepared in either MeCN, MeOH, water, or 10% DMSO in MeCN, in accordance 
with the solubility of each compound, and stored at −80 °C.  
Organic beef muscle tissue samples were acquired from three different local grocery stores 




Table 4.1 Physico-chemical properties, class, and supplier information for analytes under study. 





1 2-Aminoflubendazole Sigma-Aldrich Anthelmintics C14H10FN3O 255.2 1.96 
2 2-Amino mebendazole Sigma-Aldrich Anthelmintics C14H11N3O 237.3 1.74 
3 2-Mercaptobenzimidazole Sigma-Aldrich Anthelmintics C7H6N2 150.2 -0.38 
4 2-Quinoxalinecarboxylic acid Sigma-Aldrich Others C9H6N2 174.2 1.80 
5 2-Thiouracil Sigma-Aldrich Thyreostats C4H4N2 128.2 -1.85 
6 5-Hydroxythiabendazole Sigma-Aldrich Anthelmintics C10H7N3OS 217.3 1.73 
7 6-Methyl-2-thiouracil Sigma-Aldrich Thyreostats C5H6N2 142.2 0.31 
8 6-Phenyl-2-thiouracil Sigma-Aldrich Thyreostats C10H8N2OS 204.3 -0.10 
9 6-Propyl-2-thiouracil Sigma-Aldrich Thyreostats C7H10N 170.2 1.37 
10 Acepromazine Maleate Sigma-Aldrich Tranquilizers C19H22N2OS 326.5 4.08 
11 Albendazole Sigma-Aldrich Anthelmintics C12H15N3O2S 265.3 3.07 
12 Albendazole-2-aminosulfone Sigma-Aldrich Anthelmintics C10H13N3O2S 239.3 0.12 
13 Albendazole Sulfone Sigma-Aldrich Anthelmintics C12H15N3O4S 297.1 0.86 
14 Albendazole Sulfoxide Sigma-Aldrich Anthelmintics C12H15N3O3S 281.3 0.91 
15 Ampicillin Sigma-Aldrich β-Lactams/cephalosporins C16H19N3O4S 349.4 1.35 
16 Azaperone Sigma-Aldrich Tranquilizers C19H22FN3O 327.4 2.50 
17 Bacitracin Sigma-Aldrich Others C66H103N17O16S 1422.7 -2.21 
18 Betamethasone Sigma-Aldrich Anti-inflammatories C22H29FO5 392.2 1.87 
19 Bithionol Sigma-Aldrich Anthelmintics C12H6Cl 356.1 5.51 
20 Cambendazole Sigma-Aldrich Anthelmintics C14H14N4O2S 302.4 2.90 




Table 4.1 continued 





22 Carbadox Sigma-Aldrich Others C11H10N4O4 262.2 -1.22 
22 Carbadox Sigma-Aldrich Others C11H10N4O4 262.2 -1.22 
23 Cefazolin Sigma-Aldrich β-Lactams/cephalosporins C14H14N8O4S3 454.507 1.13 
24 Cephapirin  Sigma-Aldrich β-Lactams/cephalosporins C17H17N3O6S2 423.5 0.79 
25 Chloramphenicol Sigma-Aldrich Phenicols C11H12Cl2N2O5 323.1 1.02 
26 Chlorpromazine HCl Sigma-Aldrich Tranquilizers C17H20Cl2N2S 355.3 5.20 
27 Chlortetracycline HCl Sigma-Aldrich Tetracyclines C22H24Cl2N2O8 515.3 1.11 
28 Ciprofloxacin Sigma-Aldrich Fluoroquinolones C17H18FN3O3 331.341 0.65 
29 Clenbuterol HCl Sigma-Aldrich β-Agonists C12H19Cl3N2O 313.7 2.61 
30 Clindamycin HCl Sigma-Aldrich Macrolides/lincosamides C18H34Cl2N2O5S 461.4 1.83 
31 Clorsulon Sigma-Aldrich Anthelmintics C8H8Cl3N3O4S2 380.7 1.04 
32 Closantel Sigma-Aldrich Anthelmintics C22H14Cl2I2N2O2 663.1 9.08 
33 Cloxacillin Sodium Salt Sigma-Aldrich β-Lactams/cephalosporins C19H17ClN3NaO5S 457.9 2.53 
34 Danofloxacin Sigma-Aldrich Fluoroquinolones C19H20FN3O3 357.1 1.20 
35 Desacetyl cephapirin Toronto Research Chemicals β-Lactams/cephalosporins C15H15N3O5S2 381.427 0.32 
36 Desethylene ciprofloxacin HCl Toronto Research Chemicals Fluoroquinolones C15H17ClFN3O3 341.8 -0.14 
37 Diclofenac Sodium Sigma-Aldrich Anti-inflammatories C14H10Cl2NNaO2 318.1 4.06 




39 Difloxacin HCl Sigma-Aldrich Fluoroquinolones C21H20ClF2N3O3 435.9 2.78 




Table 4.1 continued 





41 Doxycycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O8 480.9 -0.54 
42 Emamectin Benzoate Sigma-Aldrich Anthelmintics C56H81NO15 1008.2 6.84 
43 Enrofloxacin Sigma-Aldrich Fluoroquinolones C19H22FN3O3 359.4 1.88 
44 Eprinomectin Sigma-Aldrich Anthelmintics C50H75NO14 914.1 6.22 
45 Erythromycin Sigma-Aldrich Macrolides/lincosamides C37H67NO13 733.9 2.83 
46 Fenbendazole Sulfone Sigma-Aldrich Anthelmintics C15H13N3O4S 331.3 1.70 
47 Florfenicol Sigma-Aldrich Phenicols C12H14Cl2FNO4S 357.0 -0.12 
48 Florfenicol amine Sigma-Aldrich Phenicols C10H14FNO3S 247.3 -0.80 
49 Flubendazole Sigma-Aldrich Anthelmintics C16H12FN3O3 313.3 3.05 
50 Flunixin Sigma-Aldrich Anti-inflammatories C14H11F3N2O2 296.2 5.40 
51 Gamithromycin Sigma-Aldrich Macrolides/lincosamides C40H76N2O12 776.5 3.89 
52 Haloperidol Sigma-Aldrich Tranquilizers C21H23ClFNO2 375.9 3.01 
53 Hydroxy dimetridazole Toronto Research Chemicals Coccidiostats C5H7N3O3 157.1 -0.49 
54 Hydroxy ipronidazole Sigma-Aldrich Coccidiostats C7H11N3O3 185.2 0.21 
55 Hydroxy metronidazole Sigma-Aldrich Coccidiostats C6H9N3O4 187.15 -0.81 
56 Ipronidazole Sigma-Aldrich Coccidiostats C7H11N3O2 169.2 1.18 
57 Ketoprofen Sigma-Aldrich Anti-inflammatories C16H14O3 254.3 2.81 
58 Lasalocid A Sigma-Aldrich Coccidiostats C34H54O8 590.8 6.55 
59 Levamisole HCl Sigma-Aldrich Anthelmintics C11H13ClN2S 240.8 1.85 
60 Lincomycin HCl Monohydrate Sigma-Aldrich Macrolides/lincosamides C18H37ClN2O7S 461.0 0.91 




Table 4.1 continued 





62 Melengestrol Acetate Sigma-Aldrich Others C25H32O4 396.5 4.21 
63 Meloxicam Sigma-Aldrich Anti-inflammatories C14H13N3O4S2 351.0 2.71 
64 Metamizole Sigma-Aldrich Anti-inflammatories C13H17N3O4S 311.0 -0.74 
65 Metronidazole Sigma-Aldrich Coccidiostats C6H9N3O3 171.2 -0.01 
66 Morantel Tartrate Hydrate Sigma-Aldrich Anthelmintics C16H22N2O6S xH2O 370.4 1.97 
67 Nafcillin Sigma-Aldrich β-Lactams/cephalosporins C21H22N2O5S 414.1 3.52 
68 Nitroxynil Sigma-Aldrich Anthelmintics C7H3IN2O3 290.0 2.80 
69 Norfloxacin Sigma-Aldrich Fluoroquinolones C16H18FN3O3 319.3 0.82 
70 Novobiocin Sigma-Aldrich Novobiocin C31H36N2O11 612.2 2.86 
71 Orbifloxacin Sigma-Aldrich Fluoroquinolones C19H20F3N3O3 395.4 2.37 




73 Oxfendazole Sigma-Aldrich Anthelmintics C15H13N3O3S 315.3 1.36 
74 Oxyclozanide Sigma-Aldrich Anthelmintics C13H6Cl5NO3 401.5 8.67 
75 Oxyphenylbutazone Sigma-Aldrich Anti-inflammatories C19H20N2O3 324.4 2.72 
76 Oxytetracycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O9 496.9 -1.50 
77 Penicillin G Toronto Research Chemicals β-Lactams/cephalosporins C16H18N2O4S 334.0 1.67 
78 Phenylbutazone Sigma-Aldrich Anti-inflammatories C19H20N2O2 308.4 3.16 
79 Pirlimycin HCl Toronto Research Chemicals Macrolides/lincosamides C17H32Cl2N2O5S 447.4 1.47 
80 Prednisone Sigma-Aldrich Anti-inflammatories C21H26O5 358.4 1.57 
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82 Propionylpromazine HCl Sigma-Aldrich Tranquilizers C20H25ClN2OS 376.9 4.61 
83 Ractopamine HCl Sigma-Aldrich β-Agonists C18H24ClNO3 337.8 1.65 
84 Rafoxanide Sigma-Aldrich Anthelmintics C19H11Cl2I2NO3 626.0 9.36 
85 Ronidazole Sigma-Aldrich Coccidiostats C6H8N4O4 200.0 -0.45 
86 Salbutamol Sigma-Aldrich β-Agonists C13H21NO3 239.1 0.01 




88 Sulfachloropyridazine Sigma-Aldrich Sulfonamides C10H9ClN4O2S 284.7 1.02 
89 Sulfadiazine Sigma-Aldrich Sulfonamides C10H10N4O2S 250.277 -0.12 
90 Sulfadimethoxine Sigma-Aldrich Sulfonamides C12H14N4O4S 310.3 1.48 
91 Sulfadoxine Sigma-Aldrich Sulfonamides C12H14N4O4S 310.3 0.34 
92 Sulfaethoxypyridazine Sigma-Aldrich Sulfonamides C12H14N4O3S 294.3 0.85 
93 Sulfamerazine Sigma-Aldrich Sulfonamides C11H12N4O2S 264.0 0.34 
94 Sulfamethazine Sigma-Aldrich Sulfonamides C12H14N4O2S 278.0 0.80 
95 Sulfamethizole Sigma-Aldrich Sulfonamides C9H10N4O2S2 270.0 0.51 
96 Sulfamethoxazole Sigma-Aldrich Sulfonamides C10H11N3O3S 253.0 0.89 
97 Sulfamethoxypyridazine Sigma-Aldrich Sulfonamides C11H12N4O3S 280.3 0.32 
98 Sulfanitran Sigma-Aldrich Sulfonamides C14H13N3O5S 335.3 2.98 
99 Sulfapyridine Sigma-Aldrich Sulfonamides C11H11N3O2S 249.3 0.03 
100 Sulfaquinoxaline Sigma-Aldrich Sulfonamides C14H12N4O2S 300.0 1.30 
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102 Tetracycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O8 480.9 -1.47 
103 Thiabendazole Sigma-Aldrich Anthelmintics C10H7N3S 201.0 2.47 
104 Thiamphenicol Sigma-Aldrich Phenicols C12H15Cl2NO5S 356.2 -0.27 
105 Tildipirosin Sigma-Aldrich Macrolides/lincosamides C41H71N3O8 733.5 4.70 
106 Tilmicosin Sigma-Aldrich  Macrolides/lincosamides C46H80N2O13 868.5 4.95 
107 Tolfenamic acid Sigma-Aldrich Anti-inflammatories C14H12ClNO2 261.7 5.76 
108 Triclabendazole Sigma-Aldrich Anthelmintics C14H9Cl3N2OS 359.7 5.97 
109 Triclabendazole Sulfoxide Sigma-Aldrich Anthelmintics C14H9Cl3N2O2S 375.7 4.12 
110 Triflupromazine HCl Sigma-Aldrich Tranquilizers C18H20ClF3N2S 388.9 5.70 
111 Tulathromycin Toronto Research Chemicals Macrolides/lincosamides C41H79N3O12 805.5 4.07 
112 Tylosin Toronto Research Chemicals Macrolides/lincosamides C46H77NO17 916.1 3.27 
113 Virginiamycin M1 Sigma-Aldrich Others C28H35N3O7 525.6 -0.66 
114 Xylazine HCl Sigma-Aldrich Tranquilizers C12H17ClN2S 256.8 2.37 




Figure 4.1 Schematics of the blade with the undercoat layer (A) and the blade position in the sample 
during extraction (B). 
4.3.3 Sample Preparation 
Utilizing a Freezer/Mill® Cryogenic Grinder (SPEX SamplePrep, LLC, Metuchen, NJ, 
USA), beef tissue samples were homogenized and mixed in equal portions under liquid nitrogen 
to produce a uniform fine powder. Homogenized samples were stored in glass jars at −80 °C until 
analysis. Spiked tissue samples were prepared by weighing 2.0 g of homogenized tissue that had 
been brought to room temperature into a 50 mL polypropylene (PP) tube. Each sample was then 
spiked with 100 μL of a working solution containing all analytes under study at their respective 
designated concentrations, and 60 µL of the IS working solution containing 1 ng µL-1 of each IS. 
Samples were vortexed for 1 min, then placed on a benchtop agitator for 1h. Subsequently, samples 
were stored in a 4ºC fridge overnight so as to allow for proper equilibration and matrix binding of 
target analytes prior to extraction. Prior to extraction, samples were placed on the benchtop agitator 




individual spiked tissue sample and vortexed for 1 min in order to attain homogeneous consistency 
suitable for pipetting of samples to the wells of the 96 well-plates. 1500 µL of diluted beef sample 
was then transferred to each well of the 96 well-plate. A detailed schematic of the sample 
preparation steps is illustrated in Figure 4.2. 
4.3.4 Analytical protocols. 
The CBS analytical workflow consisted of four main steps: (1) Conditioning of the blades 
with MeOH:H2O (50:50, v/v/), (2) Extraction of target analytes from the matrix prepared as 
described above; (3) rinsing of coating with 15:85 acetone:H2O to remove any fatty residue, salts, 
or loose debris from the blade; (4) analyte desorption and ionization, whereby 12 µL of 
MeOH:MeCN:H2O (80:15:5, v/v/v) with 5 mM ammonium fluoride was pipetted onto the coating 
of individual blades as they were placed in front of the MS inlet. We observed that negative mode 
does not drive the elution/ionization solvent to the tip of the blade. Therefore, in order to achieve 
a stable spray in negative ionization mode and ensure reproducible results, it is crucial to make 
sure that the tip of the blade is properly wetted with the elution/ionization solvent prior to applying 
the voltage. Another factor that possibly helped us achieve successful negative ionization was the 
addition of a small concentration of ammonium fluoride (5mM) to the elution/ionization solvent 
as a means to increase ionization efficiency in negative ionization mode.212 The enhanced 
ionization may be explained by the strong electronegativity of the fluoride ion, which enhances 
deprotonation in negative mode. Steps 1-3 were automated with the use of a Concept-96 system 
(Professional Analytical Systems (PAS) Technology, Magdala, Germany), as described 




rinsing solvent and time were investigated for optimum S/N ratio rather than signal only.208 The 
CBS extraction and desorption/ionization workflow with the final optimized parameters as well as 
the developed analytical workflow are illustrated in further details in Figure 4.2. All CBS devices 
were single use. 
4.3.5 Instruments and Conditions 
Analysis was carried out on a TSQ Quantiva from Thermo Scientific (San Jose, CA, USA) 
with data analysis completed using TraceFinder 4.1, also from Thermo Scientific. Desorption and 
ionization experiments were performed using a custom CBS interface that was built at the 
University of Waterloo.210 
After 10s of analyte desorption/elution with the desorption solvent mentioned above, 
analyses were performed in negative ionization mode at minus 3.8 kV voltage for the first 10s of 
the analytical run, followed by 27s in positive mode at a plus 5 kV voltage, whereupon an 
electrospray event was produced at the tip of the blade, directly introducing the eluted analytes 
into the MS, as illustrated in Figure 4.2. Two single reaction monitoring (SRM) transitions were 
used for each analyte, one for quantitation and one for confirmation, whereas only one transition 
was needed for each IS. MS/MS analyte transitions and conditions were optimized via direct 
infusion from methanolic and acetonitrile standards. The transitions (shown in Table 4.2) were 
selected based on the optimal S/N at a 1 MRL concentration level in beef matrix. Detailed 




and monitored SRM transitions can be found in Table 4.2. The SRM dwell time was set at 5 ms 
per transition. Transfer line temperature was set to 300 °C.  
Figure 4.2 Proposed experimental setup for the conditioning, extraction, rinsing (A), and 
elution/ionization (B) of analytes from complex matrices via optimized CBS method. 











1 2-Aminoflubendazole 256 95, 123  27, 37  93 + 
2 2-Amino mebendazole 238 77, 105  34, 25 88 + 
3 2-Mercaptobenzimidazole 151 93, 118 23, 25 70 + 
4 2-Quinoxalinecarboxylic acid 175 104, 131  29, 22 191 + 
5 5-Hydroxythiabendazole 218 147, 191  32, 26 85 + 
6 2- Thiouracil 127 42, 58 33, 16 34 - 
7 6-Phenyl-2-thiouracil 205 103, 188  26, 17 69 + 
8 6-Propyl-2-thiouracil 171 112, 154 19, 17 57 + 
9 Acepromazine Maleate 327 86, 254 19, 23 65 + 
10 Albendazole 266 191, 234  32, 19 71 + 
11 Albendazole sulfone 298 159, 266 36, 19 79 + 
12 Albendazole sulfoxide 282 240, 208  23, 10 75 + 
13 Albendazole-2-aminosulfone 240 133,198 28,19 75 + 
14 Amoxicillin 366 114, 349  20, 10 48 + 
15 Ampicillin 350 106, 160 18, 10 54 + 
16 Azaperone 328 123,165 29, 20 66 + 














18 Betamethasone 393 325, 373  12, 14 59 + 
19 Bithionol 355 161, 192  22, 24 72 - 
20 Cambendazole 303 217, 261 27, 17 66 + 
21 Carazolol 299 116, 222 19, 19 63 + 
22 Carbadox 263 231, 245 10, 16 67 + 
23 Cephapirin 424 152, 292 22, 14 66 + 
24 Cefazolin 455 323, 333 10, 19 72 + 
25 Chloramphenicol 321 152, 257 16, 10 53 - 
26 Chlortetracycline HCl 479 444, 462 19, 17 70 + 
27 Chlorpromazine HCl 319 58, 86 30, 19 63 + 
28 Ciprofloxacin 332 288, 314 17, 19 72 + 
29 Clenbuterol HCl 277 168, 203  29, 16 47 + 
30 Clindamycin HCl 425 126, 377 27, 18 78 + 
31 Clorsulon 380 342, 344 10, 12 46 - 
32 Closantel 661 315, 345 32, 35 207 - 
33 Cloxacillin Sodium Salt 436 160, 277  10, 12 56 + 
34 Danofloxacin 358 314, 340 17, 21 80 + 
35 Desacetyl cephapirin 382 226, 292 17, 10 73 + 
36 Desethylene Ciprofloxacin  306 268, 288  24, 17 67 + 
37 Diclofenac Sodium 296 214, 277 33, 11 112 + 
38 Dicloxacillin Sodium Salt  470 212, 355 26, 16 124 + 
39 Difloxacin HCl 400 356, 382  18, 21 82 + 
40 Dimetridazole 142 96, 101 16, 10 38 + 
41 Doxycycline HCl 445 321, 428  30, 17 66 + 
42 Emamectin Benzoate 887 158, 868 33, 21 120 + 
43 Enrofloxacin 360 316, 342 18, 20 79 + 
44 Eprinomectin 937 490, 504 79, 50 164 + 
45 Erythromycin 735 522, 558 17, 34 85 + 
46 Fenbendazole Sulfone 332 159, 300  37, 21 81 + 
47 Florfenicol 357 182, 198 16, 14 73 + 
48 Florfenicol amine 248 151, 230  25, 10 50 + 
49 Flubendazole 314 123, 282 35, 22 80 + 
50 Flunixin 297 264, 279  33, 22 75 + 
51 Gamithromycin 778 601, 619  31, 28 121 + 
52 Haloperidol 376 123, 165  36, 22 78 + 
53 Hydroxy dimetridazole 158 80,140 10, 10 30 + 














55 Hydroxy metronidazole 188 123, 126 10, 17 47 + 
56 Ipronidazole 170 109, 124 24, 17 54 + 
57 Ketoprofen 255 105, 209  23, 14 59 + 
58 Lasalocid A 589 235, 571 30, 28 113 - 
59 Levamisole HCl 205 123, 178 28, 21 66 + 
60 Lincomycin HCl 
Monohydrate 
407 126, 359 26, 18 76 + 
61 Mebendazole 296 105, 264,  33, 20 75 + 
62 Melengestrol Acetate 397 279, 337 20, 13 88 + 
63 Meloxicam 352 115, 141 19, 20 67 + 
64 Metamizole 218 56, 97 17, 12 47 + 
65 Metronidazole 172 82, 128  23, 14 48 + 
66 Morantel Tartrate Hydrate 221 123, 111 35, 25 73 + 
67 Nafcillin 415 171, 199  34, 14 78 + 
68 Nitroxynil 289 127, 192 27, 20 99 - 
69 Norfloxacin 320 276, 302  17, 20 76 + 
70 Novobiocin 613 218, 396 13, 15 80 + 
71 Orbifloxacin 396 295, 352  23, 17 83 + 
72 Oxacillin Sodium Salt 
Monohydrate 
402 160, 243 11, 13 68 + 
73 Oxfendazole 316 191, 284 20, 18 68 + 
74 Oxyclozanide 400 364, 382 17, 22 84 - 
75 Oxyphenylbutazone 325 160, 162 20, 19 69 + 
76 Oxytetracycline HCl 461 426, 443 18, 10 67 + 
71 Orbifloxacin 396 295, 352  23, 17 83 + 
72 Oxacillin Sodium Salt 
Monohydrate 
402 160, 243 11, 13 68 + 
73 Oxfendazole 316 191, 284 20, 18 68 + 
74 Oxyclozanide 400 364, 382 17, 22 84 - 
75 Oxyphenylbutazone 325 160, 162 20, 19 69 + 
76 Oxytetracycline HCl 461 426, 443 18, 10 67 + 
77 Penicillin G 335 202, 217  23, 14 80 + 
78 Phenylbutazone 309 120, 160 42, 19 71 + 
79 Pirlimycin HCl 411 112, 363 25, 16 77 + 
81 Prednisone 359 237, 341  19, 10 65 + 
82 Promethazine HCl 285 86, 198 17, 25 46 + 
83 Propionylpromazine HCl 341 58, 268 30, 23 68 + 
84 Ractopamine HCl 302 164, 284 15, 10 53 + 
85 Rafoxanide 624 345, 513 32, 36 188 - 














87 Salbutamol 240 148, 222 17, 10 42 + 
88 Sarafloxacin HCl Hydrate  386 342, 368 18, 21 85 + 
89 Sulfachloropyridazine 285 108, 156 24, 16 57 + 
90 Sulfadiazin 251 92, 108 24, 22 48 + 
91 Sulfadimethoxine 311 108, 156 27, 20 72 + 
92 Sulfaethoxypyridazine 295 108, 140 25, 18 64 + 
93 Sulfamerazine 265 108, 172  24, 16 59 + 
94 Sulfamethazine 279 156, 186 18, 17 65 + 
95 Sulfamethizole 271 92, 108 24, 22 47 + 
96 Sulfamethoxazole 254 108, 156 23, 15 154 + 
97 Sulfamethoxypyridazine 281 108, 156  24, 16 63 + 
98 Sulfanitran 334 198, 270 28, 24 94 - 
99 Sulfapyridine 250 108, 184 24, 18 57 + 
100 Sulfaquinoxaline 301 108, 156  25, 17 69 + 
101 Sulfathiazole 256 108, 156  22, 15 52 + 
102 Tetracycline HCl 445 410, 154 18, 28 67 + 
103 Thiabendazole 202 131, 175  32, 25 74 + 
104 Thiamphenicol 354 185, 290 19, 13 77 - 
105 Tildipirosin 368 88, 98 19, 28 64 + 
106 Tilmicosin 435 174, 695 23, 16 75 + 
107 Tolfenamic Acid 262 209, 244 27, 15 47 + 
108 Triclabendazole 359 274, 344 37, 25 101 + 
109 Triclabendazole Sulfoxide 375 357, 360 17, 21 79 + 
110 Triflupromazine HCl 353 86, 248 20, 42  68 + 
111 Tulathromycin 404 72, 230 19, 10 62 + 
112 Tylosin 917 174, 772  35, 27 134 + 
113 Virginiamycin  526 355, 508  17, 12  72 + 
114 Xylazine HCl 221 90, 147  22, 23 68 + 
115 Enrofloxacin-d5 365 321 19 149 + 





4.4 Results and discussion  
4.4.1 Matrix effects 
The occurrence of matrix effects is undoubtedly a major drawback of ESI due to co-eluting 
matrix interferences and ionization competition.213 In the absence of chromatographic separation, 
matrix effects become even more pronounced, especially when more than 100 extracted analytes 
are ionized simultaneously. To the best of our knowledge, an evaluation of matrix effects for such 
a large number of analytes in a complex matrix such as tissue has yet to be reported in the literature 
for any ambient MS technique. 
In this study, matrix effects were examined by comparing the slopes of matrix-matched 
calibration curves and reagent-only calibration curves via the following equation: ME% = (slope 
of matrix-matched calibration curve − slope of reagent-only calibration curve) × 100% / slope of 
reagent-only calibration curve. For matrix effects evaluation, matrix matched samples in the range 
of 0.5-3X were prepared by blotting the proper amount of calibration solutions on blades that were 
exposed to the blank matrix as per the analytical procedure described above, while reagent-only 
samples were prepared using the same procedure but using water as a matrix instead of beef. For 
the matrix effects calibration curves, the amount of analyte spotted on the blade was determined 




Figure 4.3 %MEs of selected drug analytes in beef tissue vs. their precursor molecular weight. Points 
above or below the red lines indicate %MEs ±60%. Compounds that underwent suppression or 
enhancement by more than 100% are labeled. 
Figure 4.3 shows the matrix effects for the analytes studied versus their precursor molecular 
weight. Internal standard correction was not used when evaluating matrix effects. While there is 
no reference or golden standard to compare these results to, they are somewhat comparable to what 
is usually attained with LC-MS/MS methods using conventional sample preparation techniques.91 
As shown in Figure 4.3, and Table 4.3,while most of the analytes underwent signal 
suppression, signal suppression or enhancement for the majority of analytes (69%) was less than 




than 100 analytes are being ionized simultaneously. This promising outcome is not surprising due 
to the biocompatible nature of the SPME coating used in the CBS devices and its ability to 
simultaneously isolate and enrich a wide variety of analytes with minimal co-extraction of 
proteins, lipids, salts, and other matrix macromolecules present in the matrix.147,151 In addition, 
optimizing the extraction time based on S/N has proven again that shorter extraction times 
minimize the unnecessary coextraction of undesired molecules that may cause higher noise or 
ionization suppression, without compromising detection limits.204 With that said, matrix effects in 
direct-to-MS methods cannot be eliminated entirely. However, they can be minimized and/or 
compensated by using matrix matched calibration curves and labeled isotopic internal standards 
with structural analogues that mimic the analytes of interest. The ideal internal standard for any 
analyte is a stable isotope labeled form of said analyte. However, due to the large number of 
analytes included in this study, this approach is not practical. A more practical approach is to use 
one class specific internal standard for each class of drugs, especially for analytes that exhibited 
significant matrix effects. 
4.4.2 Selectivity 
One potential drawback of direct-to-MS techniques is the lack of retention time, a factor that 
might lead to selectivity issues. Selectivity, which is the ability of a method to discriminate 
between the analyte of interest and closely related matrix components is typically the main 
consideration for identification of analytes in regulatory methods.93,214 In the absence of retention 
time, another criterion that can be used for identification of target analytes is the ion ratio between 




might be affected by interfering matrix components.95,215 Matrix components in challenging 
matrices might interfere with either the qualifying ion or the quantifying ion, resulting in a 
significant deviation in ion ratios which can negatively impact qualitative outcome. Criteria for 
acceptable ion ratio deviations from the expected ion ratio vary depending on the country, 
however, a recent study by Berendsen et al. recommended a fixed ion ratio deviation tolerance of 
±50% for veterinary drugs in challenging matrices such as animal tissue to minimize false negative 
findings.214,215  
To study the influence of matrix components on ion ratio behavior, the data obtained from 
the matrix-matched calibration and reagent-only calibration, as described in the matrix effects 
section above, was used to calculate ion ratios in both matrix and reagent-only samples. Ion ratios 
were calculated by dividing the area of the less intense ion by the area of the higher intensity ion 
to ensure that the ion ratio was less than 1, although for certain analytes, the less intense ion was 
used for quantitative purposes, due to better S/N in the sample matrix. The reference ion ratio for 
each analyte was calculated as the average ratio obtained from all concentrations of the reagent-
only calibration standards in the same sequence as the matrix calibration standards. The average 
matrix ion ratio for each analyte was the average ratio obtained from all concentrations of the 
matrix calibration standards. The relative deviation of matrix ion ratios from the corresponding 
reference ion ratios, in percent, was calculated by subtracting the reference ion ratio from each of 




Figure 4.4 Distribution of relative ion ratio deviation value for target analytes in beef tissue from the 
average reference ratio. 
As presented in figure 4.4, the majority of analytes (71%) exhibited relative ion ratio 
deviation values that were within ±10% of the reference ion ratio value. Only 9% of the analytes 
exhibited relative ion ratio deviation values that fell outside the ±50% level proposed by Berendsen 
at al.214 
The extent of ion ratio variability in the matrix was also assessed at three different 
concentrations (0.75X, 1X, and 1.5X). As shown in Figure 4.5, the trend of variation was mostly 
independent on the concentrations except for four analytes, namely 6-phenyl thiouracil, cefazolin, 
diclofenac, and emamectin. Individual ion ratio deviation values for each analytes at each 




mainly due to the presence of matrix components that interfere with qualifier ions that have low 
S/N range (<10) as also observed by Mol et al.216 One particular compound, 6-phenyl thiouracil, 
displayed a significantly high relative ion ratio deviation (average 403%) due to a significant 
matrix interference with the qualifier ion transition (205→188). It is also worth noting that this 
transition is a neutral loss which is not favored for selectivity purposes. This observation further 
validates recommendations by Berendsen et al. to avoid neutral losses of 17 and 18 Da for proper 
identification of target analytes.214 In future studies, we suggest the re-evaluation of the most 
intense ion transitions for these analytes and the selection of qualifier ions based on S/N levels in 
the matrix similar to the procedure followed with quantifier ion transitions. 
Figure 4.5 Relative ion ratio deviation (%) at three concentration levels (0.75X, 1X, and 1.5X) versus 




4.4.3 Linearity and limits of quantitation 
Matrix-matched calibration curves were used to assess linearity and limits of quantitation. 
Calibration functions were constructed on the basis of the signal ratio of the analyte and IS (A/Is) 
for 7 concentration levels (from 0.25–2.5X) in three independent replicates. The calibration range 
was selected to include concentration levels bracketing the MRL. Despite the use of only one 
internal standard per ionization mode for correction for all the analytes, as illustrated in Figure 4.6, 
the majority of the target analytes (55%) achieved R2 values higher than 0.99, while the other 45% 
achieved R2 values between 0.95 and 0.99. While most analytes exhibited excellent linearity 
results, the suboptimal linearity results for the remaining analytes could be attributed to 
inappropriate internal standard correction or low detectability due to suboptimal coating chemistry 
or inappropriate desorption solvent. 
LOQ was established as the lowest point of the matrix-matched calibration curve that 
produced a response that is both accurate when compared to the expected value (calculated via 
linear regression), within a 70−120% range of the true concentrations, as well as precise (≤25% 
RSD). As shown in Table 4.3, all analytes under study achieved low enough LOQs to ensure proper 
determination at the maximum residue levels set in Canada and the US. Individual determination 






Figure 4.6 Linearity results of the optimized CBS method for the selected drug analytes in beef tissue 
expressed in percentage of analytes corresponding to R2 value ranges. 
 
4.4.4 Accuracy and precision 
To evaluate the accuracy and precision of the method with respect to intra-day repeatability, 
pooled matrix blanks were spiked at three validation levels; low, mid, and high (0.4X, 0.75X and 
1.5X) for each analyte, using six replicates per concentration (n=6). Accuracy was calculated based 
on estimated concentration values calculated from the linear regression equation of the matrix-
matched calibration curve. 
As presented in Figure 4.7 and Table 4.3, the majority of the analytes fell within a 70−120% 




1.5X concentration levels, thus confirming that they can be quantitatively determined. Individual 
accuracy and %RSD values are listed on Table 4.3 for each analyte under study. 
While the majority of analytes exhibited excellent results in terms of linearity, accuracy, and 
repeatability, the suboptimal analytical figures of merit for other compounds could be attributed 
to many reasons, such as inappropriate internal standard correction, unsuitable coating chemistry, 
or inappropriate elution/ionization solvent. These results were expected, considering that only one 
internal standard was used for correction per ionization mode and that the elution/ionization 
solvent was mainly optimized for negative ionization mode. The main purpose of this work was 
not SPME method optimization or validation, rather it was designed mainly to evaluate and report 
the ability of CBS to perform direct extraction from homogenized tissue samples and perform 
screening and quantitation in both negative and positive ionization modes with a single device in 
a single analytical run. Therefore, compromises were made, as it is usually the practice in multi-




Figure 4.7 Accuracy and repeatability results of the optimized CBS method for the target analytes 
fortified at the 0.4, 0.75 and 1.5X levels in beef tissue (n = 6). 
4.5 Conclusion and future perspectives 
The present study demonstrates that the optimized CBS technique with the undercoating is 
a suitable approach to facilitate both rapid and high-throughput screening and quantitative 
determination of multi-residue drugs in complex matrices such as beef tissues in both negative and 
positive ionization modes, even when using only one IS per each ionization mode for such a wide 
range of analytes. Pairing the current method with automated CBS desorption/ionization will 
further improve the efficiency and robustness of the CBS technique for complex matrices such as 
biological tissues. Quantitative results can be further improved by using more analyte-specific 




that without the use of ion mobility or chromatography for separation prior to MS, it is difficult to 
distinguish between isomeric and isobaric analytes when employing direct-to-MS technology. In 
addition, while matrix effects can be minimized, they cannot be completely eliminated in direct to 
MS methods; thus, the use of matrix-matched calibration curves and the incorporation of analyte-





Table 4.3 Figures of merit for the quantitation of multi-residue veterinary drugs in beef tissue via undercoated CBS-MS/MS 
Compound 





Ion Ratio Average  
(all concentrations)  
  
% Ion Ratio Deviation  
Matrix 




0.75X 1X 1.5X 
2-amino mebendazole 10 0.9931 0.5X  108 98   19 7  -52  0.98 0.91 -7  -7 -9 -3 
2-Aminoflubendazole 10 0.9932 0.5X  110 97   17 7  -55  0.19 0.12 -37  -36 -35 -52 
2-Mercaptobenzimidazole 25 0.9768 1X   67    19  167  0.04 0.11 171  162 161 153 
2-Thiouracil 400 0.9448 1X   116    27  92  0.08 0.03 -66  -61 -74 -63 
5-Hydroxythiabendazole 100 0.9809 0.5X  107 107   7 6  -43  0.80 0.80 0  1 1 -1 
6-phenyl-thiouracil 400 0.9824 0.75X  105 102   16 17  -36  0.68 3.42 403  601 538 268 
6-propyl-2-thiouracil 50 0.9934 0.75X   109    12  175  0.60 0.62 3  3 2 8 
Acepromazine 10 0.9884 0.5X  108 91   7 8  -46  0.14 0.14 0  5 -4 -1 
Albendazole 50 0.9714 0.5X  119 101   12 5  -48  0.44 0.44 0  -2 1 1 
Albendazole 2-aminosulfone 50 0.9961 0.25X 79 92 97  7 11 10  -36  0.40 0.37 -9  -10 -9 -3 
Albendazole sulfone 50 0.9967 0.25X 83 107 114  3 10 8  -53  0.93 0.92 -1  -1 -1 -1 
Albendazole sulfoxide 50 0.9965 0.25X 76 102 110  6 5 8  -55  0.98 0.98 1  1 -1 2 
Azaperone 10 0.9932 0.25X 77 104 98  8 5 9  -33  0.83 0.83 0  2 -1 0 
Betamethasone 100 0.9980 0.25X 94 111 113  7 18 9  -57  0.06 0.06 5  7 14 -3 
Bithionol 10 0.9827 0.5X  91 113   24 22  21  0.89 0.86 -4  1 -3 -7 
Cambendazole 10 0.9946 0.5X  108 101   8 4  -48  0.74 0.75 2  0 1 1 
Carazolol 10 0.9924 0.25X 86 103 98  4 8 7  -61  0.45 0.46 3  4 3 1 
Carbadox 30 0.9984 0.25X 79 96 99  7 7 6  -55  0.69 0.72 4  8 -2 -16 
Cefazolin 100 0.9904 0.5X  109 100   8 9  -66  0.05 0.11 130  132 126 84 









Ion Ratio Average  
(all concentrations)  
  
% Ion Ratio Deviation  
Matrix 
(ng g-1) R2 LOQ 0.4X 0.75X 1.5X   0.4X 0.75X 1.5X     Reagent Matrix 
% 
Deviation 
  0.75X 1X 1.5X 
Chloramphenicol 10 0.9950 0.5X  104 104   5 7  17  0.93 1.18 27  16 30 3 
Chlortetracycline 200 0.9986 0.25X 82 98 104  8 15 10  -29  0.01 0.01 -6  1 -12 -14 
Chlorpromazine 10 0.9605 0.5X 90 99 86  10 12 8  -43  0.47 0.44 -5  -2 -4 -2 
Clorsulon 100 0.9577 1X     100    12  -35  0.43 0.40 -8  -7 -5 -5 
Cimaterol 10 0.9755 0.5X  98 81   11 10  -57  0.59 0.51 -13  -14 -11 -8 
Ciprofloxacin 50 0.9983 0.25X 79 90 97  5 9 6  -35  0.81 1.15 42  34 49 40 
Clenbuterol 10 0.9909 0.25X 79 96 96  13 9 6  -60  0.33 0.31 -6  -9 -4 0 
Clindamycin 100 0.9860 0.25X 83 97 97  8 9 9  -16  0.09 0.09 -1  -2 -1 -1 
Closantel 50 0.9899 1X     135    26  -17  0.84 0.85 1  -1 1 5 
Cloxacillin 10 0.9792 0.25X 91 118 106  16 19 16  -62  0.69 0.57 -18  -19 -10 -15 
Danofloxacin 70 0.9982 0.25X 73 92 99  6 8 5  -1  0.22 0.21 -5  -12 -5 -5 
Desacetyl Cephapirin 100 0.9988 0.25X 88 91 90  8 13 11  -71  0.82 0.83 1  4 0 -4 
Desethylene Ciprofloxacin 100 0.9987 0.25X 77 89 96  11 15 11  -20  0.28 0.27 -3  -3 -3 0 
Diclofenac 200 0.9800 0.25X 90 108 103  8 20 10  -75  0.22 0.62 182  187 156 81 
Dicloxacillin 100 0.9713 0.5X 94 111 97  12 20 10  -69  0.31 0.18 -42  -50 -39 -11 
Difloxacin 100 0.9988 0.25X 88 104 97  5 5 4  -42  0.90 0.85 -5  -8 -5 1 
Dimetridazole 50 0.9948 0.25X 83 81 82  11 17 20  -30  0.49 0.35 -30  -41 -19 -18 
Doxycycline 100 0.9971 0.25X 86 104 104  7 13 11  30  0.10 0.11 7  7 8 7 
Emamectin 10 0.9798 0.5X 84 120 94  18 13 12  -50  0.06 0.14 140  151 129 46 
Enrofloxacin 20 0.9997 0.25X 83 99 98  2 2 2  -33  0.55 1.25 127  125 125 132 










Ion Ratio Average  
(all concentrations)  
  
% Ion Ratio Deviation  
Matrix 




0.75X 1X 1.5X 
Erythromycin 100 0.9929 0.25X 80 106 99  11 17 7  -38  0.73 0.67 -8  -9 -7 -9 
Fenbendazole Sulfone 400 0.9956 0.25X 93 112 107  9 13 6  -62  0.54 0.54 -1  0 -1 -1 
Flubendazole 10 0.9869 0.25X 95 109 107  13 15 6  -64  0.31 0.33 4  2 5 1 
Flunixin 20 0.9900 0.5X  112 97   20 5  -55  0.35 0.34 -3  -3 -2 0 
Gamithromycin 20 0.9814 0.25X 81 111 107  18 20 10  -33  0.19 0.19 -2  1 -2 2 
Haloperidol 10 0.9850 0.5X  105 94   5 7  -51  0.98 0.99 1  1 2 1 
Hydroxy ipronidazole 10 0.9445 0.5X  98 88   11 11  -42  0.34 0.39 14  11 15 13 
Ipronidazole 10 0.9762 0.25X 82 101 104  10 21 17  -29  0.91 0.98 8  6 6 5 
Ketoprofen 10 0.9760 0.5X  112 101   12 10  -44  0.52 0.49 -5  -5 -7 -7 
Lasalocid A 1000 0.9791 0.5X  112 104   25 12  -7  0.19 0.20 5  3 2 9 
Levamisole 100 0.9361 0.5X  98 89   40 28  -59  0.37 0.36 -2  -3 -2 -1 
Lincomycin 100 0.9977 0.25X 74 87 97  13 10 10  -13  0.11 0.11 -2  -3 -1 2 
Mebendazole 10 0.9892 0.25X 91 108 106  8 14 6  -66  0.21 0.24 17  20 14 8 
Melengestrol Acetate 25 0.9508 0.5X  119 105   12 8  -64  0.82 0.95 16  13 16 13 
Meloxicam 20 0.9924 0.5X  106 106   11 2  -48  0.41 0.41 1  1 0 0 
Metamizole 200 0.9675 0.25X 66 78 77  22 18 14  129  0.56 0.43 -23  -20 -26 -27 
Metronidazole 10 0.9641 0.5X  81 98   13 32  -50  0.48 0.48 0  3 0 -2 
Morantel 100 0.9757 0.25X 78 106 102  18 12 7  -69  0.86 0.86 -1  -2 0 0 
Nafcillin 100 0.9922 0.25X 92 115 112  6 12 8  -66  0.54 0.55 0  -1 2 -2 
Nitroxynil 50 0.9787 0.5X 107 99 101   14 22  47  0.38 0.38 0  0 -1 1 









Ion Ratio Average  
(all concentrations)  
  
% Ion Ratio Deviation  
Matrix 
(ng g-1) R2 LOQ 0.4X 0.75X 1.5X   0.4X 0.75X 1.5X     Reagent Matrix 
% 
Deviation 
  0.75X 1X 1.5X 
Novobiocin 1000 0.9727 0.5X  109 97   15 9  -69  0.89 0.90 0  1 2 -1 
Orbifloxacin 50 0.9969 0.25X 86 97 97  5 4 3  -41  0.88 0.86 -1  -2 -1 -1 
Oxacillin 100 0.9819 0.25X 88 120 127  4 18 12  -68  0.94 0.94 -1  2 -1 2 
Oxfendazole 800 0.9923 0.25X 94 107 101  7 11 6  -54  0.97 0.97 0  -1 -1 0 
Oxyclozanide 10 0.9455 1X     119    21  30  0.52 0.54 4  4 -1 5 
Oxyphenylbutazone 100 0.9820 0.5X 95 113 109  9 16 11  -62  0.38 0.38 -2  -2 -3 -3 
Oxytetracycline 200 0.9995 0.25X 82 96 104  11 11 9  64  0.38 0.39 3  2 3 2 
Phenylbutazone 100 0.9903 0.5X  116 101   13 10  -53  0.31 0.33 6  5 5 2 
Pirlimycin 300 0.9902 0.25X 72 92 106  15 15 18  -8  0.38 0.38 1  -1 2 2 
Prednisone 100 0.9940 0.25X 94 114 117  7 15 13  -65  0.19 0.09 -52  -55 -52 -43 
Promethazine 10 0.9905 0.5X  110 89   8 6  -51  0.58 0.57 0  1 0 -1 
Propionylpromazine 10 0.9812 0.5X 65 101 111   21 13  -47  0.88 0.72 -18  -12 -28 -29 
Ractopamine 30 0.9961 0.25X 83 95 99  11 8 9  -53  0.80 0.98 22  24 17 10 
Rafoxanide 10 0.9589 1X   126    19  -11  0.27 0.27 1  4 -1 -2 
Ronidazole 10 0.9581 0.75X   82 86   24 31  -48  0.29 0.43 47  49 39 14 
Salbutamol 10 0.9874 0.25X 72 83 82  6 14 12  -51  0.52 0.68 29  32 24 11 
Sarafloxacin 50 0.9978 0.25X 86 96 94  3 12 6  -85  0.95 1.37 45  37 54 41 
Sulfachloropyridazine 100 0.9948 0.25X 84 106 109  5 8 8  -64  0.54 0.54 1  2 1 1 
Sulfadiazin 100 0.9913 0.25X 76 97 100  9 12 5  -59  0.96 0.95 -1  -2 -1 -2 
Sulfadimethoxine 100 0.9951 0.25X 84 106 103  4 3 2  -49  0.46 0.46 0  0 0 -1 









Ion Ratio Average  
(all concentrations)  
  
% Ion Ratio Deviation  
Matrix 
(ng g-1) R2 LOQ 0.4X 0.75X 1.5X   0.4X 0.75X 1.5X     Reagent Matrix 
% 
Deviation 
  0.75X 1X 1.5X 
Sulfamerazine 100 0.9910 0.25X 74 100 104  5 9 3  -56  0.95 0.94 0  1 -1 0 
Sulfamethazine 100 0.9902 0.25X 75 102 105  6 8 5  -51  0.24 0.24 -2  -3 -3 0 
Sulfamethizole 100 0.9923 0.25X 84 105 103  5 4 6  -67  0.92 0.92 -1  -1 -1 0 
Sulfamethoxazole 100 0.9966 0.25X 82 105 108  4 7 7  -61  0.94 0.93 -1  0 -2 -1 
Sulfamethoxypyridazine 100 0.9923 0.25X 82 102 104  5 3 6  -55  0.76 0.75 0  -1 0 0 
Sulfanitran 10 0.9773 0.25X 109 109 114  12 12 7  -44  0.33 0.34 1  1 0 2 
Sulfapyridine 100 0.9901 0.25X 74 98 103  8 7 2  -55  0.99 0.97 -3  -3 -1 -2 
Sulfaquinoxaline 100 0.9941 0.25X 91 108 107  5 14 6  -65  0.60 0.59 -2  -4 -1 0 
Sulfathiazole 100 0.9902 0.25X 82 99 99  7 5 3  -59  0.61 0.63 3  2 2 3 
Tetracycline 200 0.9903 0.25X 86 97 99  10 8 7  111  0.38 0.38 1  0 0 2 
Thiabendazole 100 0.9963 0.25X 87 109 101  8 6 6  -42  0.71 0.72 1  2 0 1 
Thiamphenicol 10 0.9986 0.25X 83 101 102  8 5 5  30  0.99 0.98 -1  6 -2 -5 
Tildipirosin 400 0.9855 0.25X 70 99 106  9 17 15  289  0.16 0.15 -6  -6 -6 -8 
Tilmicosin 100 0.9974 0.25X 84 100 103  9 9 8  -45  0.33 0.34 2  3 2 0 
Tolfenamic acid 200 0.9653 1X     103    24  -80  0.21 0.13 -40  -37 -43 -35 
Triclabendazole 50 0.9707 0.75X  123 109   20 21  -81  0.86 0.84 -2  -3 -4 2 
Triclabendazole Sulfoxide 50 0.9934 1X     106    12  -83  0.53 0.19 -64  -67 -63 -47 
Trifluropromazine 10 0.9881 0.25X 84 122 100  23 16 14  -45  0.27 0.26 -3  -4 2 -2 
Tulathromycin 1000 0.9878 0.25X 71 99 100  11 30 20  144  0.30 0.30 0  -2 1 3 
Tylosin 200 0.9935 0.25X 75 106 103  8 17 9  -44  0.50 0.50 1  1 1 2 
Virginiamycin 100 0.9958 0.25X 89 113 103  9 13 7  -25  0.33 0.28 -17  -16 -17 -9 





Rapid and High‐throughput Screening of Multi-residue 
Pharmaceutical Drugs in Bovine Tissue using Solid Phase 
Microextraction and Direct Analysis in Real Time-Tandem Mass 
Spectrometry (SPME-DART-MS/MS) 
 
5.1 Preamble  
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in Real Time-Tandem Mass Spectrometry (SPME-DART-MS/MS). Talanta 2020, 121095. 
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publications and any further request for re-use of this information should be requested directly 
from them (DOI: https://doi.org/10.1016/j.talanta.2020.121095).  
The contribution of co-author Joao Raul Belinato to the work described in this chapter 
include assistance in the execution of selected experiments and in processing data. All of the 
experimental planning, design, and experimental work conducted in the laboratory, data analysis, 
interpretation, and writing were performed by the author of the thesis. 
I, Joao Raul Belinato, authorize Abir Khaled to use the material for her thesis. 
5.2 Introduction 
Many pharmaceutical compounds are considered as emerging contaminants in both 
environment and food.217 One source of these contaminants in animal-derived food is the 
widespread use of veterinary drugs as therapeutic drugs and growth promoters in animal 
husbandry.218,219 The monitoring of veterinary drug residues in food-producing animal tissues has 
gained significance for several reasons, including their potential risk to human health as well as 
their potential role on microbial antibiotic resistance.7,14–17,197,198 These concerns have led to 
stringent food safety regulations, prompting increased demand for rapid and high-throughput 
analysis of real samples. Mass spectrometry (MS) is presently recognized as one of the most 
powerful techniques available for qualitative and quantitative analysis of a wide range of analytes 
and matrices due its speed, selectivity, and high detectability.5,199,220–222 However, conventional 
MS instrumental analysis is typically preceded by a classical analytical workflow that often 




sample clean-up and separation considered as the two main bottlenecks of the process.92,96,98,202,223–
225 While every step of the analytical workflow is crucial for method performance, the slowest 
steps determine the overall speed of the process.223–226 
In the food analysis field, where fast decisions need to be made regarding food safety, use 
of conventional sample preparation and chromatographic methods may not always be suitable.22 
Given the perishable nature of food, as well as the potential catastrophic risks to human health 
associated with the distribution of contaminated food, food safety investigations demand the use 
of extremely fast, efficient, and reliable analytical methods. An alternative to overcome lengthy 
workflows and improve efficiency is to minimize sample preparation steps and skip 
chromatographic separation altogether.96,225,227,228 
This solution to the constraints of conventional analytical techniques has laid the foundation 
for the development of ambient ionization mass spectrometry (AIMS), which encompasses a group 
of direct-to-MS techniques where analyte desorption/ionization take place in the atmospheric 
environment.139,208,221,222,225,229,230 The direct analysis in real time (DART) approach, introduced 
by Cody and Laramee in 2005, is one of the pioneers in this increasingly popular field.231 Since its 
first introduction, DART has become one of the most commonly used analytical techniques in the 
food analysis field due to its commercial availability and its versatile sample-introduction 
approach.225,232 However, despite the abundance of applications of DART‐MS in food analysis, 
there are no studies on the analysis of multi-residue veterinary drugs in food-animal tissue.233,234 
To the best of our knowledge, there is only one reported use of DART-MS in this field to date: a 




benzimidazoles in bovine milk and coccidiostats in chicken feed.235 The reported method entailed 
extensive QuEChERS sample preparation and clean-up steps. We believe the evidenced lack of 
research in this field could be attributed to many factors, such as the complex nature of animal 
tissue and the tendency of DART to break down labile compounds, such as some pharmaceutical 
drugs, compared to other soft ionization techniques such as electrospray ionization (ESI) 
techniques.54,96,221,222,226,236–239 
To maximize the performance of DART, an ideal sample introduction method should be able 
to enrich analytes and reduce matrix interferences to minimal levels while maintaining accuracy 
and reproducibility. As already demonstrated by its successful coupling with many other AIMS 
techniques, SPME stands as an ideal candidate for this application due to its intrinsic features, 
which allow integration of sampling, extraction, clean-up, and instrumental introduction into a 
single step.120,141,204,207,208,221,222,240 Another distinctive feature of SPME in ambient MS analysis is 
that SPME devices can be used as the desorption/ionization probe.225 Moreover, biocompatible 
coatings used in SPME have proven to minimize co-extraction of interferences commonly found 
in biological samples such as macromolecules, phospholipids, and salts 120,147,189,206. Furthermore, 
SPME can be successfully automated and used in high-throughput format for rapid qualitative and 
quantitative analyses of complex matrices.139,189,204,206,240 
SPME–DART-MS/MS has been successfully applied to different food matrices and 
biofluids using a variety of geometrical SPME configurations; of these, meshes have been shown 
to offer the best detectability and successful geometry for most biological matrices.139–141,230 




applicable due to potential attachment of matrix debris and macromolecules to the mesh. Recently, 
an alternative geometry of SPME, namely the SPME pin, was developed specifically for direct 
immersion extraction of diluted homogenized biological tissue samples. Comprised of stainless-
steel rods coated with biocompatible hydrophilic–lipophilic balance HLB/ polyacrylonitrile 
(PAN), these SPME pins were successfully used for high-throughput extraction and quantitative 
analysis of more than 100 multi-residue veterinary drugs in chicken and beef tissue via LC-
MS/MS.189,206 In this study, we investigate the feasibility of using the said SPME pins with DART-
MS/MS for rapid monitoring and quantitation of multi-residue drugs in animal-food tissue. 
To the best of our knowledge, this is the first study entailing the use of DART-MS/MS for 
screening of multi-residue drugs in beef tissue. In addition, the developed method was evaluated 
with respect to selectivity, linearity, accuracy, intra-day repeatability, and limit of quantitation 
(LOQ). 
5.3 Materials and Methods 
5.3.1 Target Analytes 
A total of 98 veterinary drugs encompassing a wide range of physico-chemical properties 
(log P −1.85–9.36) were initially selected for analysis as part of this study. These compounds were 
successfully quantified below their MRLs in our previous reports using SPME-LC-ESI-MS/MS,206 
and coated blade spray (CBS)-MS/MS,240 with the exception of florfenicol and florfenicol amine 
in case of CBS-MS/MS. Analytes were selected from the list of standards specified in the official 




of animal drug residues (CLG-MRM1.08).31 Further details pertaining to these compounds, 
including their physico-chemical properties, drug classes, and supplier information, are provided 
in Table 5.1. 
A total of 46 analytes (bolded in Table 5.1) were excluded from further evaluation studies 
following final method optimization due to a lack of quantifiable signals at their respective MRLs. 
The MRL of a given compound is defined by Health Canada as the maximum concentration of 
residue that could safely remain in the tissue or food product derived from a food-producing animal 
that has been treated with a veterinary drug.82 MRL values utilized in this work (listed in Table 
5.1) were based primarily on Canadian MRL values and US tolerances in beef tissues.82,91 In 
general, Canadian MRLs are either equal or lower than US tolerances; however, in cases where 
Canadian MRLs were higher than US tolerances, the US regulatory value was selected, as is the 
case for morantel and ketoprofen. Sulfadoxine was also not evaluated in this study as it is an isobar 
of sulfadimethoxine. Two isotopically labelled internal standards (IS), namely sulfamethazine-




Table 5.1 Physico-chemical properties, class, and supplier information for analytes under study. 







1 2-Aminoflubendazole Sigma-Aldrich Anthelmintics C14H10FN3O 255.2 1.96 10 
2 2-Amino mebendazole Sigma-Aldrich Anthelmintics C14H11N3O 237.3 1.74 10 
3 
2-Quinoxalinecarboxylic 
acid Sigma-Aldrich Others C9H6N2 174.2 1.80 100 
4 5-Hydroxythiabendazole Sigma-Aldrich Anthelmintics C10H7N3OS 217.3 1.73 100 
5 6-Phenyl-2-thiouracil Sigma-Aldrich Thyreostats C10H8N2OS 204.3 -0.10 400 
6 6-Propyl-2-thiouracil Sigma-Aldrich Thyreostats C7H10N 170.2 1.37 50 
7 Acepromazine Maleate Sigma-Aldrich Tranquilizers C19H22N2OS 326.5 4.08 10 
8 Albendazole Sigma-Aldrich Anthelmintics C12H15N3O2S 265.3 3.07 50 
9 
Albendazole-2-
aminosulfone Sigma-Aldrich Anthelmintics C10H13N3O2S 239.3 0.12 50 
10 Albendazole Sulfone Sigma-Aldrich Anthelmintics C12H15N3O4S 297.1 0.86 50 
11 Albendazole Sulfoxide Sigma-Aldrich Anthelmintics C12H15N3O3S 281.3 0.91 50 
12 Ampicillin Sigma-Aldrich β-Lactams/cephalosporins C16H19N3O4S 349.4 1.35 10 
13 Azaperone Sigma-Aldrich Tranquilizers C19H22FN3O 327.4 2.50 10 
14 Betamethasone Sigma-Aldrich Anti-inflammatories C22H29FO5 392.2 1.87 100 
15 Cambendazole Sigma-Aldrich Anthelmintics C14H14N4O2S 302.4 2.90 10 
16 Carazolol Sigma-Aldrich Tranquilizers C18H22N2O2 298.4 3.59 10 
17 Carbadox Sigma-Aldrich Others C11H10N4O4 262.2 -1.22 30 











19 Chlorpromazine HCl Sigma-Aldrich Tranquilizers C17H20Cl2N2S 355.3 5.20 10 
20 Chlortetracycline HCl Sigma-Aldrich Tetracyclines C22H24Cl2N2O8 515.3 1.11 200 
21 Ciprofloxacin Sigma-Aldrich Fluoroquinolones C17H18FN3O3 331.341 0.65 50 
22 Clenbuterol HCl Sigma-Aldrich β-Agonists C12H19Cl3N2O 313.7 2.61 10 
23 Clindamycin HCl Sigma-Aldrich Macrolides/lincosamides C18H34Cl2N2O5S 461.4 1.83 100 
24 Cloxacillin Sodium Salt Sigma-Aldrich β-Lactams/cephalosporins C19H17ClN3NaO5S 457.9 2.53 100 
25 Danofloxacin Sigma-Aldrich Fluoroquinolones C19H20FN3O3 357.1 1.20 70 
26 Desacetyl cephapirin TRC2 β-Lactams/cephalosporins C15H15N3O5S2 381.427 0.32 100 
27 Desethylene ciprofloxacin TRC2 Fluoroquinolones C15H17ClFN3O3 341.8 -0.14 100 
28 Diclofenac Sodium Sigma-Aldrich Anti-inflammatories C14H10Cl2NNaO2 318.1 4.06 200 
29 Dicloxacillin  Sigma-Aldrich β-Lactams/cephalosporins C19H16Cl2N3NaO5S.xH2O 492.3 3.02 100 
30 Difloxacin HCl Sigma-Aldrich Fluoroquinolones C21H20ClF2N3O3 435.9 2.78 50 
31 Dimetridazole Sigma-Aldrich Coccidiostats C5H7N3O2 141.0 0.31 50 
32 Doxycycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O8 480.9 -0.54 100 
33 Emamectin Benzoate Sigma-Aldrich Anthelmintics C56H81NO15 1008.2 6.84 10 
34 Enrofloxacin Sigma-Aldrich Fluoroquinolones C19H22FN3O3 359.4 1.88 20 
35 Erythromycin Sigma-Aldrich Macrolides/lincosamides C37H67NO13 733.9 2.83 125 
36 Fenbendazole Sulfone Sigma-Aldrich Anthelmintics C15H13N3O4S 331.3 1.70 400 
37 Florfenicol Sigma-Aldrich Phenicols C12H14Cl2FNO4S 357.0 -0.12 300 
38 Florfenicol amine Sigma-Aldrich Phenicols C10H14FNO3S 247.3 -0.80 100 
39 Flubendazole Sigma-Aldrich Anthelmintics C16H12FN3O3 313.3 3.05 10 
40 Flunixin Sigma-Aldrich Anti-inflammatories C14H11F3N2O2 296.2 5.40 20 











42 Haloperidol Sigma-Aldrich Tranquilizers C21H23ClFNO2 375.9 3.01 10 
43 Hydroxy dimetridazole TRC2 Coccidiostats C5H7N3O3 157.1 -0.49 50 
44 Hydroxy ipronidazole Sigma-Aldrich Coccidiostats C7H11N3O3 185.2 0.21 10 
45 Hydroxy metronidazole Sigma-Aldrich Coccidiostats C6H9N3O4 187.15 -0.81 10 
46 Ipronidazole Sigma-Aldrich Coccidiostats C7H11N3O2 169.2 1.18 10 
47 Ketoprofen Sigma-Aldrich Anti-inflammatories C16H14O3 254.3 2.81 10 
48 Levamisole HCl Sigma-Aldrich Anthelmintics C11H13ClN2S 240.8 1.85 100 
49 
Lincomycin HCl 
Monohydrate Sigma-Aldrich Macrolides/lincosamides C18H37ClN2O7S 461.0 0.91 100 
50 Mebendazole Sigma-Aldrich Anthelmintics C16H13N3O3 295.3 2.83 10 
51 Melengestrol Acetate Sigma-Aldrich Others C25H32O4 396.5 4.21 25 
52 Meloxicam Sigma-Aldrich Anti-inflammatories C14H13N3O4S2 351.0 2.71 20 
53 Metamizole Sigma-Aldrich Anti-inflammatories C13H17N3O4S 311.0 -0.74 200 
54 Metronidazole Sigma-Aldrich Coccidiostats C6H9N3O3 171.2 -0.01 10 
55 Morantel Tartrate Hydrate Sigma-Aldrich Anthelmintics C16H22N2O6S xH2O 370.4 1.97 150 
56 Nafcillin Sigma-Aldrich β-Lactams/cephalosporins C21H22N2O5S 414.1 3.52 100 
57 Norfloxacin Sigma-Aldrich Fluoroquinolones C16H18FN3O3 319.3 0.82 50 
58 Novobiocin Sigma-Aldrich Novobiocin C31H36N2O11 612.2 2.86 1000 
59 Orbifloxacin Sigma-Aldrich Fluoroquinolones C19H20F3N3O3 395.4 2.37 50 
60 Oxacillin Sodium Salt  Sigma-Aldrich β-Lactams/cephalosporins C19H18N3O5SNa H2O 441.4 2.05 100 
61 Oxfendazole Sigma-Aldrich Anthelmintics C15H13N3O3S 315.3 1.36 800 











63 Oxyphenylbutazone Sigma-Aldrich Anti-inflammatories C19H20N2O3 324.4 2.72 100 
64 Oxytetracycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O9 496.9 -1.50 200 
65 Penicillin G TRC β-Lactams/cephalosporins C16H18N2O4S 334.0 1.67 50 
66 Phenylbutazone Sigma-Aldrich Anti-inflammatories C19H20N2O2 308.4 3.16 100 
67 Pirlimycin HCl TRC2 Macrolides/lincosamides C17H32Cl2N2O5S 447.4 1.47 300 
68 Prednisone Sigma-Aldrich Anti-inflammatories C21H26O5 358.4 1.57 100 
69 Promethazine HCl Sigma-Aldrich Tranquilizers C17H21ClN2S 320.9 4.78 10 
70 Propionylpromazine HCl Sigma-Aldrich Tranquilizers C20H25ClN2OS 376.9 4.61 10 
71 Ractopamine HCl Sigma-Aldrich β-Agonists C18H24ClNO3 337.8 1.65 30 
72 Ronidazole Sigma-Aldrich Coccidiostats C6H8N4O4 200.0 -0.45 10 
73 Salbutamol Sigma-Aldrich β-Agonists C13H21NO3 239.1 0.01 10 
74 Sarafloxacin HCl Hydrate  Sigma-Aldrich Fluoroquinolones C20H17F2N3O3 HCl xH2O 421.8 2.09 50 
75 Sulfachloropyridazine Sigma-Aldrich Sulfonamides C10H9ClN4O2S 284.7 1.02 100 
76 Sulfadiazine Sigma-Aldrich Sulfonamides C10H10N4O2S 250.277 -0.12 100 
77 Sulfadimethoxine Sigma-Aldrich Sulfonamides C12H14N4O4S 310.3 1.48 100 
78 Sulfaethoxypyridazine Sigma-Aldrich Sulfonamides C12H14N4O3S 294.3 0.85 100 
79 Sulfamerazine Sigma-Aldrich Sulfonamides C11H12N4O2S 264.0 0.34 100 
80 Sulfamethazine Sigma-Aldrich Sulfonamides C12H14N4O2S 278.0 0.80 100 
81 Sulfamethizole Sigma-Aldrich Sulfonamides C9H10N4O2S2 270.0 0.51 100 
82 Sulfamethoxazole Sigma-Aldrich Sulfonamides C10H11N3O3S 253.0 0.89 100 
83 Sulfamethoxypyridazine Sigma-Aldrich Sulfonamides C11H12N4O3S 280.3 0.32 100 











85 Sulfaquinoxaline Sigma-Aldrich Sulfonamides C14H12N4O2S 300.0 1.30 100 
86 Sulfathiazole Sigma-Aldrich Sulfonamides C9H9N3O2S2 255.3 0.05 100 
87 Tetracycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O8 480.9 -1.47 200 
85 Sulfaquinoxaline Sigma-Aldrich Sulfonamides C14H12N4O2S 300.0 1.30 100 
86 Sulfathiazole Sigma-Aldrich Sulfonamides C9H9N3O2S2 255.3 0.05 100 
87 Tetracycline HCl Sigma-Aldrich Tetracyclines C22H25ClN2O8 480.9 -1.47 200 
88 Thiabendazole Sigma-Aldrich Anthelmintics C10H7N3S 201.0 2.47 100 
89 Tildipirosin Sigma-Aldrich Macrolides/lincosamides C41H71N3O8 733.5 4.70 400 
90 Tilmicosin Sigma-Aldrich  Macrolides/lincosamides C46H80N2O13 868.5 4.95 100 
91 Tolfenamic acid Sigma-Aldrich Anti-inflammatories C14H12ClNO2 261.7 5.76 200 
92 Triclabendazole Sigma-Aldrich Anthelmintics C14H9Cl3N2OS 359.7 5.97 50 
93 Triclabendazole Sulfoxide Sigma-Aldrich Anthelmintics C14H9Cl3N2O2S 375.7 4.12 50 
94 Triflupromazine HCl Sigma-Aldrich Tranquilizers C18H20ClF3N2S 388.9 5.70 10 
95 Tulathromycin TRC2 Macrolides/lincosamides C41H79N3O12 805.5 4.07 150 
96 Tylosin TRC2 Macrolides/lincosamides C46H77NO17 916.1 3.27 200 
97 Virginiamycin M1 Sigma-Aldrich Others C28H35N3O7 525.6 -0.66 100 
98 Xylazine HCl Sigma-Aldrich Tranquilizers C12H17ClN2S 256.8 2.37 10 
1 Data taken from www.chemspider.com, accessed Nov, 2019, LogP data taken from computational predictions ACD/LogP 
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5.3.2 Reagents and materials 
LC-MS-grade methanol (MeOH), acetonitrile (MeCN), and water were purchased from 
Fisher Scientific (Mississauga, ON, Canada). Polyacrylonitrile (PAN), and Dimethyl Sulfoxide 
(DMSO) were purchased from Sigma Aldrich (Oakville, ON, Canada). SPME pins, shown in 
Figure 5.1, were manufactured in-house using high-tolerance 304 stainless steel rods (1/16” 
diameter) purchased from McMaster-Carr (Aurora, OH, USA). The pins were cut to a length of 55 
mm at the University of Waterloo's Science Technical Services (UW-STC) and coated with a 
slurry of HLB particles suspended in PAN as a binder at a thickness of 30 μm and a length of 1 
cm. HLB particles were synthesized in house and characterized as previously described.189 The 
SPME coating was immobilized on the stainless-steel rod surface by dip coating, as per the 
protocol developed by Gomez-Ríos at al.209 Utilization of this dip-coating procedure, along with 
the use of small HLB particles (5 µm), provided a smooth coating surface that prevented 
attachment of matrix debris to the SPME coating. To ensure good reproducibility and a high-
throughput desorption process, a custom-made SPME holder compatible with the commercial 
DART rail was designed at UW-STC to accommodate up to 12 SPME pins, as can be seen in 
Figure 5.1. Nunc U96 600 µL, 1 mL Deep, and 2mL well-plates made of polypropylene were 
purchased from VWR International (Mississauga, ON, Canada). Individual stock standard 
solutions were prepared in either MeCN, MeOH, water, or 10% DMSO in MeCN as described 
previously, in accordance with the solubility of each compound, and stored at −80 °C.189 
Assorted organic beef muscle samples were used to serve as a pooled blank matrix. These 
samples were obtained from three different local grocery stores and carefully selected to ensure 




or pharmaceutical drugs. Three distinct samples of non-organic beef were purchased from different 
local grocery stores for analysis of market samples.  
5.3.3 Sample Preparation 
Utilizing a Freezer/Mill® Cryogenic Grinder (SPEX SamplePrep, LLC, Metuchen, NJ, 
USA), beef tissue samples were homogenized under liquid nitrogen to produce a uniform fine 
powder. Organic beef samples were mixed in equal portions and homogenized to obtain a pooled 
blank matrix. Homogenized samples were stored in glass jars at −80 °C until analysis. Sample 
preparation procedure was carried out in accordance with previously optimized and described 
protocol.189,206 A detailed schematic of the sample preparation steps is illustrated in Figures 2.2 
and 2.3 in chapter 2. 
Spiked tissue samples were prepared by weighing 2.0 g of room-temperature homogenized 
tissue into a 50 mL polypropylene (PP) tube. Each sample was then spiked with 100 μL of a 
working solution containing all analytes under study at their respective designated concentrations, 
and 60 µL of the IS working solution containing 1 ng µL-1 of each IS. Samples were vortexed for 
1 min, and then placed on a benchtop agitator for 1h. Subsequently, samples were stored in a 4ºC 
fridge overnight to allow for proper equilibration and matrix binding of target analytes prior to 
extraction. Prior to extraction, samples were placed on the benchtop agitator for 1h to allow 
samples to reach room temperature. Next, 6mL of water were added to each individual spiked 
tissue sample, which was then vortexed for 1 min in order to attain a homogeneous consistency 




plate. A schematic of the detailed sample preparation steps is illustrated in Figures 2.2 and 2.3 in 
chapter 2. 
5.3.4 Extraction and Analytical Procedure 
As shown in Figure 5.1, the SPME-DART analytical workflow consisted of the following 
steps: (1) conditioning of the SPME coating for 15 minutes with MeOH:H2O (50:50, v/v); (2) 
static extraction of target analytes from matrix (prepared as described above) for 45 minutes; (3) 
rinsing of coating in water for 10 seconds so as to remove any loosely attached matrix constituents 
that could induce ion enhancement or suppression; and (4) placement of SPME pins in the 12-pin 
SPME holder, with subsequent positioning of holder on the DART rail for thermal desorption. 
Steps 1-3 were performed automatically using a Concept-96 system (Professional Analytical 
Systems (PAS) Technology, Magdala, Germany) as described elsewhere 137,189. Sample 
preparation details and extraction parameters are illustrated in Figures 2.2 and 2.3 in chapter 2, 
and Figure 5.1. While we determined that the pins can be reused by implementing a thorough 
cleaning step with a mixture of 50:25:25 v/v/v, MeOH:Isopropanol:MeCN for 30 min following 
desorption, pins were not re-used in this study. 
Extraction parameters were evaluated and optimized in a previous study.189 However, 
extraction time was re-optimized for this study and a pre-equilibrium extraction time of 45 min 




30 °C so as to avoid temperature fluctuations originating from ambient temperature changes during 
extraction. 
Figure 5.1 SPME-DART-MS/MS analytical workflow, A: Automated high-throughput extraction, B: 
Automated high-throughput desorption/ionization 
5.3.5 SPME-DART-MS Setup 
All experiments were performed using a DART-Standardized Voltage and Pressure (DART-
SVP) model ion source (IonSense, Inc., Saugus, MA, USA) coupled to a TSQ Quantiva from 
Thermo Scientific (San Jose, CA, USA) via a Vapur interface (IonSense, Inc.). Data analysis was 
completed using TraceFinder 4.1, also from Thermo Scientific. Two single reaction monitoring 
(SRM) transitions were used for each analyte, one for quantitation and one for confirmation, 
whereas only one transition was used for each IS. MS/MS analyte transitions and conditions were 
optimized via direct infusion from methanolic and acetonitrile standards. Detailed information 
regarding optimized instrumental parameters (collision energy and RF-lens values) and monitored 
SRM transitions can be found in Tables 5.2. The SRM dwell time was set at 10 ms per transition. 




The DART-SVP was fitted with a single dimensional motorized linear rail, which was 
controlled through the DART-SVP web-based software to automatically position the SPME pins 
in front of the DART source by manipulating the 12-pin SPME holder. Each SPME pin was 
directly positioned between the DART source and MS inlet, where the analytes enriched on the 
SPME coating were thermally desorbed by the heated gas stream and then ionized by the plasma 
excited-state species for MS analysis. 
The DART ion source was operated in positive ion mode with helium as the ionizing 
medium, using the following conditions: high voltage (HV) electrode, −3000 V; discharge 
electrode, +350 V; grid voltage, +350 V. Since DART-SVP utilizes N2 and He gas during active 
runs, the amount of gas entering the mass spectrometer was reduced using a membrane pump 
(adjusted to blue indicator, position 4 to avoid compromising the vacuum. Prior to analyses, the 
level of background noise was assessed by obtaining background signals for both ambient air and 
preconditioned pins at the MS/MS transitions of the monitored analytes. 
Table 5.2 MS/MS optimized parameters, (m/z), ions used for quantification are bolded. 






S-Lens value Polarity 
1 2-Aminoflubendazole 256 123, 95 37, 27 93 + 
2 2-Amino mebendazole 238 105, 77 25, 34 88 + 
4 2-Quinoxalinecarboxylic acid 175 131, 104 22, 29 191 + 
5 5-Hydroxythiabendazole 218 191, 147 26, 32 85 + 
6 6-Phenyl-2-thiouracil 205 103, 188 17, 26 69 + 
7 6-Propyl-2-thiouracil 171 154, 112 17, 19 57 + 
8 Acepromazine Maleate 327 86, 254 19, 23 65 + 
9 Albendazole 266 234, 191 19, 32 71 + 
10 Albendazole sulfone 298 266,159 19, 36 79 + 










S-Lens value Polarity 
12 Albendazole-2-aminosulfone 240 133,198 28,19 75 + 
13 Ampicillin 350 106, 160 18, 10 54 + 
14 Azaperone 328 165,123 20, 29 66 + 
15 Betamethasone 393 325, 347 14, 12 59 + 
16 Cambendazole 303 217, 261 27, 17 66 + 
17 Carazolol 299 116, 222 19, 19 63 + 
18 Carbadox 263 231, 245 10, 16 67 + 
19 Cefazolin 455 323, 333 10, 19 72 + 
20 Chlortetracycline HCl 479 462,444 17, 19 70 + 
21 Chlorpromazine HCl 319 86, 58 19, 30 63 + 
22 Ciprofloxacin 332 288, 314 17, 19 72 + 
23 Clenbuterol HCl 277 203, 168 16, 29 47 + 
24 Clindamycin HCl 425 126, 377 27, 18 78 + 
25 Cloxacillin Sodium Salt 436 277, 160 12, 10 56 + 
26 Danofloxacin 358 340, 314 21, 17 80 + 
27 Desacetyl cephapirin 382 292, 226 10, 17 73 + 
28 Desethylene Ciprofloxacin 
HCl 
306 288, 268 17, 24 67 + 
29 Diclofenac Sodium 296 214, 277 33, 11 112 + 
30 Dicloxacillin Sodium Salt 
Hydrate 
470 452, 212 16, 26 124 + 
31 Difloxacin HCl 400 382, 356  21, 18 82 + 
32 Dimetridazole 142 96, 101 16, 10 38 + 
33 Doxycycline HCl 445 321, 428  30, 17 66 + 
34 Emamectin Benzoate 887 158, 868 33, 21 120 + 
35 Enrofloxacin 360 342,316  20, 18 79 + 
36 Erythromycin 735 522, 558 17, 34 85 + 
37 Fenbendazole Sulfone 332 300, 159 21, 37 81 + 
38 Florfenicol 357 198, 182 14, 16 73 + 
39 Florfenicol amine 248 230, 130 10, 25 50 + 
40 Flubendazole 314 282, 123 22, 35 80 + 
41 Flunixin 297 279, 264 22, 33 75 + 
42 Gamithromycin 778 619, 601 28, 31 121 + 
43 Haloperidol 376 165,123 22, 36 78 + 
44 Hydroxy dimetridazole 158 80,140 10, 10 30 + 
45 Hydroxy ipronidazole 186 168, 122 10, 19 37 + 
46 Hydroxy metronidazole 188 123, 126 10, 17 47 + 
47 Ipronidazole 170 124, 109 17, 24 54 + 










S-Lens value Polarity 
49 Levamisole HCl 205 178, 123 21, 28 66 + 
50 Lincomycin HCl 
Monohydrate 
407 126, 359 26, 18 76 + 
51 Mebendazole 296 264, 105 20, 33 75 + 
52 Melengestrol Acetate 397 279, 337 20, 13 88 + 
53 Meloxicam 352 115, 141 19, 20 67 + 
54 Metamizole 218 56, 97 17, 12 47 + 
55 Metronidazole 172 128, 82 14, 23 48 + 
56 Morantel Tartrate Hydrate 221 123, 111 35, 25 73 + 
57 Nafcillin 415 199, 171 14, 34 78 + 
58 Norfloxacin 320 302, 276 20, 17 76 + 
59 Novobiocin 613 218, 396 13, 15 80 + 
60 Orbifloxacin 396 352, 295 17, 23 83 + 
61 Oxacillin Sodium Salt 
Monohydrate 
402 243, 160 13, 11 68 + 
62 Oxyclozanide 402 186, 83 22, 22, 62 + 
63 Oxfendazole 316 191, 284 20, 18 68 + 
64 Oxytetracycline HCl 461 426, 443 18, 10 67 + 
65 Penicillin G 335 217, 202 14, 23 80 + 
66 Phenylbutazone 309 120, 160 42, 19 71 + 
67 Pirlimycin HCl 411 363,112 16, 25 77 + 
68 Prednisone 359 341, 237 10, 19 65 + 
69 Promethazine HCl 285 86, 198 17, 25 46 + 
70 Propionylpromazine HCl 341 58, 268 30, 23 68 + 
71 Ractopamine HCl 302 164, 284 15, 10 53 + 
72 Ronidazole 201 140, 55 10, 21 30 + 
73 Salbutamol 240 148, 222 17, 10 42 + 
74 Sarafloxacin HCl Hydrate  386 342, 368 18, 21 85 + 
75 Sulfachloropyridazine 285 156, 108 16, 24 57 + 
76 Sulfadiazin 251 92, 108 24, 22 48 + 
77 Sulfadimethoxine 311 156, 108 20, 27 72 + 
78 Sulfaethoxypyridazine 295 108, 140 25, 18 64 + 
79 Sulfamerazine 265 172, 108 16, 24 59 + 
80 Sulfamethazine 279 186, 156 17, 18 65 + 
81 Sulfamethizole 271 92, 108 24, 22 47 + 
82 Sulfamethoxazole 254 108, 156 23, 15 154 + 
83 Sulfamethoxypyridazine 281 156, 108 16, 24 63 + 
84 Sulfapyridine 250 108, 184 24, 18 57 + 










S-Lens value Polarity 
86 Sulfathiazole 256 156, 108 15, 22 52 + 
87 Tetracycline HCl 445 410, 427 18, 10 67 + 
88 Thiabendazole 202 175, 131 25, 32 74 + 
89 Tildipirosin 368 98, 88 28, 19 64 + 
90 Tilmicosin 435 174, 695 23, 16 75 + 
91 Tolfenamic Acid 262 244, 209 15, 27 47 + 
92 Triclabendazole 359 274, 344 37, 25 101 + 
93 Triclabendazole Sulfoxide 375 357, 360 17, 21 79 + 
94 Triflupromazine HCl 353 248, 86  42, 20 68 + 
95 Tulathromycin 404 72, 230 19, 10 62 + 
96 Tylosin 917 772, 174 27, 35 134 + 
97 Virginiamycin  526 508, 355 12, 17 72 + 
98 Xylazine HCl 221 90, 147  22, 23 68 + 
99 Sulfamethazine-(phenyl-13C6) 285 186 19 149 + 
100 Xylazine-d6 227 90 22 71 + 
 
5.4 Results and discussion  
5.4.1 Optimization of DART parameters 
Ionization gas temperature is considered one of the most critical parameters influencing the 
outcome of DART–MS analysis.225,241,242 For this reason, the ionization gas temperature was 
investigated in the range of 200–500 °C in 50 °C increments. The optimum temperature was 
determined by plotting the intensity of the quantifier ion signal onto a graph against the 
temperature as shown in Figure 5.2. While 500 °C yielded higher intensities for all analytes, we 
observed discoloration of the coating at this temperature. The observed discoloration could be due 
to thermal degradation of PAN which is not stable at such high temperatures. No visible 




the microscope and no visible damage was observed. Moreover, as shown by the results in Figure 
5.2, the efficiency of extraction was improved at high temperatures. As a result, 450 °C was 
selected as the optimum temperature. Figure 5.2 shows the effect of temperatures on signal 
intensities of quantifier ions for representative target analytes. The same trend was observed for 
all detected analytes. None of the analytes was detected at 200 °C. It is important to note that the 
software’s set temperature is usually higher than the real temperature of the ionization region due 
to the mixing of ionization gas with cooler atmospheric gas.242 A study by Rothenbacher et al. 
indicated that a temperature of 450°C set by the DART software corresponded to an actual 
temperature of 310°C in the ionization region.243 
Other key parameters influencing DART performance are the distance between the DART 
gun and the sample, and the distance between the sample and the MS inlet. Higher signal intensities 
were observed for all detected analytes when the DART gun was closer to the SPME pin. This 
could be caused by an increase in thermal desorption due to the increase in the sample temperature 
as the distance from the DART source is decreased. Another explanation for this is that the rapidly 
moving ionization gas exiting from the DART source disperse and dilute as it moves farther from 
the DART source. To ensure reproducibility and avoid contact between the DART gun and the 
SPME pin, we selected a distance of 2mm between the DART gun and the sample as optimum. 
The placement of the tip of the SPME pin with respect to the DART gun was also optimized with 
regards to intensity of the analyte signal. Optimum positioning of the pin tip was found to be at 




desorbed analyte ions into MS. The distance between the SPME pin and the MS inlet was also 
optimized at 4 mm. 
Another important factor that affects the intensity of the signal and number of scans per peak 
is the DART rail speed.242 Rail speed was thus investigated to ensure adequate interaction between 
the sample and the ionizing gas. Optimum speed was found to be the lowest setting possible on 
the DART software, which is 0.2 mm s–1. The lowest speed ensured maximum interaction 
between the analytes and the ionization gas. At this speed, we estimated the desorption time of 
analytes from the surface of the SPME coating to be 15 s. This demonstrates that prolonged 
exposure of analytes to the ionizing gas increases the probability of analyte molecules colliding 














5.4.2 DART ionization of veterinary drugs 
Under the above tested parameters, no quantifiable signals were detected for 46 analytes at 
their respective MRL levels. These analytes are listed in bold font in Table 5.1. However, all of 
these compounds were successfully quantified well below their MRL levels using SPME-LC- ESI-
MS/MS206 and CBS-MS/MS with the exception of florfenicol and florfenicol amine in case of 
CBS-MS/MS. The lack of quantifiable signals in DART for these target analytes compared to ESI 
could be due to many factors. One of these factors could be the fact that in DART, desorption takes 
place from a smaller surface area of the coating in comparison to solvent desorption typical of LC 
applications. Other factors include a combination of volatility versus thermal stability of analytes, 
since DART has a tendency to break down labile bonds in comparison to the soft ionization in 
ESI.226,238 For example, none of the 8 β-Lactams/cephalosporins and four tetracyclines, which are 
considered thermally labile and prone to heat degradation,54,245 were detected in DART at the 
MRL. Conversely, all 12 sulfonamides, which are considered more thermotolerant, were detected 
below their MRLs. This disadvantage limits the scope of DART applicability to somewhat volatile 
and thermally stable analytes.232,242,246,247 
While Cody et al. have suggested that desorption in DART may include both thermal and 
non-thermal processes, according to the results presented by Harris et al., thermal desorption can 
be considered as the predominant pathway for energy deposition.238 In our investigation, we found 
that lower temperatures did not provide higher signals for any of the compounds under 
investigation. The strong dependence of DART on thermal desorption might pose an even bigger 




variety of physico-chemical characteristics, since certain less volatile analytes need very high 
temperatures to be desorbed, while others might undergo thermal degradation or pyrolysis at such 
high temperatures.242,247 On the other hand, very volatile compounds could desorb too quickly, 
thus resulting in insufficient scans per peak. One possible solution for this is to couple DART to a 
temperature-programmable sample heater as suggested in previous studies, a technique which 
could also facilitate thermal separation 248–250. However, this solution might significantly extend 
analysis run time, as an additional cooling period for DART would be necessary before the 
introduction of each new sample. Another useful solution would be to lower the current rail speed 
limit and introduce a programmable rail speed option that would allow the rail to reduce speed or 
even pause when the pin is positioned directly in front of the MS inlet. This option would extend 
the interaction time between the sample and the ionization gas, and thus increase the probability 
of analyte molecules colliding with the gas, resulting in higher signals.  
We also observed that the highest molecular weight precursor detected in this study was 425 
(clindamycin). While factors such as molecular weight, volatility, and thermal stability of the 
analyte might influence DART ionization, unfortunately, our limited knowledge of the underlying 
mechanisms of the DART ionization and desorption processes, which are beyond the scope of this 
study, does not allow us to fully explain the reasons why several target analytes were not detected. 
5.4.3 Selectivity 
In the absence of chromatography, one of the main drawbacks of AIMS techniques is the 




retention time, another criterion that can be used for identification of target analytes is the ion ratio 
between the quantifying and qualifying ion transition signals. 
In this study, no significant interferences were observed in blank samples near LOQ levels 
for any of the 52 detected analytes (listed in Table 5.3). 
Another main drawback of AIMS techniques is the lack of means for separating isomers and 
isobars prior to MS analysis. Selectivity issues in AIMS techniques can be addressed without 
compromising analysis time by coupling said techniques with a complementary rapid ion 
separation/filter device such as an ion mobility spectrometer (IMS). Likewise, high resolution 
mass analyzers combined with MSn capabilities may also provide solutions to obtain higher levels 
of confidence in the process of analyte identification and confirmation. 
5.4.4 Linearity and limits of quantitation 
Matrix-matched calibration curves were used to assess linearity and limits of quantitation of 
the detected analytes. Calibration curves were constructed using analyte/IS peak area ratios (A/Is) 
for 7 concentration levels (0.25–3X), using three independent replicates for each level. The 
calibration range was selected to include concentration levels bracketing the MRLs of the selected 
analytes. Despite the use of only two internal standards for all analytes, 32 target analytes (62% of 
the total number of analytes detected) achieved determination coefficients (R2) higher than 0.99. 
These results can be further improved by using more analyte-specific internal standards. Moreover, 
a lack-of-fit test was performed with the use of Statistica 13.0 software (TIBCO® Statistica™, 
CA, USA) at the 5% level to confirm linearity of the calibration curves. None of the detected 




confidence level relative to pure error and thus confirming a good fit for all compounds, except 
for 5-hydroxythiabendazole and oxfendazole. 
LOQ was established as the lowest point of the matrix-matched calibration curve that 
produced a response that is both accurate when compared to the expected value (calculated via 
linear regression) with a range of deviation ≤25%, as well as precise (≤25% RSD). As shown in 
Table 5.3, all analytes under study achieved low enough LOQs to ensure proper determination at 
the maximum residue levels set for Canada and the US. Individual determination coefficients (R2), 
LOQ values, and lack-of-fit test results are presented in Table 5.3.  
In terms of detectability and in comparison to other ESI based AIMS techniques such as 
CBS-MS/MS240, it is important to recognize that DART has limited analyte scope which limits its 
application to compounds that are somewhat volatile and thermally stable.232 Unfortunately, this 
limitation of DART excludes its application to many pharmaceutical compounds which are usually 
thermally labile. 
5.4.5 Accuracy and precision  
To evaluate the accuracy and precision of the method with respect to intra-day repeatability, 
pooled matrix blanks were spiked at three levels; low, mid, and high (0.5X, 1X and 2X), for each 
analyte using six replicates per concentration (n=6). Accuracy was calculated based on estimated 





As presented in Figure 5.3 and Table 5.3, the majority of analytes fell within the 70−120% 
range of the true concentrations of compounds, with RSD values ≤25% at the 0.5, 1, and 2X 
concentration levels, thus indicating that these compounds can be quantitatively determined by the 
optimized DART method.  
Individual accuracy and %RSD values are listed Tables 5.3 for each analyte under study. 
The results showed that two internal standards were sufficient to ensure reliable, precise, and 
accurate analytical data. For quantitative performance criteria such as linearity, repeatability, and 
accuracy DART performance was found to be comparable to CBS-MS/MS for compounds that 




for rapid screening and semi-quantitative multi-residue analysis of certain classes of veterinary 
drugs in animal tissue. 
Figure 5.3 Accuracy and repeatability results of the optimized DART method for target analytes 
fortified at the 0.5, 1, and 2X levels in beef tissue (n = 6). 
Individual accuracy and %RSD values are listed Tables 5.3 for each analyte under study. 
The results showed that two internal standards were sufficient to ensure reliable, precise, and 





Table 5.3 Figures of merit for the quantitation of multi-residue veterinary drugs in beef tissue via 
DART-MS/MS. 
        Accuracy (%)   Repeatability (%) 
Compound  R2 p-value LOQ 0.5X 1X 2X  0.5X 1X 2X 
2-Aminoflubendazole 0.9958a 0.8714 0.25X 91 85 107   8 6 8 
5-Hydroxythiabendazole 0.9614a 0.0000 0.25X 99 82 85   7 3 7 
6-phenyl-thiouracil 0.9895b 0.2779 0.25X 87 87 97   8 3 13 
Acepromazine 0.9919b 0.3575 0.25X 92 100 109   6 13 27 
Albendazole 0.9919b 0.0619 0.75X   100 80    9 3 
Albendazole 2-aminosulfone 0.9958b 0.4335 0.25X 105 101 129   6 10 28 
Albendazole sulfoxide 0.9789b 0.0538 0.75X   109 77    9 7 
Azaperone 0.9848c 0.1165 0.25X 119 107 107   6 4 20 
Cambendazole 0.9990a 0.9038 0.25X 99 98 95   8 3 8 
Carazolol 0.9965 b 0.3685 0.25X 97 99 100   12 4 19 
Carbadox 0.992 a 0.7490 0.25X 97 98 105   10 5 12 
Chlorpromazine 0.9951 a 0.8568 0.25X 102 99 85   19 14 23 
Clindamycin 0.9902 b 0.0891 0.25X 110 99 106   12 11 18 
Danofloxacin 0.9740 b 0.1183 0.25X 111 113 105   25 9 25 
Diclofenac 0.9928 a 0.6758 0.25X 105 126 123   12 5 3 
Dimetridazole 0.9916 a 0.9095 0.25X 78 81 80   8 8 14 
Fenbendazole Sulfone 0.9784 b 0.0642 0.25X 86 90 95   25 16 9 
Haloperidol 0.9919 a 0.0503 0.25X 108 101 107   12 6 21 
Hydroxy dimetridazole 0.9919 a 0.8280 0.75X   74 82    8 13 
Hydroxy metronidazole 0.9961 a 0.0583 0.25X 118 120 95   14 5 16 
Ipronidazole 0.9951 a 0.9482 0.25X 74 88 85   22 14 19 
Levamisole 0.9962 a 0.0994 0.25X 96 88 85   4 5 12 
Lincomycin 0.9755 a 0.2257 0.25X 116 96 92   20 10 15 
Mebendazole  0.9731 a 0.2323 0.25X 107 83 105   9 10 25 
Meloxicam 0.9863 a 0.1598 0.25X 91 86 79   14 4 13 
Metamizole 0.9812 a 0.1723 0.25X 104 83 79   14 8 15 




Table 5.3 continued 
        Accuracy (%)   Repeatability (%) 
Compound  R2 p-value LOQ 0.5X 1X 2X  0.5X 1X 2X 
Morantel 0.9912 b 0.5398 0.25X 115 103 124   14 13 36 
Orbifloxacin 0.9896 a 0.6392 0.25X 107 101 118   19 8 25 
Oxfendazole 0.9887 b 0.0012 0.75X  102 75    9 6 
Phenylbutazone 0.9889 c 0.2747 0.75X   117 97    10 9 
Pirlimycin 0.9811 a 0.1656 0.25X 111 91 86   12 9 19 
Promethazine 0.9899 a 0.1832 0.25X 97 92 81   15 10 9 
Propionylpromazine 0.9795 a 0.7307 0.25X 74 88 90   12 9 13 
Ronidazole 0.9861 a 0.8379 0.25X 76 72 82   12 12 24 
Sulfachloropyridazine 0.9967 a 0.0755 0.25X 97 85 95   11 9 11 
Sulfadiazin 0.9996 a 0.8323 0.25X 96 88 102   9 4 5 
Sulfadimethoxine 0.9997 a 0.9629 0.25X 97 99 101   3 3 6 
Sulfaethoxypyridazine 0.9971 c 0.4047 0.25X 107 101 109   8 4 11 
Sulfamerazine 0.9998 a 0.9474 0.25X 99 96 102   6 4 6 
Sulfamethazine 0.9996 a 0.9512 0.25X 99 97 97   2 3 2 
Sulfamethizole 0.9929 a 0.2125 0.25X 105 92 103   2 4 12 
Sulfamethoxazole 0.9954 a 0.5247 0.25X 106 93 100   9 3 11 
Sulfamethoxypyridazine 0.9970 b 0.4465 0.25X 91 91 105   15 8 9 
Sulfapyridine 0.9992 a 0.5705 0.25X 96 92 100   10 4 4 
Sulfaquinoxaline 0.9969 a 0.6650 0.25X 86 89 96   9 8 18 
Sulfathiazole 0.9992 a 0.9042 0.25X 91 92 104   6 3 8 
Thiabendazole 0.9973 a 0.9148 0.25X 82 87 89   8 5 16 
Tolfenamic acid 0.9750 a 0.7471 0.50X 116 90 109   3 3 22 
Triclabendazole 0.9826 a 0.6715 0.25X 70 94 129   1 22 24 
Trifluropromazine 0.9950 a 0.7250 0.25X 81 90 83   15 9 9 






5.5 Analysis of market beef samples 
The proposed method was used to analyze beef samples purchased from three local grocery 
stores. All the samples analyzed were free from the target analytes near or above their LOQ levels, 
however traces of phenyl thiouracil were detected below quantitation limits in two market samples. 
6-phenyl-thiouracil was tentatively identified based on the presence of detectable signals for both 
SRM transition ions corresponding to 6-phenyl-thiouracil (205→188) and (205→103) as shown 
Figure 5.4. 
Figure 5.4 Ion chronograms obtained for desorption of 3x extraction from one market beef sample and 
3x extraction from pooled blank matrix for 6-phenyl-thiouracil (precursor ion 205), TIC (black), 





Despite the limited analyte scope and lower detectability levels of SPME-DART-MS/MS 
compared to ESI-based methods for veterinary drugs, this study has demonstrated that the method 
can be successfully used for rapid screening and semi-quantitative multi-residue analysis of certain 
classes of veterinary drugs in complex matrices such as beef tissues. Its main attractive features 
are high-throughput, simplicity, operational cost, and real-time analysis. It is important however 
to recognize the limitations of this method for certain analytes which lack enough volatility and 
thermal stability. Unlike soft ionization methods such as ESI, DART tends to break down some 
labile bonds. DART-MS/MS is still a relatively new technology and more in-depth studies are 
needed to understand the underlying ionization mechanisms and limitations of this technique in 
order to increase its detectability for a wider range of analytes. 
Similar to all AIMS techniques, another limitation of this method is the compromise on 
selectivity due to the absence of chromatographic separation; however, this can be compensated 
for by using ion mobility spectrometry and high resolution mass analyzers with MSn capabilities. 
It is envisioned that the described approach can be implemented on site for rapid and real-time 
screening of food products or living animals by performing in-vivo chemical biopsy sampling 






Summary and Future Perspectives 
6.1 Summary 
Rigorous monitoring of veterinary drug residues in food-producing animal tissues plays a 
crucial role in the protection of human health. Given the perishable nature of food, residue 
investigations demand the use of extremely fast, efficient, and reliable analytical methods. Recent 
advances in liquid chromatography and mass spectrometry in terms of speed and detectability have 
put the pressure on analytical scientists to explore and develop new sampling technologies that 
meet the demand for fast and accurate chemical analysis methods. Solid phase microextraction 
(SPME) techniques have been well explored in terms of their applicability in food and biological 
analysis for determination of a wide range of analytes with different physical and chemical 
properties. Accordingly, this thesis presented novel methodologies based on SPME technology as 
an alternative tool for efficient high-throughput sample preparation and reliable analysis of multi-
class multi-residue pharmaceutical drugs in animal-derived tissue samples. 
Aiming to take advantage of their mechanical robustness and high recovery extraction, the 
suitability of thin film SPME blades (TFME) for the abovementioned application was initially 
assessed as the starting point of this thesis. However, the sharp edges of the blades and the rough 
surface of the extractive phase were shown to cause adhesion of matrix components to the coating 
that proved difficult to dislodge by just rinsing the coating. The extent of adhesion was exacerbated 
when agitating the sample during extraction due to fat destabilization and its agglomeration on the 




were taken: i) employment of a geometry with no edges such as round pins with a large outer 
diameter to maintain the advantage of a large surface area, ii) preparation of a smoother coating, 
which was accomplished by synthesizing HLB particles characterized by a smaller size (~5 µm) 
in comparison to commercial particles (30-60 µm), iii) exploration of new coating techniques such 
as dip coating to achieve a smoother coating surface, and iv) performance of static extraction to 
prevent destabilization of fat. The combination of the first three approaches succeeded in creating 
a smooth coating, while static extraction prevented the destabilization of fat and its agglomeration 
on the coating. Consequently, the developed round SPME pins, with their large surface area and 
smooth coating surface, allowed successful direct immersion extraction in homogenized animal 
tissue. 
After establishing a successful direct immersion extraction protocol capable of avoiding 
fouling of the coating, a fully automated high-throughput multi-class, multi-residue method was 
successfully developed and validated for quantitative analysis of 77 veterinary drugs in 
homogenized chicken muscle via SPME and UHPLC-ESI-MS/MS. The developed method is the 
first and most comprehensive SPME approach in terms of the number of analytes tested as well as 
with respect to the range of physical and chemical properties covered. Further, in an evaluative 
comparison against SE and QuEChERS, the SPME method was demonstrated to produce extracts 
with significantly less matrix effects compared to SE and QuEChERS, while also offering better 
accuracy, precision, and improved limits of quantification, in addition to significant improvement 




The clean extracts provided by SPME, evidenced by the minimal to almost non-existent 
matrix effects in comparison to conventional methods, motivated us to push the limits of SPME 
even further so as to achieve methods as short as 1 minute per sample, a feat accomplished by 
skipping liquid chromatography altogether by direct coupling SPME to mass spectrometry. In 
addition, we aimed to develop short methods that allow rapid screening in both positive and 
negative modes. As a result, we added 11 veterinary drugs that ionize in negative mode to 
investigate the suitability of coated blade spray for rapid screening of multi-residue drugs in both 
negative and positive mode. Since CBS employs sword-like, stainless steel blades that are 
characterized by sharp edges, minor attachment of matrix components was initially observed, 
although this drawback was mainly observed to occur on the uncoated part of the blade, most 
specifically at the junction between the bare stainless pin and the coating. In order to prevent 
adhesion of macromolecules to the uncoated part of the blade, we applied a thin layer of PAN to 
the blade prior to application of the HLB/PAN extraction phase. The length of the undercoat PAN 
layer was 10 mm longer than that of the HLB coating so as to ensure no contact between the bare 
stainless-steel and sample during the extraction step. This improvement to the CBS blades 
successfully ensured that matrix components did not adhere to any part of the sampling device. In 
addition, we shortened the extraction time to 15 minutes as shorter extraction times were shown 
to lead to better signal to noise ratios (S/N) as well as minimize the unnecessary co-extraction of 
undesired molecules that may cause higher noise or ionization suppression. The optimized CBS 
device allowed for rapid and high-throughput screening and quantitation of 105 veterinary drugs 




single CBS device, achieving analysis times as short as 1 min per sample. In chapter 5, we explored 
another well-known ambient ionization technique, DART. While meshes have been shown to offer 
the best detectability and successful geometry for biological matrices, they are not applicable for 
extraction from diluted homogenized animal tissue samples due to potential attachment of matrix 
debris and macromolecules to the mesh. As a result, we investigated the applicability of the SPME 
pins designed and used in chapter 2 and 3 for coupling with DART. While CBS-MS/MS 
demonstrated a much wider analytical scope than SPME-DART-MS/MS, both methods 
demonstrated suitability for rapid screening and quantitation of multi-residue residue veterinary 
drugs in beef muscle. 
6.2 Future directions 
The advancements and applications introduced in this thesis bespeak a promising future for 
the applicability of the SPME as an alternative sample preparation tool for direct-immersion 
extraction from highly complex samples such as diluted homogenized beef and chicken tissue. The 
wide range of analytes and the challenging matrices covered by these methods demonstrate SPME 
as a universal sample preparation tool suitable for a wide range of analytes and complex solid 
sample matrices.  
This work opens new paths for new applications, such as untargeted analyses and 
metabolomics studies aimed at profiling animal tissue samples for a variety of purposes; for 
instance, to study the effect of animal feed on the quality of meat, although the possibilities are 
virtually limitless. One such application we are currently working on is the detection of meat 




Chapter 2 with HRMS for untargeted metabolomics of beef and pork muscle so as to detect 
adulteration or contamination of ground beef samples with pork meat. The results obtained so far 
allowed us to detect ground beef samples containing over 5% pork meat. 
In terms of residue analysis, the use of SPME with HRMS can be very useful to monitor 
fraudulent practices such as using mixtures of several unknown pharmaceutical drugs at very low 
amounts to obtain a synergistic effect for growth promotion. 
While this work has demonstrated the suitability of SPME for extraction of a wide range of 
analytes characterized by a wide range of polarities, it is worth pointing out that the HLB coating 
still has limitations in terms of extracting very polar compounds (i.e. log p < - 2). Accordingly, 
future work should be aimed towards the discovery of novel coating chemistries that can continue 
to drive possibilities for a more universal extractive phase that further expands the SPME 
analytical scope to include very non-polar compounds. 
Certainly, the direct coupling of SPME to MS has great potential for rapid qualitative and 
semi-quantitative analysis in food safety applications, especially when used with portable mass 
spectrometers for in-vivo and on-site analysis. However, similar to all AIMS techniques, the direct 
coupling of SPME to MS has a number of challenges due to the absence of chromatographic 
retention and lack of selectivity and reproducibility. While the collection of MS3 spectra and 
accurate mass capabilities of the latest HRMS instruments can enhance the selectivity of AIMS 
techniques, future work needs to be directed towards coupling SPME to non-chromatographic 
separations, such as ion mobility or differential mobility, prior to MS detection so as to reduce 




the case of DART for example, additional compound identification information can be provided 
by introducing a thermal desorption gradient to selectively desorb analytes at different 
temperatures. 
In contrast to clinical applications, where the in-vivo DI-SPME approach was successfully 
utilized to analyze intact tissue samples that were incurred with target drugs,120,153–157 in case of 
food producing animals, it was extremely challenging to obtain intact animal tissue samples that 
were naturally incurred with measurable concentrations of veterinary drugs. This would have 
enabled us to assess the detection capability of the developed SPME methods to extract from intact 
tissue. However, given the proven success of DI-SPME in clinical studies for measuring the 
concentrations of targeted drugs in intact tissue samples, we have no doubt that the techniques 
developed in this thesis can be implemented successfully in the future on site for rapid and real-
time screening of living animals by performing in-vivo chemical biopsy sampling using 
appropriate SPME devices. 
Finally, this thesis has effectively demonstrated the development and validation of novel 
SPME-based technologies for reliable automated and high-throughput multi-class multi-residue 
analysis in animal tissue samples. Further work involving these methods will likely expand upon 
their applications to different food matrices such as animal feed and other foods derived from 
animals such as organs and eggs. Ultimately, one of the main future directions of this work is the 
possible implementation of these methods as fully validated official methods in regulatory 
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Evaluation of four SPME coatings 
Table 6.1 Evaluation of 4 SPME coatings (HLB, mix-mode, PS-DVB-WAX and 50:50 [w/w] HLB:PS-DVB-WAX in different desorption solutions (MeCN/H2O 50/50, MeCN/MeOH/H2O/FA 40/40/20/0.1 and MeCN/IPA/H2O/FA 40/40/20/0.1). 
Results are expressed as amount (ng) of compound extracted. The %RSD of three replicates are also shown. Extraction volume: 1000 µL, extraction time: 120 min, concentration of analytes: 50 ng mL-1, extraction matrix: PBS. Desorption 
time: 120 min, desorption volume: 1000 µL. All results are based on 3 replicates. 
Compound 
HLB PS-DVB-WAX 50:50 [w/w] HLB:PS-DVB-WAX Mix-mode 
MeCN/H2O MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ 
(50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) 
ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% 
2-Amino flubendazole 38.4 23 38.7 3 37.5 27 47.9 7 40.2 7 36.3 26 41.6 14 40.8 5 43.0 7 25.8 10 15.7 6 19.0 4 
5-HydroxyThiabendazole 49.8 2 44.9 5 47.7 8 64.3 4 49.9 5 48.4 13 56.9 5 49.7 3 49.6 6 14.9 15 10.1 6 9.7 26 
Acepromazine 16.3 16 41.7 4 35.9 4 1.2 44 46.1 6 38.5 4 2.7 3 47.3 4 39.5 4 12.6 16 28.5 5 25.0 6 
Albendazole 34.9 6 36.2 3 35.0 3 47.1 2 45.0 2 40.4 2 41.8 2 44.6 2 41.3 1 38.9 11 34.9 5 36.4 1 
Albendazole Sulfone 47.0 2 48.7 2 51.3 7 52.0 3 47.2 5 46.4 6 48.3 4 50.4 4 49.7 8 26.4 11 28.2 6 27.0 9 
Albendazole Sulfoxide 60.5 4 58.7 4 57.4 4 60.7 6 49.4 7 44.9 8 57.3 5 52.3 5 49.7 4 25.8 13 24.4 6 22.4 8 
Albendazole-2-
aminosulfone 
48.8 3 43.7 4 40.6 6 60.3 4 44.8 8 40.3 7 52.7 7 46.7 3 42.5 5 11.4 11 6.6 8 5.7 20 
Azaperone 41.5 13 20.2 7 37.4 7 27.1 10 45.2 3 47.5 8 32.9 3 32.9 7 40.6 4 47.8 41 4.3 49 10.5 14 
Betamethasone 48.2 2 46.6 2 47.0 3 45.9 6 39.8 10 36.8 11 48.0 5 48.9 3 46.4 3 41.1 11 40.9 4 40.6 5 
Cambendazole 46.5 3 48.1 3 47.2 4 55.3 4 49.0 4 45.1 5 50.4 3 50.6 2 47.9 2 37.0 13 30.8 5 31.7 2 
Carbadox 38.4 5 38.3 5 35.8 7 47.3 6 39.2 9 33.3 8 42.5 6 40.5 5 37.3 8 8.6 19 9.1 13 7.2 20 
Chlorpromazine 7.7 26 32.9 9 31.4 5 0.5 54 37.5 7 32.4 9 1.3 5 38.8 5 33.1 8 9.1 18 23.4 5 22.2 8 
Chlortetracycline 30.1 6 21.5 33 10.2 48 14.7 19 16.7 8 6.1 63 26.9 7 23.4 11 10.4 69 20.3 14 4.8 51 2.6 13 
Clenbuterol 34.1 8 48.8 4 45.5 3 2.1 58 47.3 14 41.7 8 5.3 3 50.5 3 45.3 4 9.1 20 15.4 13 12.6 12 
Clindamycin 41.5 5 41.0 1 41.0 4 42.1 4 39.3 8 35.6 9 46.0 4 48.0 2 45.5 2 37.3 13 30.3 5 30.7 6 
Cloxacillin 47.7 1 46.6 5 42.7 7 35.4 11 32.1 9 25.1 15 47.9 6 47.6 5 41.3 8 35.4 12 37.8 8 33.4 5 
Danofloxacin 38.8 21 61.2 15 9.3 12 22.2 29 43.9 23 8.7 30 26.7 21 57.2 10 14.8 17 4.4 8 6.2 8 2.5 41 
Desethylene Ciprofloxacin 25.7 27 19.1 23 47.7 34 15.1 32 13.3 37 36.9 37 15.8 33 17.7 22 53.1 22 4.2 16 2.6 41 4.4 42 
Diclofenac 51.5 7 47.2 1 43.7 5 33.9 11 40.8 10 34.4 11 45.0 7 46.8 2 41.6 6 31.1 12 30.5 6 26.4 8 
Dicloxacillin 51.4 2 46.9 3 44.6 12 39.1 2 31.9 9 27.0 19 51.2 4 45.4 7 42.8 14 43.9 11 42.4 9 41.3 6 
Difloxacin 36.3 5 51.8 7 36.1 2 30.7 10 35.0 11 23.1 12 39.6 8 51.0 4 29.7 37 23.5 13 12.8 28 10.0 39 
Dimetridazole 25.3 5 26.5 5 17.3 10 39.2 13 34.9 8 20.2 15 27.1 7 30.3 10 20.6 29 2.0 11 2.2 8 1.2 44 
Emamectin 1.0 32 4.0 17 4.2 8 0.5 19 2.0 26 2.2 18 0.9 13 4.0 8 4.2 6 0.9 26 3.0 5 3.9 12 




Table A.1 continued 
Compound 
HLB PS-DVB-WAX 50:50 [w/w] HLB:PS-DVB-WAX Mix-mode 
MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ 
(50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) 
ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% 
Fenbendazole 45.3 3 45.6 1 42.7 1 49.5 4 48.6 3 42.9 2 43.7 5 48.3 1 43.3 3 41.3 10 38.9 4 39.1 5 
Fenbendazole Sulfone 48.2 1 48.1 1 45.6 5 57.0 3 47.3 4 43.1 5 51.9 8 50.3 3 45.7 1 39.1 9 38.2 5 35.6 4 
Florfenicol amine 31.8 10 28.1 21 18.7 19 41.3 8 29.3 21 21.6 11 33.8 13 24.8 9 18.5 17 3.1 17 1.9 8 1.1 23 
Flubendazole 47.6 3 49.1 1 47.5 2 55.5 4 51.5 5 45.5 4 49.9 2 52.6 2 47.7 1 41.0 15 41.4 3 40.3 3 
Flunixin 50.3 4 46.7 1 44.8 1 34.3 7 39.0 11 34.9 9 44.7 6 45.6 5 43.5 4 27.3 13 26.6 7 24.5 9 
Haloperidol 17.9 19 49.9 5 43.7 3 1.2 39 55.0 17 46.3 9 2.7 5 54.1 12 47.2 6 20.0 11 39.8 14 34.8 5 
Hydroxy dimetridazole 12.2 12 13.9 8 9.6 16 28.9 9 23.9 13 18.3 12 21.9 10 20.5 14 16.8 8 0.5 10 0.6 18 0.2 58 
Hydroxy Ipronidazole 35.4 5 35.6 4 31.2 4 43.3 5 35.7 9 30.5 10 39.1 7 36.8 6 33.7 5 3.1 14 3.4 9 2.5 23 
Ipronidazole 44.8 2 46.0 2 43.5 3 52.0 4 45.1 6 41.3 5 46.3 5 45.3 3 44.1 4 6.7 14 7.1 7 5.9 20 
Ketoprofen 44.7 5 45.7 2 42.7 4 39.8 5 39.1 9 33.4 7 42.4 4 44.0 4 40.9 5 18.0 18 19.6 8 15.8 12 
Levamisole 25.4 12 44.9 9 38.8 5 28.7 13 48.5 6 42.0 5 31.2 8 48.1 7 42.0 4 9.4 12 11.2 4 6.9 12 
Lincomycin 46.2 5 36.8 4 36.3 7 34.6 15 23.8 14 20.9 15 46.7 10 36.1 7 35.9 6 23.3 6 14 10 13.9 2 
Mebendazole 46.2 4 46.1 1 42.8 2 54.7 2 46.2 5 40.9 3 47.7 6 48.1 1 43.0 3 38.9 9 37.0 5 35.4 5 
Mebendazole amine 54.3 2 48.2 3 44.8 2 63.5 3 51.4 4 45.4 6 55.8 7 50.2 3 46.3 2 33.0 8 20.2 5 20.6 4 
Melengestrol Acetate 36.9 7 41.0 6 39.7 4 32.6 2 33.0 7 30.5 8 35.9 6 42.0 6 39.1 8 32.6 39 41.0 10 37.8 8 
Orbifloxacin 43.1 14 42.1 11 37.0 4 31.0 28 25.7 23 20.4 16 40.4 15 37.1 7 33.5 5 13.8 20 12.0 12 7.7 16 
Oxacillin 48.6 5 48.4 3 44.4 9 37.1 10 32.2 11 26.0 13 48.3 6 45.2 3 41.6 6 30.2 18 31.4 8 28.5 10 
Oxfendazole 46.1 4 43.0 6 44.7 5 49.9 4 39.1 8 37.6 7 47.5 10 41.7 5 41.0 5 31.4 7 26.1 2 28.0 6 
Oxyphenylbutazone 22.6 4 21.3 6 24.3 8 16.1 8 20.1 12 20.2 10 24.2 5 26.7 7 28.9 4 4.8 28 8.0 7 7.6 16 
Oxytetracycline 43.6 5 310 27 24.6 18 14.8 40 17.2 14 9.6 25 32.5 3 29.7 12 20.4 29 11.8 26 2.5 36 2.4 27 
Phenylbutazone 22.4 4 17.0 4 21.4 6 16.8 6 17.0 11 18.7 13 23.5 5 22.0 9 25.0 5 10.4 25 13.0 13 13.8 11 
Pirlimycin 36.0 10 37.7 1 37.6 4 14.3 11 28.1 12 24.8 14 23.4 5 39.7 4 39.0 5 16.2 6 18.5 7 19.1 5 
Prednisone 48.3 1 48.9 2 48.1 6 47.0 9 40.7 9 37.7 10 49.3 3 48.8 3 47.3 4 39.2 12 40.8 8 38.8 1 
Promethazine 12.5 19 41.2 6 34.8 7 1.0 43 46.1 6 38.7 2 2.3 3 47.4 2 39.1 3 12.0 14 28.8 4 23.7 24 
Propionylpromazine 11.4 21 38.6 5 21.2 4 0.7 48 41.4 8 21.8 5 1.8 5 43.5 5 23.2 4 10.2 12 28.0 5 15.4 4 
Ractopamine 44.7 2 50.8 2 47.9 3 7.5 27 52.3 9 45.3 5 13.6 2 54.9 3 48.7 1 13.1 11 17 6 14.3 12 
Sarafloxacin 29.6 12 42.8 12 36.6 8 22.5 11 28.7 14 20.9 14 30.1 13 40.7 5 30.8 12 7.7 6 6.8 20 6.2 11 
Sulfachloropyridazine 29.5 7 27.3 6 24.6 9 31.3 13 26.0 12 22.0 16 32.7 11 29.1 10 27.1 10 1.4 20 1.5 14 1.1 23 




Table A.1 continued 
Compound 
HLB PS-DVB-WAX 50:50 [w/w] HLB:PS-DVB-WAX Mix-mode 
MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ MeCN/H2O  MeCN/MeOH/H2O/ MeCN/IPA/H2O/ 
(50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) (50/50) FA (40/40/20/0.1) FA (40/40/20/0.1) 
ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% ng RSD% 
Sulfamerazine 34.1 5 34.7 4 32.4 8 36.4 7 29.6 15 26.1 10 37.2 8 34.7 10 33.6 11 1.6 13 1.9 7 1.2 40 
Sulfamethazine 42.4 6 39.2 3 34.5 12 40.5 6 32.3 10 28.4 12 42.5 9 38.4 7 34.7 5 4.9 21 4.7 9 3.7 24 
Sulfamethizole 21.3 8 21.2 3 19.2 12 26.8 10 23.9 11 22.0 18 25.3 11 24.7 11 23.7 8 1.5 15 1.3 35 1.4 29 
Sulfamethoxazole 26.1 7 25.1 2 23.1 7 28.4 9 23.9 12 21.0 15 30.8 7 28.1 12 28.0 10 0.7 12 0.8 10 0.4 51 
Sulfapyridine 43.0 5 41.3 2 42.6 11 50.9 6 40.3 8 40.6 12 46.8 7 43 6 44.5 4 3.4 17 3.5 8 2.5 19 
Sulfaquinoxaline 48.2 9 43.9 3 38.5 7 45.1 9 38.1 10 31.0 12 48.7 10 45.1 4 37.1 8 6.5 19 6.4 12 4.6 23 
Sulfathiazole 34.6 7 30.2 12 34.7 12 43.7 7 35.5 185 37.8 10 39.9 6 35 7 36.6 8 2.1 9 2.4 7 1.5 32 
Tetracycline 46.0 5 34.4 29 26.0 18 18.6 15 20.6 11 10.6 30 35.2 9 32.3 11 21.3 29 18.2 7 4.0 32 3.9 21 
Tolfenamic Acid 51.5 4 48.0 2 42.9 4 32.0 10 47.0 10 39.5 9 42.1 6 49.0 5 41.7 9 37.9 10 40.0 4 35.2 9 
Trifluropromazine 8.8 22 39.5 4 39.1 5 0.6 51 41.8 5 39.0 5 1.4 3 44.0 3 40.1 4 8.6 14 31.3 5 29.6 5 
Tylosin 8.0 12 8.0 5 7.7 12 4.1 19 3.6 10 3.4 9 6.9 9 7.0 5 6.9 5 8.4 42 7.3 12 8.8 13 
Virginiamycin 42.4 8 36.2 3 37.1 7 32.9 12 26.1 12 24.1 15 41.5 6 37.8 2 36.3 3 35.9 24 34.8 6 34.3 6 
Xylazine 19.4 17 50.7 6 46.6 2 1.5 53 52.3 10 45.5 10 3.5 4 53.8 5 47.5 3 11.5 20 21.5 13 17.1 13 
Tetracycline 46.0 5 34.4 29 26.0 18 18.6 15 20.6 11 10.6 30 35.2 9 32.3 11 21.3 29 18.2 7 4.0 32 3.9 21 
Tolfenamic Acid 51.5 4 48.0 2 42.9 4 32.0 10 47.0 10 39.5 9 42.1 6 49.0 5 41.7 9 37.9 10 40.0 4 35.2 9 
Trifluropromazine 8.8 22 39.5 4 39.1 5 0.6 51 41.8 5 39.0 5 1.4 3 44.0 3 40.1 4 8.6 14 31.3 5 29.6 5 
Tylosin 8.0 12 8.0 5 7.7 12 4.1 19 3.6 10 3.4 9 6.9 9 7.0 5 6.9 5 8.4 42 7.3 12 8.8 13 
Virginiamycin 42.4 8 36.2 3 37.1 7 32.9 12 26.1 12 24.1 15 41.5 6 37.8 2 36.3 3 35.9 24 34.8 6 34.3 6 
Xylazine 19.4 17 50.7 6 46.6 2 1.5 53 52.3 10 45.5 10 3.5 4 53.8 5 47.5 3 11.5 20 21.5 13 17.1 13 
 
